{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Python Project - Drugs Data. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "#pip install sqlalchemy\n",
    "from sqlalchemy import create_engine\n",
    "#pip  install  altair   vega\n",
    "import altair as alt\n",
    "alt.renderers.enable('notebook')\n",
    "import re"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Creating Database in Mysql with Username -> root and Password -> root \n",
    "#### Database Command -> create database lb3;"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Global variable('engine') to interact with the database using sqlalchemy and pymysql tools.\n",
    "engine = create_engine(\"mysql+pymysql://root:root@localhost/lb3\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugs = pd.read_sql_query(\"select * from scraped\", engine)\n",
    "tas = pd.read_sql_query(\"select * from therapyareas\", engine)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 20 columns):\n",
      "id             398 non-null int64\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "url            398 non-null object\n",
      "rr_start       366 non-null object\n",
      "rr_end         398 non-null object\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      383 non-null object\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null object\n",
      "latest         398 non-null object\n",
      "ema_url        398 non-null object\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](1), int64(4), object(15)\n",
      "memory usage: 62.3+ KB\n"
     ]
    }
   ],
   "source": [
    "#checking data in the rows and columns of the scraped table, which is stored in drugs varaible using info function.\n",
    "drugs.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "#deleting unwanted column(id)using drop function\n",
    "drugs.drop('id',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "#deleting unwanted column(url) using drop function\n",
    "drugs.drop('url',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "#deleting unwanted(ema_url) column using drop function\n",
    "drugs.drop('ema_url',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Removing unwanted text within paranthesis \n",
    "drugs['drug_name'] = drugs['drug_name'].str.replace(r\"\\(.*\\)\",\"\")\n",
    "drugs['indication'] = drugs['indication'].str.replace(r\"\\(.*\\)\",\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                             Abatacept \n",
       "1                         Abiraterone acetate  for mHSPC\n",
       "2                Abiraterone acetate  for mCRPC post ADT\n",
       "3                         Abiraterone Acetate  for mCRPC\n",
       "4                                           Aceclofenac \n",
       "5                                    Aclidinium bromide \n",
       "6      Aclidinium bromide / formoterol fumarate dihyd...\n",
       "7                                            Adalimumab \n",
       "8                                              Adenuric \n",
       "9                                              Afatinib \n",
       "10                                          Aflibercept \n",
       "11                                          Aflibercept \n",
       "12                                          Agomelatine \n",
       "13                                            Alectinib \n",
       "14                                          Alemtuzumab \n",
       "15                                           Alirocumab \n",
       "16                                           Alogliptin \n",
       "17                                          Ambrisentan \n",
       "18                                        Amifampridine \n",
       "19                                            Amsacrine \n",
       "20        Apixaban , and prevention of recurrent DVT and\n",
       "21     Apixaban  for the prevention of venous thrombo...\n",
       "22     Apremilast  for moderate to severe chronic pla...\n",
       "23                  Apremilast  for psoriatic arthritis.\n",
       "24                                         Aripiprazole \n",
       "25                                            Asenapine \n",
       "26                                         Atezolizumab \n",
       "27                                             Avanafil \n",
       "28                                             Avelumab \n",
       "29                       Aspirin 81mg/Esomeprazole 20mg \n",
       "                             ...                        \n",
       "368                                       Teriflunomide \n",
       "369                                          Ticagrelor \n",
       "370                                          Ticagrelor \n",
       "371                            Tisagenlecleucel  for ALL\n",
       "372                          Tisagenlecleucel  for DLBCL\n",
       "373                                          Tobramycin \n",
       "374                                      Tocilizumab SC \n",
       "375                  Tofacitinib  for Ulcerative Colitis\n",
       "376                                         Tofacitinib \n",
       "377                                           Tolvaptan \n",
       "378                Tramadol hydrochloride/dexketoprofen \n",
       "379                                          Trametinib \n",
       "380                               Trastuzumab emtansine \n",
       "381                              Trifluridine/tipiracil \n",
       "382           Ulipristal acetate  intermittent treatment\n",
       "383          Ulipristal acetate  single course treatment\n",
       "384                             Umeclidinium/vilanterol \n",
       "385                                                Urea \n",
       "386                     Ustekinumab  for Crohn’s Disease\n",
       "387                                         Ustekinumab \n",
       "388                                          Vandetanib \n",
       "389                      Vedolizumab  in Crohn’s Disease\n",
       "390                   Vedolizumab  in Ulcerative Colitis\n",
       "391                                  Velaglucerase Alfa \n",
       "392            Venetoclax  in combination with rituximab\n",
       "393                                          Venetoclax \n",
       "394                                         Vemurafenib \n",
       "395                                         Vernakalant \n",
       "396                                          Vismodegib \n",
       "397                                        Vortioxetine \n",
       "Name: drug_name, Length: 398, dtype: object"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#checking drug_name after removing unwanted text within paranthesis\n",
    "drugs['drug_name'] "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0               Subcutaneous Abatacept -alpha inhibitor.\n",
       "1                                  Abiraterone acetate .\n",
       "2      Pharmacoeconomic evaluation of Abiratone aceta...\n",
       "3      Pharmacoeconomic evaluation and resource impli...\n",
       "4      Aceclofenac  is indicated for the relief of pa...\n",
       "5      Indicated as a maintenance bronchodilator trea...\n",
       "6      Brimica® Genuair® is indicated as a maintenanc...\n",
       "7      Economic evaluation of Adalimumab  in patients...\n",
       "8      NCPE review of Adenuric  a xanthine oxidase in...\n",
       "9      GIOTRIF as monotherapy is indicated for the tr...\n",
       "10                                         Aflibercept .\n",
       "11     Aflibercept for the treatment of metastatic co...\n",
       "12     Economic evaluation of Agomelatine  for the tr...\n",
       "13     Alectinib  whose disease has progressed follow...\n",
       "14     Alemtuzumab  with active disease defined by cl...\n",
       "15     Praluent® is indicated for both primary hyperc...\n",
       "16     Alogliptin is indicated in adults aged 18 year...\n",
       "17     Cost Effectiveness of ambrisentan  in the trea...\n",
       "18     For Lambert Eaton Myasthenic Syndrome .  This ...\n",
       "19     Amsidine® is indicated for the induction and m...\n",
       "20     Apixaban , and prevention of recurrent DVT and...\n",
       "21     Apixaban  for the prevention of venous thrombo...\n",
       "22     Indicated for the treatment of moderate to sev...\n",
       "23     Apremilist , alone or in combination with DMAR...\n",
       "24     Aripiprazole  for maintenance treatment of sch...\n",
       "25     Asenapine  for the treatment of moderate to se...\n",
       "26     Atezolizumab as monotherapy is indicated for t...\n",
       "27     Avanafil  is indicated for the treatment of er...\n",
       "28     Avelumab  is indicated for the treatment of ad...\n",
       "29     Prevention of thrombotic cardiovascular and ce...\n",
       "                             ...                        \n",
       "368    Aubagio® is indicated for the first line treat...\n",
       "369    Ticagrelor  and a high risk of developing an a...\n",
       "370                  Economic Evaluation of Ticagrelor .\n",
       "371    Tisagenlecleucel  that is refractory, in relap...\n",
       "372    Tisagenlecleucel  after two or more lines of s...\n",
       "373    Tobramycin  for the suppressive therapy of chr...\n",
       "374    It is licensed for the treatment of moderate t...\n",
       "375    Tofacitinib is indicated for the treatment of ...\n",
       "376    Tofacitinib  in adult patients who have respon...\n",
       "377    Jinarc®) to slow the progression of cyst devel...\n",
       "378    Tramadol hydrochloride/dexketoprofen  for the ...\n",
       "379    Mekinist® for the treatment of adult patients ...\n",
       "380    Trastuzumab emtansine  is indicated for the tr...\n",
       "381    Trifluridine/tipiracil  is indicated for the t...\n",
       "382    Ulipristal acetate is indicated for the interm...\n",
       "383    Ulipristal acetate  is indicated for the pre-o...\n",
       "384    Umeclidinium/vilanterol  is indicated as a mai...\n",
       "385    GlucoRx Allpresan® Diabetic Foam Cream for the...\n",
       "386    Ustekinumab is indicated for the treatment of ...\n",
       "387    Cost-effectiveness of Ustekinumab  in the trea...\n",
       "388    Vandetanib  in patients with unresectable loca...\n",
       "389                             Vedolizumab  antagonist.\n",
       "390                             Vedolizumab  antagonist.\n",
       "391    VPRIV is indicated for long-term enzyme replac...\n",
       "392    Venetoclax  in combination with rituximab is i...\n",
       "393    Venetoclax monotherapy is indicated for the tr...\n",
       "394    Vemurafenib for the treatment of adult patient...\n",
       "395    Economic evaluation of Vernakalant  for haemod...\n",
       "396    Vismodegib  is indicated for the treatment of ...\n",
       "397    Vortioxetine  is indicated for the treatment o...\n",
       "Name: indication, Length: 398, dtype: object"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Checking text for indication column after removing unwanted text within paranthesis\n",
    "drugs['indication']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Data cleaning, converting object data into datetime using to_datetime\n",
    "drugs['rr_start'] = drugs['rr_start'].apply(pd.to_datetime)\n",
    "drugs['rr_end'] = drugs['rr_end'].apply(pd.to_datetime)\n",
    "drugs['eu_market'] = drugs['eu_market'].apply(pd.to_datetime)\n",
    "drugs['earliest'] = drugs['earliest'].apply(pd.to_datetime)\n",
    "drugs['latest'] = drugs['latest'].apply(pd.to_datetime)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 398 entries, 0 to 397\n",
      "Data columns (total 17 columns):\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "rr_start       366 non-null datetime64[ns]\n",
      "rr_end         398 non-null datetime64[ns]\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null int64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null int64\n",
      "eu_market      383 non-null datetime64[ns]\n",
      "company        398 non-null object\n",
      "orphan         398 non-null int64\n",
      "earliest       398 non-null datetime64[ns]\n",
      "latest         398 non-null datetime64[ns]\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "dtypes: datetime64[ns](6), int64(3), object(8)\n",
      "memory usage: 52.9+ KB\n"
     ]
    }
   ],
   "source": [
    "#Re-checking the rows and columns data in scraped table stored in drugs varaible using info function\n",
    "drugs.info()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Visualisation 1 : \n",
    "### How many drugs are applied for rapid review per year?\n",
    "###  Reason : \n",
    "### I have done this  Visualisation to predict the total count of drugs for the rapid review for the year 2019. As the trend from past 3 years i.e 2016-2018 clearly depicts that each year drug count for rapid review has increased . This clearly helps to give an idea that for 2019, application of drugs for rapid review will increase. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"data\": {\"name\": \"data-3d759ccdd22257fc2c40e3e6d3ddc040\"}, \"mark\": {\"type\": \"bar\", \"color\": \"red\"}, \"encoding\": {\"x\": {\"type\": \"nominal\", \"axis\": {\"title\": \"The NCPE Year\"}, \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Total no. of drugs\"}, \"field\": \"drug_name\"}}, \"height\": 300, \"title\": \"Rapid Review Outcome Analysis: All Drugs upto 2018\", \"width\": 600, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-3d759ccdd22257fc2c40e3e6d3ddc040\": [{\"last_scrape\": \"2018-12-13T16:24:32\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept \", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept -alpha inhibitor.\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:36\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mHSPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:41\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mCRPC post ADT\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate  in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:46\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate  for mCRPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \\u00ae  who have received prior docetaxel-based chemotherapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:49\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac \", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac  is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:56\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide \", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease \", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:00\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate \", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\\u00ae Genuair\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:37\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab \", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab  in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:40\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric \", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric  a xanthine oxidase inhibitor for the treatment of gout.\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:45\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib \", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:49\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:52\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid  that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:58\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine \", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine  for the treatment of major depressive disorder.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:26:06\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib \", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib  whose disease has progressed following treatment with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:12\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab \", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab  with active disease defined by clinical or imaging features\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:14\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab \", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\\u00ae is indicated for both primary hypercholesterolaemia  or mixed dyslipidaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:16\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin \", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:21\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan \", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan  in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:23\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine \", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome .  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:29\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine \", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\\u00ae is indicated for the induction and maintenance of remission in acute leukaemia of adults.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:35\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban , and prevention of recurrent DVT and\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:39\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:45\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for moderate to severe chronic plaque psoriasis.\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:47\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for psoriatic arthritis.\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist , alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:49\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole \", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole  for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:55\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine \", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine  for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:00\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab \", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK\\u2011positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:05\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil \", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil  is indicated for the treatment of erectile dysfunction in adult men.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:06\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab \", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab  is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:08\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg \", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:14\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.\\n \", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel \", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:23\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib \", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma  after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:24\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment not Recommended.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate \", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:25\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan \", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:27\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib \", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib  is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:33\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene \", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene  for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:36\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline \", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline  is indicated for use as part of an appropriate combination regimen for pulmonary MDR\\u2011TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:37\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept \", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid -2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:40\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab \", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab \", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:46\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine \", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine \", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:50\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"Full pharamcoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab \", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab  is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting \\u03b2-agonists.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:56\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab \", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab  in adults at high risk for recurrence of CDI.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:58\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\\u00ae for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:01\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine \", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine  and urticaria.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:05\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo\\u00ae at this point in time.\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab \", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\\u00ae is indicated for the treatment of adults with Philadelphia chromosome negative  relapsed or refractory\\nB-precursor acute lymphoblastic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:11\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir \", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:28:16\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan \", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan  III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:18\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"At the current price a full HTA would be required.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib \", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase  and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:19\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  after at least 1 prior systemic therapy. This is a license extension.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:23\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:29\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\\n \", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib \", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib  is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:30\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel \", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel  is indicated for the treatment of facial erythema of rosacea in adult patients.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:36\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam \", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam  with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:40\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab \", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab  is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:44\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"Full HTA recommended\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder \", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\\u00ae \\u2013 Mannitol dry powder for inhalation for the treatment of cystic fibrosis \", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:46\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:53\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor \", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor \", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:55\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib -targeted therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:58\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib  is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:01\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium \", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\\u00ae is indicated for the cutaneous treatment of external genital and perianal warts  in immunocompetent patients from the age of 18 years.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:04\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin \", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin  is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:09\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch \", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch  for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:11\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel \", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel  for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:16\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib \", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\\u00ae  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:22\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab \", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab  for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:25\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline \", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:29\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam \", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam  and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:34\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended at the Submitted Price.\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam \", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\\u00ae is indicated for the treatment of complicated urinary tract infections  in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:36\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib \", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\\u00ae is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:40\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa \", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:44\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol \", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol  for the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:29:49\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops \", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\\u00ae is indicated for the treatment of severe keratitis in adult patients with dry eye disease , which has not improved despite treatment with tear substitutes.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:54\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine \", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine  as defined by clinical or imaging features\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:58\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% \", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025%  is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:02\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib \", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\\u00ae is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:03\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam \", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam \", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:06\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium \", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium  aged 6 years and older.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:17\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum \", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum  is indicated for the treatment of Dupuytren\\u2019s contracture in adult patients with a palpable cord.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:20\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa \", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa .\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:24\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for first line ALK+ NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:29\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for ROS1 NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:34\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib \", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase \", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:37\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release \", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\\u00ae for the treatment of proven nephropathic cystinosis.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:43\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the treatment of DVT and PE\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:51\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate  \\u2013 for the prevention of stroke and systematic embolisom in atrial fibrillation\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate  for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:57\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:59\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib \", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib  is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:02\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir \", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir . \", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:08\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab \", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:12\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin \", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin  in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:18\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin \", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin  is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\\nMonotherapy\\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\\nAdd-on combination therapy\\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:21\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab \", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:25\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide \", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide  is indicated for the treatment of HIV-1 in adults and adolescents.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:30\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat \", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:35\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel \", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel  for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn\\u2019s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:40\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine \", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine  is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:44\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide \", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide  therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:47\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix \", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix \", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:52\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex\\u00ae compared with the current standard of care.\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD \", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:59\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol \", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:04\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab  for the Prevention of Osteoporotic Fractures in Postmenopausal Women.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:08\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab  for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:12\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant \", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\\u00ae in the treatment of macular oedema following Retinal Vein Occlusion.\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:15\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine \", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine  for the treatemnt of ICU adult patients requiring light to moderate sedation.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:21\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest \", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest  for the Treatment of Endometriosis\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:24\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate  for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:26\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:29\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"Following assessment of the applicant\\u2019s submission, the NCPE recommends that dinutuximab beta (Qarziba\\u00ae) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta \", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients \\u2265 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:34\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine \", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:36\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir \", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir  infected adults and adolescents above 12 years of age.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:39\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone \", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:42\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide \", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:46\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab \", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab  is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:53\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab \", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab  in the Irish healthcare setting.\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:55\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban \", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:00\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir \", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir .\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:03\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat \", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat  is indicated for the long-term treatment of adult patients with Gaucher disease type 1.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:05\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa \", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa  in patients of all ages.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:12\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag  for Thrombocytopenia in HCV\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag  infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:17\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag \", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\\u00ae for the treatment adult patients with acquired severe aplastic anaemia  who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:23\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag  for ITP\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag .\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:26\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide \", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\\u00ae is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus \\u2013 1 .\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:32\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin \", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:37\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate \", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\\u00ae is indicated in combination with safer sex practices for pre\\u2011exposure prophylaxis  to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:43\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil \", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil  for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:48\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\\u00ae  type 1.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:52\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide  on or after chemotherapy\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide  whose disease has progressed on or after docetaxel therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:59\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol \", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\\u00ae is indicated for the treatment of pulmonary arterial hypertension  in patients with WHO FC III\\u2013IV symptoms to improve exercise capacity.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:03\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab \", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab   is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig\\u00ae.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:07\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin \", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin  for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:09\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine \", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine  for the treatment of Epilepsy\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:12\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept \", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\\u00ae is a biosimilar of the TNF-\\u03b1 inhibitor Etanercept  for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:15\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide \", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide  on haemodialysis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:21\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin \", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\\u00ae  for uncomplicated malaria caused by the Plasmodium falciparum parasite\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:24\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive , in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:26\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus : adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:29\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus  who require therapeutic intervention but are not amenable to surgery\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:36\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab \", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab  is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:34:41\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide \", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide  for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:44\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine \", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine .\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:48\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol \", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia  in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:34:51\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin \", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:56\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod \", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod  for the treatment of highly active relapsing-remitting multiple sclerosis.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:01\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide \", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\\u00ae is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema  considered insufficiently responsive to available therapies.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:05\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy\\u2122 Ellipta\\u2122 be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero \", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\\u2122 Ellipta\\u2122 which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:09\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\\n\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta \", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta  cycle\", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:12\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib \", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib  for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:15\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin \", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin  which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:19\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir \", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir  infection in adults \\u2013 pangenotypic GT1-6.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:25\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate \", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate  for the treatment of oestoarthritis in the Irish Healthcare setting.\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:32\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti\\u00ae) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate \", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:38\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:40\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide  in children and adolescents aged 3 years and older with chronic neurological disorders\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:47\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab  for UC\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:54\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab \", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab  in the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:56\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract \", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract  with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:00\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride \", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\\u00ae is indicated for the treatment of attention deficit hyperactivity disorder  in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:02\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab \", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab  for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI .\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:14\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\\u00ae is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency  as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:17\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 \", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10  for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:22\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  \", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone  for the treatment of adrenal insufficiency in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:27\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide \", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide  is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:32\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for previously untreated CLL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib . This indication is an extension to the original licence in the relapsed/refractory setting.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:36\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for MCL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:40\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant \", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant .\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:43\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab \", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa  when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:50\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone \", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\\u00ae is indicated for the treatment of visual impairment in adolescent and adult patients with Leber\\u2019s Hereditary Optic Neuropathy .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:56\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib \", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia  who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:59\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% \", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75% of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:01\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A \", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A  and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:04\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol \", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol  for the treatment of COPD.\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:07\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab \", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\\u00ae is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn\\u2019s disease, Paediatric Crohn\\u2019s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:37:09\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin \", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:16\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:21\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:25\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec \", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:30\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.  \", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide \", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus  or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:36\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine \", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\\u00ae is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:40\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 \", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\\u00ae is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:43\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab  melanoma in adult patients who have received prior therapy.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:49\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\\u00ae is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:52\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Monover\", \"indication\": \"Monover\\u00ae is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:02\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 \", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:07\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of invasive aspergillosis.\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated for the treatment of invasive aspergillosis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:09\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended. \", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of mucormycosis\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:15\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor \", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:21\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmaoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for patients with CF 2 years +\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating  mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:24\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for the treatment of CF patients with the R117H mutation.\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:29\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib \", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:34\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab  for psoriatic arthritis\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab  therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:37\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab \", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\\u00ae is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:39\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate \", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate  for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:44\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended at the submitted price.\\n \", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \\u00ae is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:50\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib \", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib  for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:38:56\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir \", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir   in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:05\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide \", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\\u00ae for the treatment of adult patients with previously untreated multiple myelomas .\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib -targeted therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:11\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib  for HCC\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib  which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:15\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated , refractory to radioactive iodine.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:20\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad \", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad  for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:25\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir \", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus .\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:28\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel \", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\\u2019s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa\\u00ae administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:34\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price. \", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin \", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin  is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:39\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 \", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\\u00ae   which is indicated for contraception for up to 5 years.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:44\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS \", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS  for contraception for up to three years.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:46\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters \", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection .\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:51\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide \", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide  in adults.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:54\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin \", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin  for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:57\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim \", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\\u00ae is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:00\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"A Full Pharmacoeconomic Assessment is recommended\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine \", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine  or AML with myelodysplasia-related changes.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:06\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan \", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan  is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment \", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:13\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide \", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\\u00ae  is indicated for treatment of adults with type 2 diabetes mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:17\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide \", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide  for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:19\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide \", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\\u00ae is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:22\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam \", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam  for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:24\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension \", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:30\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder \", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:34\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor \", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\\u00ae is indicated for the treatment of cystic fibrosis  in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:36\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium \", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium  in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:41\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan \", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension  II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:43\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin \", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin  For The Short-Term Treatment of Primary Insomnia.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:40:45\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab \", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab  is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:51\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane \", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\\u00ae is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:56\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for AML\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin  who are FLT3 mutation positive.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:02\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for ASM\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:04\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide \", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide  for the treatment of osteosarcoma.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:06\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat \", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:13\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron \", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder  syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:15\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel \", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel  in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:18\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene \", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene  is indicated for the reduction of alcohol consumption in those aged \\u226518 years with alcohol dependence, who do not require immediate detoxification.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel \", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:26\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion \", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion  in the presence of one or more weight-related co-morbidities.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:30\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab \", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab  for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:35\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin \", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin  versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:38\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac \", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac  for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:41\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron \", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\\u00ae is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:44\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  newly diagnosed CML\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib  for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:51\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  CML resistant/intolerant to imatinib\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib  for the treatment of chronic phase CML.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:53\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:56\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib  indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:00\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib \", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:06\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for Melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:13\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for non-squamous NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:20\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:26\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:31\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended \", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for advanced renal cell carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:33\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for classical Hodgkin Lymphoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:36\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for head and neck cancer\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  in adults progressing on or after platinum-based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:41\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for urothelial carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:46\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:42:51\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab \", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\\u00ae plus Yervoy\\u00ae Is indicated for the treatment of advanced melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:42:56\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol \", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol  oral contraception\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:02\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin \", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen \", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:07\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid \", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis  in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:10\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Follicular Lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:15\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for previously untreated advanced follicular lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:21\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Lymphocytic Leukaemia\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:24\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for PPMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:30\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for RMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  with active disease defined by clinical or imaging features.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:34\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin \", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin , including when associated with macular hole of diameter less than or equal to 400 microns.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:39\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab  who have not received prior therapy and who are not eligible for fludarabine-based therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:46\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:52\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol \", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:57\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib \", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\\u00ae is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated  to platinum-based chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:03\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib  for platinum sensitive relapsed ovarian cancer\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:08\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab  for the treatment of severe allergic asthma\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function  as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:14\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended for this indication.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab \", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab  patients with inadequate response to H1-antihistamine treatment. \", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:19\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone \", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet  for severe pain, which can be adequately managed only with opioid analgesics.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:22\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib  for the first-line treatment of metastatic NSCLC\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:39\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib \", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:40\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\\n \\n \", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin \", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin  10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:44:43\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:47\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib \", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:53\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate \", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate  is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:57\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat \", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:01\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir \", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\\u00ae is indicated in combination with other medicinal products for the treatment of chronic hepatitis c  in adults. Exviera\\u00ae must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera\\u00ae combination therapy are viekirax\\u00ae or viekirax\\u00ae   and ribavirin.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:07\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer \", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer  is indicated for the treatment of hyperkalaemia in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:10\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  1L NSCLC with chemotherapy\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:15\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Adjuvant melanoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma  as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:18\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Classical Hodgkin Lymphoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab , or who are transplant-ineligible and have failed BV.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:23\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of locally advanced or metastatic non-small cell lung carcinoma  with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:28\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:31\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:36\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab  for Urothelial  Carcinoma 1L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:38\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Urothelial Carcinoma 2L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:45\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:50\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel \", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel  indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. \", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:45:56\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab   for Adjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:02\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  in neoadjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta  is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:04\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab \", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use  in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:09\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride \", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\\u00ae is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:46:11\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone \", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency  for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:14\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin \", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined  dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:20\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride \", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride  is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone \", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\\u00ae is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas .\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:27\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:30\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide \", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:32\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib \", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib  patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:38\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel \", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel  for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:46\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of neuropathic pain\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\\u00ae is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:52\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder.\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:58\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride \", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride  for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:00\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 \", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223  is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:03\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab \", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction  adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:06\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine \", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine \", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:13\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson \", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson \", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:17\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for GIST\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI\\u2019s.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:23\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab \", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\\u00ae is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:27\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine \", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine \", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:29\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib \", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib  negative locally advanced or metastatic breast cancer as initial endocrine based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:35\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin \", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin  is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients \\u2265 18 years of age. \", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:38\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for mCRC\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:42\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1  infection in antiretroviral treatment-naive adult patients with a viral load \\u2264 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:45\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Reimbursement Not Recommeded\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\\u00ae  infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load \\u2264 100,000 HIV 1 RNA copies/ml.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:47:48\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant \", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant  in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:47:53\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"Full HTA recommended at the current price.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat \", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat .\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:59\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab \", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab :\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:05\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for Atrial Fibrillation patients undergoing PCI\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:10\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Treatment of Deep Vein Thrombosis\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban  following an acute DVT in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:15\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Prevention of Stroke in Atrial Fibrillation\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the prevention of stroke in atrial fibrillation.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:18\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the prevention of atherothrombotic events\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban  at high risk of ischaemic events.\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:25\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  low dose for prevention of recurrent venous thromboembolism\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:30\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:33\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast \", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast  for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:40\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant \", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:43\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim \", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim  is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:47\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\\u00ae\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block  via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:48:50\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib  for Polycythaemia Vera\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\\u00ae is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:55\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib \", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib , post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:58\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan \", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\\u00ae for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:04\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate \", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\\u00ae for the treatment of adult patients with idiopathic Parkinson\\u2019s disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:49:07\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin \", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:11\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price.\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab \", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab . Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:16\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa \", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:20\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Ankylosing Spondylitis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:25\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Psoriatic Arthritis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae alone or in combination with methotrexate  therapy has been inadequate.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:31\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab \", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:34\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag \", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag  inhibitor, or as monotherapy in patients who are not candidates for these therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:39\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide \", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide  for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:44\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil \", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil  is indicated for:\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:49\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir  in combination with Sofosbuvir\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:53\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir \", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  Genotypes 1 and 4 who are treatment na\\u00efve or have previously been treated.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:00\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml \", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\\u00ae is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb\\u00ae is classified as a medical device and carries a CE mark.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:06\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:15\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate \", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate  is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:18\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir \", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir  is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:22\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \" Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir  \\u2013 pangenotypic\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir  i.e. pangenotypic.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:26\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir \", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir .\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:32\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort \", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\\u00ae is indicated for the short term treatment of mild depressive symptoms.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:38\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol \", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol  for use in conjunction with clobazam and valproate as adjunctive therapy of\\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\\n whose seizures are not adequately controlled with clobazam and\\nvalproate\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:43\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil \", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years and over who are antiretroviral treatment-na\\u00efve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild\\u00ae.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:49\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy \", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy  for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:50\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone \", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:54\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil \", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil  is indicated for the management of acute moderate to severe post-operative pain in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:59\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib \", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours  was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:51:04\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil \", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil  II and III, to improve exercise capacity.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:09\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine \", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine  for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"last_scrape\": \"2018-12-13T16:51:15\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost \", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost  for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:24\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec \", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec  with no bone, brain, lung or other visceral disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:28\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol \", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol  for the management of adult patients with severe chronic/acute pain.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:34\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate \", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate  in adults\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:38\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide \", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide  is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:44\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil \", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:48\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir \", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:52\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin \", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia .  Vabitiv\\u00ae should be used only in situations where it is known or suspected that other alternatives are not suitable.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:56\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide \", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\\u00ae is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:58\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor  and a high risk of developing an atherothrombotic event.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:01\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor .\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:07\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for ALL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  that is refractory, in relapse post-transplant or in second or later relapse.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:13\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for DLBCL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:19\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin \", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin  for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:52:24\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at theSubmitted Price.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC \", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis  antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:30\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib  for Ulcerative Colitis\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:35\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib \", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib  in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:40\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan \", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\\u00ae) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease  in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:45\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"Reimursement not recommended at the submitted price\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen \", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen  for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:52:51\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib \", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\\u00ae for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:56\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine \", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine  is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:00\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil \", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil  is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:04\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended \", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  intermittent treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:08\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  single course treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate  is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:10\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol \", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol  is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:12\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is not recommended. The NCPE recommends that GlucoRx Allpresan Diabetic Foam Cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea \", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\\u00ae Diabetic Foam Cream for the treatment of dry and sensitive foot skin  in patients with Diabetes Mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:17\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab  for Crohn\\u2019s Disease\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-\\u03b1 antagonist or have medical contraindications to such therapies\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:23\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab \", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab  in the treament of moderate to severe psoriasis.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:53:29\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib \", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib  in patients with unresectable locally advanced or metastatic disease.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:32\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Crohn\\u2019s Disease\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:39\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Ulcerative Colitis\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:45\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa \", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy  in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:49\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax  in combination with rituximab\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax  in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:52\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax \", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia \", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:58\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib \", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:00\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant \", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant  for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:04\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib \", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib  is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:11\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine \", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine  is indicated for the treatment of major depressive episodes in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"55441d98-2fc2-4dad-bb02-d20647edb91a\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd7a27be0>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#55441d98-2fc2-4dad-bb02-d20647edb91a"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#55441d98-2fc2-4dad-bb02-d20647edb91a"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Graph before Cleaning\n",
    "upto_chart = alt.Chart(drugs, \n",
    "          title=\"Rapid Review Outcome Analysis: All Drugs upto 2018\").mark_bar(color=\"red\").encode(\n",
    "    alt.X('ncpe_year:N', \n",
    "          axis=alt.Axis(title='The NCPE Year'),\n",
    "         ),\n",
    "    alt.Y('count(drug_name)',\n",
    "          axis=alt.Axis(title='Total no. of drugs'),\n",
    "         ),\n",
    "  \n",
    ").properties(\n",
    "    width=600,\n",
    "    height=300,\n",
    ")\n",
    "upto_chart"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Cleaning data and excluding the entries for the year 2019, as there is no complete data for the year 2019.\n",
    "upto_2018 = drugs[drugs.ncpe_year != 2019]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"data\": {\"name\": \"data-36aaca28ef8aa350a6ec5fb9319177d4\"}, \"mark\": {\"type\": \"bar\", \"color\": \"red\"}, \"encoding\": {\"x\": {\"type\": \"nominal\", \"axis\": {\"title\": \"The NCPE Year\"}, \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"axis\": {\"title\": \"Total no. of drugs\"}, \"field\": \"drug_name\"}}, \"height\": 300, \"title\": \"Rapid Review Outcome Analysis: All Drugs upto 2018\", \"width\": 600, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-36aaca28ef8aa350a6ec5fb9319177d4\": [{\"last_scrape\": \"2018-12-13T16:24:32\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept \", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept -alpha inhibitor.\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:36\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mHSPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:41\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mCRPC post ADT\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate  in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:46\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate  for mCRPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \\u00ae  who have received prior docetaxel-based chemotherapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:49\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac \", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac  is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:56\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide \", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease \", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:00\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate \", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\\u00ae Genuair\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:37\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab \", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab  in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:40\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric \", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric  a xanthine oxidase inhibitor for the treatment of gout.\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:45\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib \", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:49\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:52\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid  that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:58\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine \", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine  for the treatment of major depressive disorder.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:26:06\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib \", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib  whose disease has progressed following treatment with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:12\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab \", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab  with active disease defined by clinical or imaging features\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:14\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab \", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\\u00ae is indicated for both primary hypercholesterolaemia  or mixed dyslipidaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:16\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin \", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:21\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan \", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan  in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:23\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine \", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome .  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:29\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine \", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\\u00ae is indicated for the induction and maintenance of remission in acute leukaemia of adults.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:35\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban , and prevention of recurrent DVT and\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:39\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:45\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for moderate to severe chronic plaque psoriasis.\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:47\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for psoriatic arthritis.\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist , alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:49\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole \", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole  for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:55\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine \", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine  for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:00\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab \", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK\\u2011positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:05\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil \", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil  is indicated for the treatment of erectile dysfunction in adult men.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:06\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab \", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab  is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:08\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg \", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:14\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.\\n \", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel \", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:23\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib \", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma  after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:24\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment not Recommended.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate \", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:25\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan \", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:27\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib \", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib  is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:33\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene \", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene  for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:36\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline \", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline  is indicated for use as part of an appropriate combination regimen for pulmonary MDR\\u2011TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:37\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept \", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid -2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:40\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab \", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab \", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:46\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine \", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine \", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:50\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"Full pharamcoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab \", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab  is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting \\u03b2-agonists.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:56\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab \", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab  in adults at high risk for recurrence of CDI.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:58\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\\u00ae for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:01\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine \", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine  and urticaria.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:05\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo\\u00ae at this point in time.\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab \", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\\u00ae is indicated for the treatment of adults with Philadelphia chromosome negative  relapsed or refractory\\nB-precursor acute lymphoblastic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:11\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir \", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:28:16\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan \", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan  III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:18\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"At the current price a full HTA would be required.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib \", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase  and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:19\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  after at least 1 prior systemic therapy. This is a license extension.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:23\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:29\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\\n \", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib \", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib  is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:30\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel \", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel  is indicated for the treatment of facial erythema of rosacea in adult patients.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:36\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam \", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam  with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:40\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab \", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab  is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:44\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"Full HTA recommended\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder \", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\\u00ae \\u2013 Mannitol dry powder for inhalation for the treatment of cystic fibrosis \", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:46\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:53\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor \", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor \", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:55\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib -targeted therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:58\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib  is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:01\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium \", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\\u00ae is indicated for the cutaneous treatment of external genital and perianal warts  in immunocompetent patients from the age of 18 years.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:04\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin \", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin  is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:09\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch \", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch  for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:11\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel \", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel  for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:16\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib \", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\\u00ae  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:22\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab \", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab  for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:25\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline \", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:29\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam \", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam  and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:34\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended at the Submitted Price.\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam \", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\\u00ae is indicated for the treatment of complicated urinary tract infections  in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:36\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib \", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\\u00ae is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:40\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa \", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:44\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol \", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol  for the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:29:49\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops \", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\\u00ae is indicated for the treatment of severe keratitis in adult patients with dry eye disease , which has not improved despite treatment with tear substitutes.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:54\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine \", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine  as defined by clinical or imaging features\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:58\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% \", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025%  is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:02\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib \", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\\u00ae is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:03\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam \", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam \", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:06\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium \", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium  aged 6 years and older.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:17\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum \", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum  is indicated for the treatment of Dupuytren\\u2019s contracture in adult patients with a palpable cord.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:20\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa \", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa .\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:24\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for first line ALK+ NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:29\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for ROS1 NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:34\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib \", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase \", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:37\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release \", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\\u00ae for the treatment of proven nephropathic cystinosis.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:43\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the treatment of DVT and PE\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:51\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate  \\u2013 for the prevention of stroke and systematic embolisom in atrial fibrillation\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate  for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:57\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:59\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib \", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib  is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:02\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir \", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir . \", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:08\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab \", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:12\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin \", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin  in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:18\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin \", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin  is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\\nMonotherapy\\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\\nAdd-on combination therapy\\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:21\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab \", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:25\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide \", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide  is indicated for the treatment of HIV-1 in adults and adolescents.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:30\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat \", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:35\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel \", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel  for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn\\u2019s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:40\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine \", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine  is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:44\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide \", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide  therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:47\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix \", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix \", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:52\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex\\u00ae compared with the current standard of care.\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD \", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:59\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol \", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:04\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab  for the Prevention of Osteoporotic Fractures in Postmenopausal Women.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:08\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab  for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:12\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant \", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\\u00ae in the treatment of macular oedema following Retinal Vein Occlusion.\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:15\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine \", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine  for the treatemnt of ICU adult patients requiring light to moderate sedation.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:21\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest \", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest  for the Treatment of Endometriosis\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:24\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate  for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:26\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:29\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"Following assessment of the applicant\\u2019s submission, the NCPE recommends that dinutuximab beta (Qarziba\\u00ae) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta \", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients \\u2265 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:34\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine \", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:36\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir \", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir  infected adults and adolescents above 12 years of age.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:39\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone \", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:42\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide \", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:46\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab \", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab  is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:53\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab \", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab  in the Irish healthcare setting.\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:55\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban \", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:00\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir \", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir .\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:03\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat \", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat  is indicated for the long-term treatment of adult patients with Gaucher disease type 1.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:05\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa \", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa  in patients of all ages.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:12\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag  for Thrombocytopenia in HCV\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag  infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:17\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag \", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\\u00ae for the treatment adult patients with acquired severe aplastic anaemia  who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:23\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag  for ITP\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag .\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:26\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide \", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\\u00ae is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus \\u2013 1 .\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:32\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin \", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:37\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate \", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\\u00ae is indicated in combination with safer sex practices for pre\\u2011exposure prophylaxis  to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:43\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil \", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil  for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:48\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\\u00ae  type 1.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:52\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide  on or after chemotherapy\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide  whose disease has progressed on or after docetaxel therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:59\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol \", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\\u00ae is indicated for the treatment of pulmonary arterial hypertension  in patients with WHO FC III\\u2013IV symptoms to improve exercise capacity.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:03\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab \", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab   is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig\\u00ae.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:07\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin \", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin  for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:09\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine \", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine  for the treatment of Epilepsy\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:12\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept \", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\\u00ae is a biosimilar of the TNF-\\u03b1 inhibitor Etanercept  for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:15\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide \", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide  on haemodialysis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:21\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin \", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\\u00ae  for uncomplicated malaria caused by the Plasmodium falciparum parasite\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:24\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive , in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:26\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus : adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:29\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus  who require therapeutic intervention but are not amenable to surgery\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:36\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab \", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab  is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:34:41\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide \", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide  for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:44\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine \", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine .\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:48\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol \", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia  in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:34:51\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin \", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:56\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod \", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod  for the treatment of highly active relapsing-remitting multiple sclerosis.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:01\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide \", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\\u00ae is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema  considered insufficiently responsive to available therapies.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:05\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy\\u2122 Ellipta\\u2122 be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero \", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\\u2122 Ellipta\\u2122 which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:12\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib \", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib  for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:15\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin \", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin  which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:19\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir \", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir  infection in adults \\u2013 pangenotypic GT1-6.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:25\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate \", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate  for the treatment of oestoarthritis in the Irish Healthcare setting.\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:32\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti\\u00ae) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate \", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:38\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:40\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide  in children and adolescents aged 3 years and older with chronic neurological disorders\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:47\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab  for UC\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:54\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab \", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab  in the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:56\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract \", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract  with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:00\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride \", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\\u00ae is indicated for the treatment of attention deficit hyperactivity disorder  in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:02\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab \", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab  for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI .\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:14\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\\u00ae is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency  as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:17\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 \", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10  for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:22\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  \", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone  for the treatment of adrenal insufficiency in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:27\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide \", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide  is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:32\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for previously untreated CLL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib . This indication is an extension to the original licence in the relapsed/refractory setting.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:36\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for MCL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:40\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant \", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant .\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:43\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab \", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa  when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:50\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone \", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\\u00ae is indicated for the treatment of visual impairment in adolescent and adult patients with Leber\\u2019s Hereditary Optic Neuropathy .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:56\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib \", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia  who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:59\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% \", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75% of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:01\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A \", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A  and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:04\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol \", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol  for the treatment of COPD.\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:07\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab \", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\\u00ae is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn\\u2019s disease, Paediatric Crohn\\u2019s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:37:09\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin \", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:16\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:21\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:25\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec \", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:30\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.  \", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide \", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus  or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:36\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine \", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\\u00ae is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:40\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 \", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\\u00ae is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:43\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab  melanoma in adult patients who have received prior therapy.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:49\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\\u00ae is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:52\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Monover\", \"indication\": \"Monover\\u00ae is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:02\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 \", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:07\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of invasive aspergillosis.\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated for the treatment of invasive aspergillosis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:09\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended. \", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of mucormycosis\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:15\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor \", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:21\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmaoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for patients with CF 2 years +\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating  mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:24\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for the treatment of CF patients with the R117H mutation.\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:29\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib \", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:34\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab  for psoriatic arthritis\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab  therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:37\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab \", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\\u00ae is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:39\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate \", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate  for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:44\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended at the submitted price.\\n \", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \\u00ae is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:50\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib \", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib  for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:38:56\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir \", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir   in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:05\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide \", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\\u00ae for the treatment of adult patients with previously untreated multiple myelomas .\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib -targeted therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:11\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib  for HCC\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib  which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:15\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated , refractory to radioactive iodine.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:20\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad \", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad  for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:25\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir \", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus .\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:28\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel \", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\\u2019s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa\\u00ae administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:34\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price. \", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin \", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin  is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:39\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 \", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\\u00ae   which is indicated for contraception for up to 5 years.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:44\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS \", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS  for contraception for up to three years.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:46\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters \", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection .\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:51\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide \", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide  in adults.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:54\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin \", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin  for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:57\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim \", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\\u00ae is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:00\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"A Full Pharmacoeconomic Assessment is recommended\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine \", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine  or AML with myelodysplasia-related changes.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:06\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan \", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan  is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment \", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:13\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide \", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\\u00ae  is indicated for treatment of adults with type 2 diabetes mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:17\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide \", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide  for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:19\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide \", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\\u00ae is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:22\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam \", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam  for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:24\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension \", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:30\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder \", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:34\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor \", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\\u00ae is indicated for the treatment of cystic fibrosis  in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:36\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium \", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium  in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:41\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan \", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension  II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:43\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin \", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin  For The Short-Term Treatment of Primary Insomnia.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:40:45\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab \", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab  is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:51\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane \", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\\u00ae is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:56\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for AML\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin  who are FLT3 mutation positive.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:02\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for ASM\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:04\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide \", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide  for the treatment of osteosarcoma.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:06\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat \", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:13\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron \", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder  syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:15\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel \", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel  in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:18\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene \", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene  is indicated for the reduction of alcohol consumption in those aged \\u226518 years with alcohol dependence, who do not require immediate detoxification.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel \", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:26\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion \", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion  in the presence of one or more weight-related co-morbidities.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:30\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab \", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab  for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:35\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin \", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin  versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:38\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac \", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac  for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:41\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron \", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\\u00ae is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:44\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  newly diagnosed CML\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib  for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:51\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  CML resistant/intolerant to imatinib\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib  for the treatment of chronic phase CML.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:53\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:56\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib  indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:00\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib \", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:06\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for Melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:13\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for non-squamous NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:20\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:26\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:31\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended \", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for advanced renal cell carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:33\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for classical Hodgkin Lymphoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:36\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for head and neck cancer\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  in adults progressing on or after platinum-based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:41\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for urothelial carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:46\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:42:51\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab \", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\\u00ae plus Yervoy\\u00ae Is indicated for the treatment of advanced melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:42:56\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol \", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol  oral contraception\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:02\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin \", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen \", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:07\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid \", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis  in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:10\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Follicular Lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:15\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for previously untreated advanced follicular lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:21\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Lymphocytic Leukaemia\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:24\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for PPMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:30\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for RMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  with active disease defined by clinical or imaging features.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:34\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin \", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin , including when associated with macular hole of diameter less than or equal to 400 microns.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:39\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab  who have not received prior therapy and who are not eligible for fludarabine-based therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:46\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:52\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol \", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:57\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib \", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\\u00ae is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated  to platinum-based chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:03\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib  for platinum sensitive relapsed ovarian cancer\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:08\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab  for the treatment of severe allergic asthma\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function  as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:14\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended for this indication.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab \", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab  patients with inadequate response to H1-antihistamine treatment. \", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:19\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone \", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet  for severe pain, which can be adequately managed only with opioid analgesics.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:22\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib  for the first-line treatment of metastatic NSCLC\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:39\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib \", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:40\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\\n \\n \", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin \", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin  10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:44:43\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:47\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib \", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:53\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate \", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate  is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:57\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat \", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:01\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir \", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\\u00ae is indicated in combination with other medicinal products for the treatment of chronic hepatitis c  in adults. Exviera\\u00ae must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera\\u00ae combination therapy are viekirax\\u00ae or viekirax\\u00ae   and ribavirin.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:07\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer \", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer  is indicated for the treatment of hyperkalaemia in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:10\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  1L NSCLC with chemotherapy\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:15\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Adjuvant melanoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma  as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:18\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Classical Hodgkin Lymphoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab , or who are transplant-ineligible and have failed BV.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:23\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of locally advanced or metastatic non-small cell lung carcinoma  with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:28\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:31\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:36\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab  for Urothelial  Carcinoma 1L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:38\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Urothelial Carcinoma 2L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:45\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:50\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel \", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel  indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. \", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:45:56\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab   for Adjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:02\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  in neoadjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta  is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:04\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab \", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use  in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:09\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride \", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\\u00ae is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:46:11\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone \", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency  for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:14\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin \", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined  dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:20\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride \", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride  is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone \", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\\u00ae is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas .\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:27\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:30\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide \", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:32\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib \", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib  patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:38\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel \", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel  for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:46\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of neuropathic pain\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\\u00ae is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:52\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder.\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:58\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride \", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride  for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:00\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 \", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223  is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:03\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab \", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction  adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:06\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine \", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine \", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:13\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson \", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson \", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:17\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for GIST\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI\\u2019s.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:23\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab \", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\\u00ae is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:27\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine \", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine \", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:29\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib \", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib  negative locally advanced or metastatic breast cancer as initial endocrine based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:35\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin \", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin  is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients \\u2265 18 years of age. \", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:38\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for mCRC\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:42\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1  infection in antiretroviral treatment-naive adult patients with a viral load \\u2264 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:45\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Reimbursement Not Recommeded\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\\u00ae  infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load \\u2264 100,000 HIV 1 RNA copies/ml.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:47:48\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant \", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant  in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:47:53\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"Full HTA recommended at the current price.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat \", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat .\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:59\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab \", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab :\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:05\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for Atrial Fibrillation patients undergoing PCI\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:10\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Treatment of Deep Vein Thrombosis\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban  following an acute DVT in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:15\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Prevention of Stroke in Atrial Fibrillation\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the prevention of stroke in atrial fibrillation.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:18\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the prevention of atherothrombotic events\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban  at high risk of ischaemic events.\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:25\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  low dose for prevention of recurrent venous thromboembolism\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:30\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:33\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast \", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast  for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:40\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant \", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:43\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim \", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim  is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:47\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\\u00ae\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block  via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:48:50\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib  for Polycythaemia Vera\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\\u00ae is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:55\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib \", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib , post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:58\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan \", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\\u00ae for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:04\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate \", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\\u00ae for the treatment of adult patients with idiopathic Parkinson\\u2019s disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:49:07\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin \", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:11\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price.\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab \", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab . Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:16\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa \", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:20\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Ankylosing Spondylitis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:25\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Psoriatic Arthritis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae alone or in combination with methotrexate  therapy has been inadequate.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:31\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab \", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:34\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag \", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag  inhibitor, or as monotherapy in patients who are not candidates for these therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:39\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide \", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide  for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:44\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil \", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil  is indicated for:\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:49\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir  in combination with Sofosbuvir\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:53\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir \", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  Genotypes 1 and 4 who are treatment na\\u00efve or have previously been treated.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:00\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml \", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\\u00ae is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb\\u00ae is classified as a medical device and carries a CE mark.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:06\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:15\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate \", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate  is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:18\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir \", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir  is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:22\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \" Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir  \\u2013 pangenotypic\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir  i.e. pangenotypic.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:26\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir \", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir .\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:32\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort \", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\\u00ae is indicated for the short term treatment of mild depressive symptoms.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:38\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol \", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol  for use in conjunction with clobazam and valproate as adjunctive therapy of\\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\\n whose seizures are not adequately controlled with clobazam and\\nvalproate\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:43\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil \", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years and over who are antiretroviral treatment-na\\u00efve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild\\u00ae.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:49\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy \", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy  for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:50\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone \", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:54\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil \", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil  is indicated for the management of acute moderate to severe post-operative pain in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:59\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib \", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours  was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:51:04\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil \", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil  II and III, to improve exercise capacity.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:09\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine \", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine  for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"last_scrape\": \"2018-12-13T16:51:15\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost \", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost  for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:24\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec \", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec  with no bone, brain, lung or other visceral disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:28\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol \", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol  for the management of adult patients with severe chronic/acute pain.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:34\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate \", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate  in adults\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:38\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide \", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide  is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:44\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil \", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:48\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir \", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:52\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin \", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia .  Vabitiv\\u00ae should be used only in situations where it is known or suspected that other alternatives are not suitable.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:56\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide \", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\\u00ae is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:58\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor  and a high risk of developing an atherothrombotic event.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:01\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor .\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:07\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for ALL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  that is refractory, in relapse post-transplant or in second or later relapse.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:13\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for DLBCL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:19\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin \", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin  for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:52:24\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at theSubmitted Price.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC \", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis  antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:30\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib  for Ulcerative Colitis\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:35\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib \", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib  in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:40\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan \", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\\u00ae) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease  in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:45\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"Reimursement not recommended at the submitted price\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen \", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen  for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:52:51\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib \", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\\u00ae for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:56\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine \", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine  is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:00\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil \", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil  is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:04\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended \", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  intermittent treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:08\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  single course treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate  is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:10\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol \", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol  is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:12\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is not recommended. The NCPE recommends that GlucoRx Allpresan Diabetic Foam Cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea \", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\\u00ae Diabetic Foam Cream for the treatment of dry and sensitive foot skin  in patients with Diabetes Mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:17\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab  for Crohn\\u2019s Disease\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-\\u03b1 antagonist or have medical contraindications to such therapies\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:23\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab \", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab  in the treament of moderate to severe psoriasis.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:53:29\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib \", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib  in patients with unresectable locally advanced or metastatic disease.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:32\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Crohn\\u2019s Disease\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:39\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Ulcerative Colitis\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:45\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa \", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy  in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:49\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax  in combination with rituximab\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax  in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:52\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax \", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia \", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:58\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib \", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:00\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant \", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant  for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:04\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib \", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib  is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:11\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine \", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine  is indicated for the treatment of major depressive episodes in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"ae14afe0-6fd0-4bf4-8284-afa26bd8d708\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd7a0f2b0>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#ae14afe0-6fd0-4bf4-8284-afa26bd8d708"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAokAAAF5CAYAAADzrbClAAAgAElEQVR4Xu3db6hl133e8ecQBJFCimVZxCQocXVfyDQvVCy9KEiBMMxUIRBiFK4UkE1JptW0jikoyJlJVUkzUtQ7o4gKijtkVGRSbEElkxBTcOMg9KYayAs5oDdF80LTcaBGxRrbcYjGb8wtP2mv6Tp79rlnr73Xb6297/4eMNa9s/Zaa3/WPvc8Z639ZyVeCCCAAAIIIIAAAgi0BFaIIIAAAggggAACCCDQFiAkckwggAACCCCAAAII3CBASOSgQAABBBBAAAEEECAkcgwggAACCCCAAAIIbBdgJnG7ESXmI/CkpGc6untB0mOSro3clbskvSrpzyQ921HXfZLelPQ5Sa+0/v225ncPdGzXVT61q9v6llrfpvI3S3pR0omowFMbPHK1WbueRyR9TdLbkh6WdClTh3KNWTi2rmQ6zm334uO1Pb7t9n7xgPfFpuM+13sy01BUrab9nmofZ7HhpmMwHEt/HP3tadf7LUl2LF+turc0PisBQuKshovObhGwkPhbrQ/yg4JbKui2D/U+IbH9Qd7V59R+WfltfRtSZ3ubrjAS2v3rxIBiH1ZmcTFHxxzraH/Q5gj0obu5xswjJIZj2fraDhdDQmJ83Iftre7DElpsn74g6YUBX0bDl5D7m/eD/fyl5u/Y3zZfyszKvug+LsnGJnYL21uZ+PiM631/yxdcx7cQVc9ZgJA459Gj722BrsDl8QG6SX5ISMwZYr2PiE2BNnUf2h+K3v0eU38cgj/VBNscs9Klgv3QfQ9j/VdNYAkBxuobGxKtjtRjZuh+lNgu99+Y2OatJtyFGcLwb2E8wuqJrXDYLHccEu3fQqD8oAmbdgwflmBeYmwX3wYhcfGHwKEC6BMSbYfj5dJ4+aYdCGxpOJ5Fac/8xLNMVs95SbaMdtByc3smsf1h2Z65Ckt9XctJ22YK4uX3sLz3mdaSeGg//PstzXKVzfDFS+oHfRCGfwvbtENgvI+2/7YkH17t/bu7+Yd4ibO9ZBkvVYa6f1+SjZf9z8biaUlnJFl97ZmwLpdNpyLE+3KkY6Y6jIuFqX/ULMO3lwTjmZ54tic+nt7oOFWhfTy3T6cIQaE9NmEMw6kN8f73CTRxmT+R9KetUyxyhMT2MdMOpfYespct84f9bL9X2suw7UAbfMMxtWmJu70/4W9ECFT2s50+8oOmT78dnXoQZvrC6Rfx2MfjlXKqQtjODML7JRi0/w5YWTt27NU+1WXb34dD9cefnfERICT6uFJrHYE+y83xt+vwxz8Et3Bu1XvNt+1N/x7OSYz/CP9NFD5TQmLc5/CBEz6cPhHNIvx5ayYgzAxYH21mq31eWFyvLTXZh5yFOAuy4b8tBIZ9CEHi082HTTxzZG0ctDTa/pB9cMuHeztEtuuOw8BfNv0NY9T+AA/9bYfg9v6E0LnJpesc0xDYw3iEtuLxDX0Px0wYs3CMdM38hFMibF/COa62TGlfXsJ4hqAX9juEexuXcKy1Q0woGy9JtvvTJyTG/u3jzs5nyxkS4z7b+cSblkvt2G2HxK6xtGAcGwXP9pej+C9U35D4ydYS8CZ/+8LR/lvUd/Y87GMIlfe23kub3oebZmbj0wYO+7nDdT51DnmrhMRDPsAL271NF660Q1t7ti4EjK4T8OM/9l0f6vHyTZ/l5vaFK10zmSFghH6GD7o4fIVzjMIyVPzhEYJgPGsZh2M7d8r6+i8l/fvoIhT7cLX9CedDxRdoeIbEgz5A2yHLLOLfhRmU9oxkMExxaZ/Q397ng87JDO1tCmHxbGIY8/h4CoE92Fu4i2eGDvqwb7dpITFcwNUO+33+JGwLOF4hsX0+8UEz0u0vDxbMNn1p2zaL1zckxu+nuK13Wl9kumbj2zOnXePQNcbbvlCFerr+9sTnNoYvijkvbupzLFFm5gKExJkPIN1fEzhoZiFcIBGCpIWKdpjqComblmy6glifkNieGepazg7LY2HnQpkws2n7crkV5rrC0KZAGgKILZFZYPyvzTKtzRrZjEsIpfESbJ/l5rBvqTOJB1280xUgu5avwxeBdrBLcWlftdxuO4T2fxZdHLUtSIYZrDCG5t01k2ghMV5KvLO1tN11VXn7FIH2jHh8HPW94KZrnIN3COI5Q2I4RaHrGDgoJIZz9eI7DWwqH/+R6ArNQ0LiQbPdXX9Hts3gxkvj8d+E9pekrtNO4i9OYZzbXzC7Zjf5+EBgqwAhcSsRBWYk0P6gCX9g2yErfJi2l/RKzCS2Z/dsxmfTLFgXfdjH/yvpf0dXFG+bMYvrCh9YP5RkS6h2wvtD0ezTpkDR98KVgz7cbam762rO+NyzuK99ZxJTQmKf2ZSuUBb3a1N7XbN68QzZpplpC4mhzX8s6eckbbpiPA4U1o+uWbXQ12C9bTatPSPVdexteh/1uQXOtnNxU0PitpnE9lXz4cth121ghoTEnDOJ8bmV7f61Q2HX+4GQOKMPqbl1lZA4txGjvwcJdH3QdM0cWh32R/7XmvN92svN9u8WnNpLNO0Pw7HnJMYfDl3nmrXPJ4s/DOy/41mR9oxW16xqV0ANH0rB4qAwEfob/Gx5tusWOF3njsXnm22aHWkvEdtSet9zEvuERAti21zC8bXp1j7t37ePiU1LvzZW4RSBcHzZ/7fvu9nndibx+XlWb7zc+e8k/YfmtIFwFetB5+G2L9gJ75f2jFv8+/byampIbJ/racdR3/OJ4+PooJWDdh/NOj7nM97vdn/C+659bnL7fMdwqkn7/ODUcxIPCvLtGcGuW+B0hUT73UFjNvaesXwSLUSAkLiQgV7IbnZ90LSDmFGEq2stIFlwal8oEl+petDVzfEf4rFXN4d2wgdOuFqyfUVmV1CzfnSdMxifo9meoQgfTO1ZzG33O+xzM+1tV33HY9IO6EOvbu4bEuMxs//edIPh4LPpfNaw5NwOetuuNDZvCzpxaIyXTMM4hiAZL4Fvukp600xY1xW3fU4biL8EtGcY+56mEbaLxzr+M9Q+rrveuynHkY2j/e8/Rl+e2m0fdDPp+HxA+3JiV6p3XZjyo+Y0j4OuYG/fnsb2e9OXr4NmrMOx176Ku+uG7ptOdYn/BnAD84V8EObcTUJiTk3qmrvAQRdnzH3f6P88BDbNYM6j93V7GV+okeupOLZH284nrLvXtI6AowAh0RGXqmcnQEic3ZAdug5vmsE8dDs6cofiGbh45i7cPDrno+cIiSMHi83nK0BInO/Y0fP8AoTE/KbU2E8gDj0sC/Yza98su+/FOf1q//+lCImpYpQ/NAKExEMzlOwIAggggAACCCCQT4CQmM+SmhBAAAEEEEAAgUMjQEg8NEPJjiCAAAIIIIAAAvkECIn5LKkJAQQQQAABBBA4NAKExEMzlOwIAggggAACCCCQT4CQmM+SmhBAAAEEEEAAgUMj4B0S7Z5VRyTZ47DsFd+yIDzpwX4f7grvdQuDQzNg7AgCCCCAAAIIIFBCwDMkth/7ZfcBOyPpZUl2N3wLhm80OxmCpIXI45KelsSzJUscAbSBAAIIIIAAAgh0CHiFRLv56Gck2XNoQwC0331B0gtNALRZRns2pr3s+bn20HoLkvYA8/OSct4xn8FHAAEEEEAAAQQQSBDwComhC/Fyc1dItAB5uRUSr8827u3tnV6tVjareP11++2361d/9VcTdpGiCCCAAAIIIIAAAtsEdnZ21nJh7ZCYPJN49uzZ/VOnTnn3e5sj/44AAggggAACCBwagXfffXe/ZkjMck4iIfHQHI/sCAIIIIAAAghMRKB2SDSG0Vc3ExIncjTRDQQQQAABBBA4NAI1QmJ2PEJidlIqRAABBBBAAIGFCxASF34AsPsIIIAAAggggECXACGR4wIBBBBAAAEEEEDgBgFCIgcFAggggAACCCCAACGRYwABBBBAAAEEEEBguwAziduNKIEAAggggAACCCxOgJC4uCFnhxFAAAEEEEAAge0ChMTtRpRAAAEEEEAAAQQWJ0BIXNyQs8MIIIAAAggggMB2AULidiNKIIAAAggggAACixMgJC5uyNlhBBBAAAEEEEBguwAhcbsRJRBAAAEEEEAAgdEC+9I7ku4aXZFvBd9YSZ+1JgiJvtDUjgACCCCAAAIIfChASKxwIJw9e3b/1KlTqwpN0yQCCCCAAAIIINBLgJDYiylvIUJiXk9qQwABBBBAAIH8AoTE/KZbayQkbiWiAAIIIIAAAghUFiAkVhgAQmIFdJpEAAEEEEAAgSQBQmISV57ChMQ8jtSCAAIIIIAAAn4ChEQ/2401ExIroNMkAggggAACCCQJEBKTuPIUJiTmcaQWBBBAAAEEEPATICT62TKTWMGWJhFAAAEEEEAgjwAhMY9jUi3MJCZxURgBBBBAAAEEKggQEiugExIroNMkAggggAACCCQJEBKTuD4sbM8wfFXS3ZKekvRsU8WTkp6R9LakhyVd2lQ1ITEdnS0QQAABBBBAoKwAITHN+2ZJZyS93IRAC4ZvNFUcaQKjhcjjkp6WdK2rekJiGjqlEUAAAQQQQKC8ACExzfw2SV+Q9EITAO+TZOHwsqQrki5KsiD5uKTzkq4SEtOAKY0AAggggAAC0xAgJKaNg4XEL0s63cwkPiLpzo6QeH22cW9v7/RqtbJZxbXX7u5uWsuURgABBBBAAAEECgrcceyYbrps82DTfX1w9Kjeu3Dhegd3dnZWcW/XfiiwGzZ7+GbTjp2b+N+b/2YmsQA+TSCAAAIIIIBAGQFmEtOc2+ck2kyihUN7cU5imiWlEUAAAQQQQGDCAoTE9MGJZxI/J+mVpgqubk63ZAsEEEAAAQQQmKgAIbHCwHB1cwV0mkQAAQQQQACBJAFCYhJXnsKExDyO1IIAAggggAACfgKERD/bjTUTEiug0yQCCCCAAAIIJAkQEpO48hQmJOZxpBYEEEAAAQQQ8BMgJPrZMpNYwZYmEUAAAQQQQCCPACExj2NSLcwkJnFRGAEEEEAAAQQqCBASK6ATEiug0yQCCCCAAAIIJAkQEpO48hQmJOZxpBYEEEAAAQQQ8BMgJPrZbqyZkFgBnSYRQAABBBBAIEmAkJjElacwITGPI7UggAACCCCAgJ8AIdHPlpnECrY0iQACCCCAAAJ5BAiJeRyTamEmMYmLwggggAACCCBQQYCQWAGdkFgBnSYRQAABBBBAIEmAkJjElacwITGPI7UggAACCCCAgJ8AIdHPdmPNhMQK6DSJAAIIIIAAAkkChMQkrjyFCYl5HKkFAQQQQAABBPwECIl+tswkVrClSQQQQAABBBDII0BIzOOYVAsziUlcFEYAAQQQQACBCgKExArohMQK6DSJAAIIIIAAAkkChMQkrjyFCYl5HKkFAQQQQAABBPwECIl+thtrJiRWQKdJBBBAAAEEEEgSICQmceUpTEjM40gtCCCAAAIIIOAnQEj0s2UmsYItTSKAAAIIIIBAHgFCYrrjXZJelXS3pKckPdtU8aSkZyS9LelhSZc2Vc1MYjo6WyCAAAIIIIBAWQFCYpr3zZLOSHq5CYEWDN9oqjjSBEYLkcclPS3pWlf1hMQ0dEojgAACCCCAQHkBQmK6+WOSvtmExPDf90q6IumiJAuSj0s6L+kqITEdmC0QQAABBBBAoL4AITF9DCwEvijphKT7m2D4SCskXp9t3NvbO71arWxWce21u7ub3jJbIIAAAggggAAChQTuOHZMN12+XKi1Yc18cPSo3rtw4frGOzs7q7imtR+GNdF7q9skfVnS6Wi5Oegxk9ibkYIIIIAAAgggMHUBZhLTRshC4nOSnmiWkm0G0V4WEDknMc2S0ggggAACCCAwYQFCYvrg3CfpzWYzm9+08xLtAhWubk63ZAsEEEAAAQQQmKgAIbHCwHB1cwV0mkQAAQQQQACBJAFCYhJXnsKExDyO1IIAAggggAACfgKERD/bjTUTEiug0yQCCCCAAAIIJAkQEpO48hQmJOZxpBYEEEAAAQQQ8BMgJPrZMpNYwZYmEUAAAQQQQCCPACExj2NSLcwkJnFRGAEEEEAAAQQqCBASK6ATEiug0yQCCCCAAAIIJAkQEpO48hQmJOZxpBYEEEAAAQQQ8BMgJPrZbqyZkFgBnSYRQAABBBBAIEmAkJjElacwITGPI7UggAACCCCAgJ8AIdHPlpnECrY0iQACCCCAAAJ5BAiJeRyTamEmMYmLwggggAACCCBQQYCQWAGdkFgBnSYRQAABBBBAIEmAkJjElacwITGPI7UggAACCCCAgJ8AIdHPdmPNhMQK6DSJAAIIIIAAAkkChMQkrjyFCYl5HKkFAQQQQAABBPwECIl+tswkVrClSQQQQAABBBDII0BIzOOYVAsziUlcFEYAAQQQQACBCgKExArohMQK6DSJAAIIIIAAAkkChMQkrjyFCYl5HKkFAQQQQAABBPwECIl+thtrJiRWQKdJBBBAAAEEEEgSICQmceUpTEjM40gtCCCAAAIIIOAnQEj0s2UmsYItTSKAAAIIIIBAHgFCYprjbZJekfRAtNlTkp6V9KSkZyS9LelhSZc2Vc1MYho6pRFAAAEEEECgvAAhcZz5v5L055I+LelIExbvknRc0tOSrnVVT0gch87WCCCAAAIIIOAvQEgcbvyIpCuSLkqK//tmSY9LOi/pKiFxODBbIoAAAggggEA9AULiMHtbdv6CpBea2cJ2SDwj6WVbct7b2zu9Wq1sVnHttbu7O6xltkIAAQQQQAABBAoI3HHsmG66fLlAS8Ob+ODoUb134cL1CnZ2dlZxbWs/DG8macv7JH2qOT/RNmQmMYmPwggggAACCCAwdQFmEoeN0GOSvhldnGKhkXMSh1myFQIIIIAAAghMUICQmD4om8455OrmdEu2QAABBBBAAIGJChASKwwMVzdXQKdJBBBAAAEEEEgSICQmceUpTEjM40gtCCCAAAIIIOAnQEj0s91YMyGxAjpNIoAAAggggECSACExiStPYUJiHkdqQQABBBBAAAE/AUKiny0ziRVsaRIBBBBAAAEE8ggQEvM4JtXCTGISF4URQAABBBBAoIIAIbECOiGxAjpNIoAAAggggECSACExiStPYUJiHkdqQQABBBBAAAE/AUKin+3GmgmJFdBpEgEEEEAAAQSSBAiJSVx5ChMS8zhSCwIIIIAAAgj4CRAS/WyZSaxgS5MIIIAAAgggkEeAkJjHMakWZhKTuCiMAAIIIIAAAhUElhQS75P0eUl/IulPJd0t6X5JF0u7ExJLi9MeAggggAACCKQKLCUk3izpxQbnR5K+1Pz3BUmPSbqWCjemPCFxjB7bIoAAAggggEAJgaWExNskfbn535OSrjQziiclfVHS1RLYoQ1CYklt2kIAAQQQQACBIQJLCYlhJvFEg/T7kh5owiIziUOOHLZBAAEEEEAAgUMtsJSQaINo5yS+Kelbkv6tpDOSTku6VHqEmUksLU57CCCAAAIIIJAqsJSQaMvNrzSzh22jtyU9XDIsEhJTD1PKI4AAAggggEBpAULiR+JFL2AhJJY+zGkPAQQQQAABBFIFlhISzcUuWHkjuuXNIw2WXcRi/2Y/F7mAhZCYephSHgEEEEAAAQRKCywlJIbl5mdbIdHum2i/syuci13lTEgsfZjTHgIIIIAAAgikCiwlJLavbg5O/635j78reb9EQmLqYUp5BBBAAAEEECgtsJSQaK7ti1fCVc7/qZlNLPbkFUJi6cOc9hBAAAEEEEAgVWBJITHVZlP5uyS92jzWL77gxc5rfEbS1qulCYm5hoJ6EEAAAQQQQMBLYCkhcdMtcGw2MeWCFVu2flzS+eYiF9vWLnyx15FmRtJC5HFJT2963B8h0etwpl4EEEAAAQQQyCVASEwLiRYAH5L0C5Ls6S1hJvHBJizaknU7SN4wVoTEXIcv9SCAAAIIIICAl8BSQmKXnz2BJcz+9fW1kGjnMNoTW+xJLeE2Ora9zSiGkGhPc3nZyuzt7Z1erVY2q7j22t3d7dsm5RBAAAEEEEAAgeICdxw7ppsuXy7ebkqDHxw9qvcu2JzdR6+dnZ1VvP3aDwkVW+Czx/Kl3PrGtvl1SS827YSgaYJxSIyXpG/oEjOJCaNEUQQQQAABBBCoIrCUmcSc5yRenyVsbsIdAiLnJFY5hGkUAQQQQAABBDwElh4SP9c80znFlqubU7QoiwACCCCAAAKzFFhaSLRzBu0JK1VfLDdX5adxBBBAAAEEEOghsJSQGJ648j8HzBz2YEwrQkhM86I0AggggAACCJQXWEpIzHVOYpYRIiRmYaQSBBBAAAEEEHAUICSm3Scxy1AQErMwUgkCCCCAAAIIOAosJSQ6EqZXTUhMN2MLBBBAAAEEECgrcNhD4qZl5qCc+li+LKNDSMzCSCUIIIAAAggg4ChASGS52fHwomoEEEAAAQQQmKvAYQ+J8bg8KemN5tF59vshj+XLMs7MJGZhpBIEEEAAAQQQcBRYSkgMy852j0S7V2IIiRYc7fnLVx2Nb6iakFhSm7YQQAABBBCoK7Av7dftQa/Wn19JJ+OSSwmJ4T6JJ1pM9kToxyRd68WXqRAhMRMk1SCAAAIIIDADAUKi6yB9YyV91lp4991393d2dlZxa2s/HNCN9kUsVS5asf4REl0PFipHAAEEEEBgUgKERNfhyBISXXuYUjkhMUWLsggggAACCMxbgJDoOn6ERFdeKkcAAQQQQAABNwFCohutVUxIdOWlcgQQQAABBBBwEyAkutGOConhgpX/Iem3JZ2WdMm1qz0qZ7m5BxJFEEAAAQQQOCQChETXgRw8k2gXq3y5+d8XCYmug0TlCCCAAAIIINAhQEh0PSxGhcRXJD2woXtVrnBmJtH1YKFyBBBAAAEEJiVASHQdjsEh0XplN8x+hpDoOkBUjgACCCCAAAIbBAiJrofGqJBoPQvLzpyT6DpOVI4AAggggAACbQFCousxMTokht7Fs4pPSbLH9BV/sdxcnJwGEUAAAQQQqCZASHSlzxISu5adqwRFQqLrwULlCCCAQBGBfekPJJ0r0ti4Rm5fSe+Pq4KtxwgQEsfobd12dEgMj+T7qiS7kMVej0j6fPP/V7d2IWMBQmJGTKpCAAEEKgkQEivBz7BZQqLroBESXXmpHAEEEEAgWYCQmEy22A0Iia5DPzokWu9yLTffJ+nNaHfvl3Qxqv9tSQ8fdNNuZhJdDxYqRwABBIoIEBKLMB+KRgiJrsOYJSSGp6+caLp6QdJjkq4ldt2Wqe0Vlq3tvy04HmkuhLlL0nFJT2+qm5CYKE5xBBBAYIIChMQJDspEu0RIdB2YLCExVw/jGckQNB+UdKWZUbQw+rik85I6z3UkJOYaCupBAAEE6gkQEuvZz61lQqLriE0mJFoAPCPp5WY5Ocwq2t7HIfF6mb29vdOr1cpmFddeu7u7rmJUjgACCCDgK/Cxl17Sx89N/+Lm77z1ln5y662+GNR+oMCdOzuTF/rho4/q+ydPrvXzjmPHdNPly5Pu+wdHj+q9CzZn99FrZ2dnFXd47YfCexKWmU2QmcTC+DSHAAII1BRgJrGm/rzaZibRdbwmM5Not9J5TtITzVKyLT2/0ew65yS6HgNUjgACCExLgJA4rfGYcm8Iia6j4xISh94nMb66Ob4ZdzhXkaubXY8FKkcAAQSmIUBInMY4zKEXhETXUZpUSBy9p1y4MpqQChBAAIHqAoTE6kMwmw4QEl2HKltI5NnNruNE5QgggMByBAiJyxnrsXtKSBwreOD2WUJirptpj95TZhJHE1IBAgggUF2AkFh9CGbTAUKi61CNDok8u9l1fKgcAQQQWJ4AIXF5Yz50jwmJQ+V6bUdI7MVEIQQQQACBYgKExGLUs2+IkOg6hKNDovWO5WbXMaJyBBBAYFkChMRljfeYvSUkjtHbum2WkJjr2c1be7utAOckbhPi3xFAAIHpCxASpz9GU+khIdF1JLKERNceplROSEzRoiwCCCAwTQFC4jTHZYq9IiS6jkqWkGg3z/5aq5vfkmS/v+ra/VblhMSS2rSFAAII+AgQEn1cD2OthETXUR0dEsPVzQ8QEl0HisoRQACBxQgQEhcz1KN3lJA4mvCgCrKFxGclXXTtao/KmUnsgUQRBBBAYOIChMSJD9CEukdIdB2M0SHRemfLylcIia4DReUIIIDAYgQIiYsZ6tE7SkgcTVhkJpHlZtdxonIEEEBgOQKExOWM9dg9JSSOFTxw+9EziZyT6Do+VI4AAggsT4CQuLwxH7rHhMShcr22Gx0Se7VSqhDnJJaSph0EEEDAT2CuIXFf+k1Jf+Enk63m+1cTuI4gx94QEnMobqyDkOjKS+UIIIAAAskChMRkstQNCImpYuPKP7+STsZV7EvvSLprXLXuWxMS3YlpAAEEEEAgSYCQmMQ1pDAhcYja8G0IicPt8m3JcnM+S2pCAAEEagkQEt3lCYnuxGsNLC4kbrpgJajwxJWyByCtIYAAAodGgJDoPpSERHdiQuIrktq3viEklj3waA0BBBA4dAKERPchJSS6Ey87JJbl7dkay809oSiGAAIITFiAkOg+OIREd2JCYhCwJ658reXNcnPZA5DWEEAAgUMjQEh0H0pCojsxIdEEuJl22QON1hBAAIFDL0BIdB9iQqI7MSExhMQvSzot6aGG5LykByX9l4FjcJ+kz0t6TNI1SU9KekbS25IelnRpU70sNw8UZzMEEEBgQgKERPfBICS6ExMSTeBmSS9K+mrD8Wbz/0OXm+3Gkq9K+usmJH5G0hFJzzY3nTwu6ekmPN4wxITEskc9rSGAAAIeAoRED9W1OgmJ7sSExCAQZv6ekPScpBOSnmqCXcowWOA8o48eFWR1Whi0Gckrze/s3x+XZDOVV7sqJiSmcFMWAQQQmKYAIdF9XAiJ7sSERBOwcxLDcnNYBm4vF/cdCltWfkPS+5LCjGE7JFqIfNmWnPf29k6vViTu1u4AAB01SURBVCsLkmuv3d3dvu1RDgEEEEBgggIfe+klffzcuQn2bL1L33nrLf3k1luv//KW11/XJ0/YPMm0X9997TX9+J57pt3Jnr27c2enZ8l6xX746KP6/sm1p/LpjmPHdNPly/U61aPlD44e1XsXLlwvubOzs4o3W/thQ32bQqIFPrvquXPGr6OurgtgbDbSBJlJ7DGYFEEAAQQOiwAzie4jyUyiO/FaA4t74ko4F3HTV6ah5ySaqp2XGGYSOSex7IFMawgggEB1AUKi+xAQEt2Jlx0Sbe9tWTlcqNLm/pwkeyLLkFccErm6eYgg2yCAAAIzFiAkug8eIdGdmJBoAl3LzWXpo9a4cKUaPQ0jgAAC2QQIidkoN1VESHQnJiTGAuFehva7IVc2ZxkuQmIWRipBAAEEqgoQEt35CYnuxITEIBAHxPC7KkGRkFj2qKc1BBBAwEOAkOihulYnIdGdmJBoAuGqZLuZdjgH0a5qtiempFzdnGW4CIlZGKkEAQQQqCpASHTnJyS6ExMSCYllDzJaQwABBBYhQEh0H2ZCojsxITEIsNxc9mCjNQQQQOBQCxAS3YeXkOhOTEgMAu17JtrtuR/b9Hxlz3FhudlTl7oRQACBMgKERHdnQqI78bJDYjgX8dnmucpluTe0RkicxDDQCQQQQGCUACFxFF+fjQmJfZTylVncE1cIifkOHmpCAAEEEIgECInuhwMh0Z2YmUS7mvmBDc5jHss3eOiYSRxMx4YIIIDAZAQIie5DQUh0JyYkEhLLHmS0hgACCCxCgJDoPsyERHdiQqKFRM5JLHug0RoCCCBw6AUIie5DTEh0JyYkEhLLHmS0hgACCCxCgJDoPsyERHfiZYfEsrw9W+OcxJ5QFEMAAQQmLEBIdB8cQqI7MSGxLHGP1giJPZAoggACCExcgJDoPkBrIXFfukvSO+6tjm/g+Er6SlzNvrQ/vlr3GhZ3Cxx30SENEBKHqLENAgggMC0BQqL7eBAS3YmZSSxL3KM1QmIPJIoggAACExcgJLoPECHRnZiQWJa4R2uExB5IFEEAAQQmLkBIdB8gQqI7MSGxLHGP1giJPZAoggACCExcgJDoPkCERHdiQmJZ4h6tERJ7IFEEAQQQmLgAIdF9gAiJ7sSExLLEPVojJPZAoggCCCAwcQFCovsAERLdiQmJZYl7tEZI7IFEEQQQQGDiAoRE9wEiJLoTExLLEvdojZDYA4kiCCCAwMQFCInuA0RIdCcmJOYmvk/Sm02lTzXPhbYfn5T0jKS3JT0s6dKmhgmJuYeE+hBAAIHyAoREd3NCojsxITEn8c2SHpd0XtIHks5IelnSJyQdaQKj3RH+uKSnJV3rapyQmHNIqAsBBBCoI0BIdHcnJLoTExK9iC0whpB4r6Qrki5KioPkVUKiFz/1IoAAAnUFCInu/oREd2JCogdxWHIOy82PtEJiCI+X9vb2Tq9WK5tVXHvt7u569Is6EUAAAQQKCXzspZf08XPnCrU2vJnvvPWWfnLrrdcruOX11/XJEyeGV1hoy+++9pp+fM8911u76fJl3XHsWKHWhzfzvbNn9fetz/g7d3aGV1hoyx8++qi+f/LkWmvmbe5Tfn1w9Kjeu3Dhehd3dnZWcX/Xfii8IxYWP9W0yUxiYXyaQwABBGoKMJPors9MojvxWgPPr6S1lLgvvSPJTqOb8usbK+mz1sF33313v2ZIvE3Sc5KekGRLyTaDaC8LiJyTOOVDiL4hgAACmQUIiZlBb6yOkOhOTEjMTRxf3Wzzm481F6hwdXNuaepDoJLAvvS95oK0Sj3o1exXVh9dJDf71/5HFwD+7sR35P2VdHvcR0Ki+4gREt2JCYlliXu0xtXNPZAogkBFAUJiWXxCorv37Svp/dDKvvSbkv7CvdXxDRASxxum1MByc4qWV1lCopcs9SKQR4CQmMexby2ExL5Sg8sREgfTDdrw+Er6SmvWeX9QTWU3IiSW9e5ujZA4hVGgDwhsFiAklj06CInu3oREd+K1BgiJZb0nc+FKlt0mJGZhpBIE3AQIiW60nRUTEt29CYnuxITEssRrrRESK+LTNAKLEyAklh1yQqK7NyHRnZiQWJaYkFjRm6YRWLYAIbHs+BMS3b0Jie7EhMSyxITEit40jcCyBQiJZcefkOjuTUh0JyYkliUmJFb0pmkEli1ASCw7/oREd29CojsxIbEsMSGxojdNI7BsAUJi2fEnJLp7ExLdiQmJZYkJiRW9aRqBZQsQEsuOPyHR3ZuQ6E5MSCxLTEis6E3TCCxbgJBYdvwJie7ehER3YkJiWWJCYkVvmkZg2QKExLLjT0h09yYkuhMTEssSExIretM0AssWICSWHX9Cors3IdGdmJBYlpiQWNGbphFYtgAhsez4ExLdvQmJ7sSExLLEhMSK3jSNwLIF5hoS96U3Jd038dG7uJLuj/tISHQfMUKiOzEhsSwxIbGiN00jsGwBQqLr+BMSXXk7KyckljU/vpK+0voitF+2C4Nae34lnWz1+x1Jdw2qrdxGPLu5nDUtIYAAIdH1GCAkuvISEsvz3tAiIbHsIBASy3rTGgLLFiAkuo4/IdGVl5BYnpeQWNmckFh5AGgegUUJEBJdh5uQ6MpLSCzPS0isbE5IrDwANI/AogQIia7DTUh05SUkluclJFY2JyRWHgCaR2BRAoRE1+EmJLryEhLL8xISK5sTEisPAM0jsCgBQqLrcBMSXXkJieV5CYmVzQmJlQeA5hFYlAAh0XW4CYmuvITE8ryExMrmkwqJdqNau2GtvS5IekzSNUlPSnpG0tuSHpZ0aRPa2bNn90+dOrWqjErzCCCwQYCQ6HpoEBJdeQmJ5XkJiZXNJxMSb5P0nKQnJF2V9EgDc0XSEUnPNjedPC7p6SY83mBHSKx8ONE8AlsECImuhwgh0ZWXkFiel5BY2XwyIbHtYLOKn4qC4kVJN0t6XNL5JkgSEisfPTSPQKoAITFVLKk8ITGJK0thnriShbF3JdxMuzdVloKTDIkWED/fLDc/KMlmE0NIPCPpZVty3tvbO71arWxWce21u7ubRYZKEEAgv8Av3XuvfuoHP8hfccYa/353V987e3atxp9/6CH99Le/nbGV/FX9+J579N3XXlur+PZTp/SzX/96/sYy1viTW2/Vd956a63Gj730kj5+7lzGVnyqsn5b/8Prltdf1ydPnPBpLGOtdpzY8RJeN12+rDuOHcvYgk9V9r6092f8unNnx6exjLX+8NFH9f2Ta0/l+9Db3Kf8+uDoUb13wc7+++i1s7OzdjpfjXP7bJn5zmZ52fpkP8chkZnEKR9R9A2BLQLMJLoeIswkuvJ2Vs5MYllzZhLLek9qJtEuULFY/UpkYLOKnJNY9qCgNQTcBAiJbrRWMSHRlZeQWJ73hhYJiWUHYTIh8S5Jr0q6O9r/zzWBkaubyx4UtIaAmwAh0Y2WkOhKu7FyZhLLuhMSy3pPJiRm2W2ubs7CSCUIuAkQEt1oCYmutITEOrzMJFZ2JyRWHgCaR2BRAoRE1+FmudmVt7NyZhLLmjOTWNabkFjWm9YQWLYAIdF1/AmJrryExPK8zCRWNickVh4AmkdgUQKERNfhJiS68hISy/MSEiubExIrDwDNI7AoAUKi63ATEl15CYnleQmJlc0JiZUHgOYRSBbYlz4h6XvJG5bf4ORKej5ulpDoOgiERFdeQmJ5XkJiZXNCYuUBoHkEkgUIiclkqRt8ZSXZc+Kvv/alNyXZfVun/CIklh8dLlwpa86FK2W9CYllvWkNgfEChMTxhltqICS6E6818P5Kur0Vyv9A0vSfyycREsseK4TEst6ExLLetIbAeAFC4nhDQqK7YUoDhMQUrTxl719JF0NV+5I90OKdPFW71kJIdOW9oXJCYllvWkNgvAAhcbwhIdHdMKUBQmKKVp6yhMQ8jn1reX4lnWzNllsot3A+5RchccqjQ98Q6BIgJLofFyw3uxOvNUBILOttrRESy5oTEst6d7fGY/mmMAr0wVuAkOgtLEKiOzEhsSzxDa0REssOACGxrDchcQre9KGOACHR3Z2Q6E5MSCxLTEis7E1IrDwAHzbPTOIURoE+eAsQEr2FmUl0F15vgOXmwuAsNxcHJyQWJ+9okJA4hVGgD94ChERvYUKiuzAhsTAxM4mVwQmJlQeAmcQpDAB9KCJASHRnZrnZnXitAWYSy3pba5yTWNackFjWu7s1ZhKnMAr0wVuAkOgtzEyiuzAziYWJmUmsDE5IrDwAzCROYQDoQxEBQqI7MzOJ7sTMJJYlJiRW9iYkVh4AQuIUBoA+FBEgJLozExLdiQmJZYkJiZW9CYmVB4CQOIUBoA9FBAiJ7syERHdiQmJZYkJiZW9CYuUBICROYQDoQxEBQqI7MyHRnZiQWJaYkFjZm5BYeQAIiVMYAPpQRICQ6M5MSHQnJiSWJSYkVvYmJFYeAELiFAaAPhQRICS6MxMS3YkJiWWJCYmVvQmJGQfgSUlvSLrY1Gk/PyPpbUkPS7q0qS1ugZNxFKhqsgKERPehISS6ExMSyxITEit7ExIzDMDNkl6UdMJu9NmExPskHZH0rKS7JB2X9LSka13tERIzjAJVTF6AkOg+RIREd2JCYlliQmJlb0JihgH4p034eyiaSXxE0pUmMFqIfFzSeUlXCYkZxKlilgKERPdhIyS6ExMSyxITEit7ExIzDkC83NwOiWckvWxLznt7e6dXq5XNKq69dnd3M3aFqhCYnsBP/eAH+qV7751ex1o9+v7Jk/rho4+u/db6bf2f8uvvd3f1vbNn17r48w89pJ/+9ren3G39+J579N3XXlvr4+2nTulnv/71Sff7J7fequ+89dZaHz/20kv6+Llzk+63dc76bf0Pr1tef12fPGGLYdN+2XFix0t43XT5su44dmzanZY+fF/a+zN+3bmzM/l+299B+3sYv8zb3Kf8+uDoUb134cL1Lu7s7Kzi/q79UHBHDgqJzCQWHAiamqYAM4nu48JMojvxWgM8u7mst7XGs5vLmjOTmNE7Domck5gRlqoOhwAh0X0cCYnuxITEssQ3tEZILDsAhMSM3lzdnBGTqg6fACHRfUwJie7EhMSyxITEyt6ExMoD8GHzXN08hVGgD94ChERvYRES3YkJiWWJCYmVvQmJlQeAkDiFAaAPRQQIie7MhER3YkJiWWJCYmVvQmLlASAkTmEA6EMRAUKiOzMh0Z2YkFiWmJBY2ZuQWHkACIlTGAD6UESAkOjOTEh0JyYkliUmJFb2JiRWHgBC4hQGgD4UESAkujMTEt2JCYlliQmJlb0JiZUHgJA4hQGYWR/2JbvF0psz6PZnV9I3Qj8Jie4jRkh0JyYkliUmJFb2JiRWHgBC4hQGYGZ9ICS6D9jJlfR83Mq+9D1Jn3BveVwDhMRxfqlbczPtVLHx5blP4njDlBoIiSlaXmW5BY6X7OGsl5DoPq6ERHfitQYurqT7W6HcHmP6u2W7kdwaITGZbPQGhMTRhEkVEBKTuJwKExKdYA9ptYRE94ElJLoTExLLEt/Q2u0r6f3w233pNyX9ReU+9WmekNhHKV8ZQmI+y+E1ERKH2y1xS0Ki+6gTEt2JCYlliQmJlb2Pr6SvtGbL9yv3qU/zhMQ+St5lCInewoerfkKi+3gSEt2JCYlliQmJlb0JiWUH4Bsr6bPW5Lvvvru/s7Oziptf+6Fsv4a1Rkgc5jZ2q/2Pznmyc5+m/vr0SroUOklIdB8uQqI7MSGxLDEhsbI3IbHsABASy3ofztYIie7jyi1w3InXGuDq5rLeXLhS1tta45zEsuYsN5f17m6NmcQ6o0BIdHcnJLoTExLLEq+1Rkgsj09ILGtOSCzrTUicgne0bMtys++AEBJ9fdu1M5NY1puQWNabmcTy3oTE8uY3tshMYp1RYCbR3Z2Q6E7MTGJZYmYSK3oTEsvjExLLmxMSp2BufSAkuo8EIdGdmJBYlpiQWNGbkFgen5BY3nxzSNz/6GamdlPTKb8uraRPT7mDfftGSOwrNbgcIXEw3aANWW4exDZ4I5abB9MN3pBzEgfTDdqQkDiILfNGYbmZkJgZdkt1hER3b0KiOzEziWWJmUms6M1MYnl8QmJ5c2YSp2BufSAkuo8EIdGdmJBYlpiQWNGbkFgen5BY3vzwhcR96ZykP5iC5UF9WElrN1onJLqPGCHRnZiQWJaYkFjRm5BYHp+QWN6ckFjLnJBYXJ6QWJaccxLLenNOYllvQmJ5b0JieXNCYi1zQmJxeUJiWXJCYllvQmJZb0JieW9CoqP5k5KekfS2pIcVPXu33ebcL1xhudnxKPqoap7d7E681gDPbi7rfXEl3R83uf/RM9XtZvdTfhESy48OVzeXNSckOnnfJ+mIpGcl3SXpuKSnJV3rao+Q6DQKrWqZSSzjHLXCTGJZcmYSy3oTEst6M5NY3puQ6GT+iKQrki5KulnS45LOS7pKSHQS71EtIbEHUt4ihMS8nttqIyRuE8r774TEvJ59amMmsY9SvjKExHyWazW1Q+IZfbR8cmlvb+/0arWyWcXrr5/5mZ/RP/zDPzh1hWoRQAABBBBAAIHlCfzyL/+yfuM3fmPtziZrP1QiSZpJ9OrjXJ8JTb+9jojN9WJe1hxvvPsIcJz0UcpbBvO8nttqq+E9hZCYdE7iNsSh/14Df2hf4+3odw7FtDowT/MaWxrvsYJp2+Od5jW29Fy9bb/n2nf63f+onUJItN72vrq5/66lleSgSfMaW3qu3vxhHDvy6dvP9Vih3+ljPWYLvMfoDdsW82FuQ7eq4T2VkDjULNt2NfBzdJ5+51BMqwPzNK+xpfEeK5i2Pd5pXmNLz9WbL8xjRz59+xrHCiGxGSe7SOYP//APT6cPW90t6Hd5f8zLmuONdx8BjpM+SnnLYJ7Xc1ttNbwJidtGhX9HAAEEEEAAAQQWKEBIXOCgs8sIIIDAIRWw89vfaO67e0h3kd1CoJzA0kOiXVn9eUlPSHpO0ok+jwYsNzydLd0m6cuSbGn8UuW+pDZv3m9KekrSZUlfm4G37aOZvyLpgWiHL0h6bNOTgVJhnMp39ftbkuy2U503q3fqx5KqDce47bM9Pq/XQwImABT6bcf1jyR9aQbvza7jO1BO+Ti3fn9B0guSbon+tky5z8GVz8yyb9bqn5lLDon2dJdw4+57Jd3Z99GAZY+RG1qzPzAnJd0h6X81fa7cpV7Nt71/pQlZv7jtUYy9avcrFPfbQrkFw29K+kT0OEm/1ofXbP1+UdJXW7Mq4Y/8VAPuXD/4baTiY+VvI/+/2fYkqeHDnGXL+ElXvyZpLu9N23n7whP+dtvPc5hJjEOiPWHMvjDbl9Cpvzf5zMzydutdySQ+M5ccEuM36oMpjwbsPcQ+BeN+fyaambNnX0/51e73p5o/jFsfxVh5p+J+2/PE7Q+59f3PJ/7B3+53YJy6t/Vz6zPcKx8Tm5pvm9vPtkLxR5J+56DHjVben7m+N+PZrSPNF+a5hcR/3XzptC+gU39v8plZ9o06ifflkkNi+NZp3+LekvTrzTf/qX9AdX34hynpKS9XTOJb0YD3eHtGzj6E7Jj5y2jJyMLj1F5znUkMjvGTmKZmu6k/7VnnEHht1taWcM9NdJm/q99zC+thFs6cvzHxcxLDbLmdimB/S640/Z36Zw+fmWX/Ek3iM3PpITF8kNq5iOE15aBlfdw0Q1T28B3WWvXzK4Z1+8OZrVcl3S3JztkK57C2l3IHVu+2GeckutFurNiOFTtf+ItRIOz6XfmeHdxiu49zPPc5vE9/b+IhMZ4BDedon5/JueZ8ZpZ951b/zFx6SCw73LSGAAIIIIAAAgjMRGDpIXGuMy30u+wbbK7eZZXytDbnC1fyCFALAgggMBGBJYfEuZ6zRb/Lvnnm6j3nsDWHc7O6jsK5mtPvsn9T8Ma7j8AkjpMlh8S5Xv1Jv/u8vfKVmau3Ccw1bFnf53jhypzN53qs0O98f+v61IR3H6V8Zap7LzkkznWGiH7newP2qWmu3mHf5hq2+ozNVMvM1Zx+lz2i8Ma7j0DV42TJIdEGZ67nmtHvPm+tfGXm6p1PgJoQQAABBBYnQEi88XFrU78FDuG2/Nt0riGRfnOs9BXgWOkrlacc3nkc+9aCd1+pVrklh8S5LiPS74EH+8DN8B4IN3CzuXrb7s617/R74ME6cDO8B8IN3AzvgXC22ZJD4lwvSKDfIw74AZviPQBtxCZz9Q4z/F+Q9IKk+Ck8c3rcGv0ecfD23HSuxzj97jnAmYpNwnvJIZFvF5mO5J7V4N0TKlMxvDNBJlSDeQJWhqJ4Z0BMqALvBKwMRSfhveSQGL75vyLpgWhAOScxw9G9oQrOC/Gz7aoZ77Le/E3Bu68A782+UnnK4T3QcekhcSAbmyGAgKNAeF6pNXF/8xzeqS/ZOnJQNQIIIFBHYOkhca4fRvS77PsF73LeFgbPSHpZ0t9KelHSVyX9jaTHJZ2XdLVcd5Jb4lhJJhu1Ad6j+JI3xjuZbNQG1b2XHBLn+mFEv0e955I3xjuZbNQG7ZO17efnJP2RpN+ZeEjkWBk19Mkb451MNmoDvEfxJW88Ce8lh8S5fhjR7+T32qgN8B7Fl7xx/IfxUrO1PZrqMUk/knRuwjOJHCvJwz1qA7xH8SVvjHcy2agNJuG95JA41w8j+j3qfZe8Md7JZKM3sFB4WtIXo0DY9bvRDWWugGMlM+iW6vDGu48Ax0kfpQ1llhwSjWSuH0b0e8RBP2BTvAegLXQTjpWyA4833n0EOE76KHWUWXpIHMjGZggggAACCCCAwOEWICQe7vFl7xBAAAEEEEAAgUEChMRBbGyEAAIIIIAAAggcbgFC4uEeX/YOAQQQQAABBBAYJEBIHMTGRggggAACCCCAwOEWICQe7vFl7xA47AJdz2S1fX5b0sOSHpL0C819Fq8NwHhS0m81ddl9G8MTEMLjAq3KRyR9Lar7c5LsmfD2su2fabUbtm1vF/c73CMy1BH3wW7pYU+i+VTT9pSfQDOAnE0QQGAqAoTEqYwE/UAAgbECFsjagbDrdynthJB3oQman5H0ZvRMaQt6X4pCpN1q41VJf9wExXb79rMFTdvu1yR9vkfQC3X+maRnNwTVlH2iLAIIINBLgJDYi4lCCCAwA4FNIdFm7n5O0t2SvhWFshC+2r+PdzWeCbR67BVC4jtNELRnS4eZwzZTu08WEP9zEyrv7RkSrc4w6/jPm5lN+509hcZmR+M+hlnMMNt4ounQU62AaUHWZlrjGdEZDDFdRACBkgKExJLatIUAAp4Cm0JiWKq1tsMs3182wc5m5i42QatrWdrq/CdNp/9Oks3m/VUTrt5v6vu9po6ufds2kxgvU9v2YcayvTQeh76wlG5L0hYef6UJjL8Y9ceWosPvbfYzBNNPNCE3XhL3HBPqRgCBGQsQEmc8eHQdAQTWBLYtN98SzfxdacJSXEE8yxh+H+oM4TCegesbEg86J7HPcnPoS3spuz1bGMqFABjPlIZgGUIiM4i8eRBAYKsAIXErEQUQQGAmAkNC4rawFOp8QtJzksLyrW03ZLk5prRZwBwh0eoMS89xuA0zqBYM2zOJ2/Z7JkNONxFAwFOAkOipS90IIFBSICUkhuVmW2p+obla+P805+3FfY7rDMu5dg5jfIVyyoUrOUOi1RVfOBPC4L+Q9G+ahiw8PhhdXMNMYskjkrYQmLkAIXHmA0j3EUDgukBKSLQLTcLtbKyCrqVm+33XOYW2fJxyC5xNt+DpugWOtblplq+93Gxl20vOYak53jc7h9Iu3LFzJ+0VX53N4YMAAghsFCAkcnAggAACCCCAAAII3CBASOSgQAABBBBAAAEEECAkcgwggAACCCCAAAIIbBdgJnG7ESUQQAABBBBAAIHFCRASFzfk7DACCCCAAAIIILBdgJC43YgSCCCAAAIIIIDA4gQIiYsbcnYYAQQQQAABBBDYLvD/ANFoApZuVK9AAAAAAElFTkSuQmCC"
     },
     "metadata": {
      "jupyter-vega": "#ae14afe0-6fd0-4bf4-8284-afa26bd8d708"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "##Graph after Cleaning\n",
    "upto_chart = alt.Chart(upto_2018, \n",
    "          title=\"Rapid Review Outcome Analysis: All Drugs upto 2018\").mark_bar(color='red').encode(\n",
    "    alt.X('ncpe_year:N', \n",
    "          axis=alt.Axis(title='The NCPE Year'),\n",
    "         ),\n",
    "    alt.Y('count(drug_name)',\n",
    "          axis=alt.Axis(title='Total no. of drugs'),\n",
    "         ),\n",
    ").properties(\n",
    "    width=600,\n",
    "    height=300,\n",
    ")\n",
    "upto_chart"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "###  Visualisation 2: \n",
    "### Which company submitted the highest number of applications for ncpe appproval?\n",
    "### Reason : \n",
    "### The graph clearly shows that  Novartis is the company that has given the maximum count for applications for ncpe appproval. On analysis with the help of web, I found that , Novartis is one of Ireland’s leading employers in the healthcare industry. It is one of the first pharmaceutical companies in Ireland from the 1950’s. Novartis mainly focuses its business on three divisions: pharmaceuticals, eye care and generics in which it is leading in the pharmaceuticals field. At the same time, Novartis is expanding its presence in the emerging market of Asia, Africa and Latin America, where there is a fast-growing demand for access to high-quality medicines and healthcare."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"layer\": [{\"mark\": {\"type\": \"rule\", \"color\": \"#ff1493\"}, \"encoding\": {\"x\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"drug_name\"}, \"y\": {\"type\": \"nominal\", \"field\": \"company\", \"sort\": {\"field\": \"drug_name\", \"op\": \"count\", \"order\": \"descending\"}}}, \"title\": \"Ncpe Appproval count(Companies)\"}, {\"mark\": {\"type\": \"text\", \"align\": \"left\", \"baseline\": \"middle\", \"color\": \"#ff1493\", \"dx\": 3}, \"encoding\": {\"text\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"drug_name\"}, \"x\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"drug_name\"}, \"y\": {\"type\": \"nominal\", \"field\": \"company\", \"sort\": {\"field\": \"drug_name\", \"op\": \"count\", \"order\": \"descending\"}}}, \"title\": \"Ncpe Appproval count(Companies)\"}], \"data\": {\"name\": \"data-3d759ccdd22257fc2c40e3e6d3ddc040\"}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-3d759ccdd22257fc2c40e3e6d3ddc040\": [{\"last_scrape\": \"2018-12-13T16:24:32\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Abatacept \", \"trade_name\": \"Orencia\", \"indication\": \"Subcutaneous Abatacept -alpha inhibitor.\", \"ncpe_year\": 2015, \"eu_market\": \"2007-05-21T00:00:00\", \"company\": \"\", \"orphan\": 0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:36\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mHSPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:41\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mCRPC post ADT\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate  in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:46\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate  for mCRPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \\u00ae  who have received prior docetaxel-based chemotherapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:49\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac \", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac  is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:56\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide \", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease \", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:00\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate \", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\\u00ae Genuair\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:37\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab \", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab  in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:40\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric \", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric  a xanthine oxidase inhibitor for the treatment of gout.\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:45\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib \", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:49\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:52\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid  that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:58\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine \", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine  for the treatment of major depressive disorder.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:26:06\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib \", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib  whose disease has progressed following treatment with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:12\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab \", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab  with active disease defined by clinical or imaging features\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:14\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab \", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\\u00ae is indicated for both primary hypercholesterolaemia  or mixed dyslipidaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:16\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin \", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:21\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan \", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan  in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:23\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine \", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome .  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:29\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine \", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\\u00ae is indicated for the induction and maintenance of remission in acute leukaemia of adults.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:35\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban , and prevention of recurrent DVT and\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:39\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:45\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for moderate to severe chronic plaque psoriasis.\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:47\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for psoriatic arthritis.\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist , alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:49\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole \", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole  for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:55\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine \", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine  for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:00\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab \", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK\\u2011positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:05\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil \", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil  is indicated for the treatment of erectile dysfunction in adult men.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:06\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab \", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab  is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:08\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg \", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:14\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.\\n \", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel \", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:23\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib \", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma  after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:24\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment not Recommended.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate \", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:25\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan \", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:27\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib \", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib  is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:33\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene \", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene  for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:36\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline \", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline  is indicated for use as part of an appropriate combination regimen for pulmonary MDR\\u2011TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:37\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept \", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid -2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:40\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab \", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab \", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:46\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine \", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine \", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:50\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"Full pharamcoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab \", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab  is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting \\u03b2-agonists.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:56\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab \", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab  in adults at high risk for recurrence of CDI.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:58\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\\u00ae for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:01\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine \", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine  and urticaria.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:05\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo\\u00ae at this point in time.\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab \", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\\u00ae is indicated for the treatment of adults with Philadelphia chromosome negative  relapsed or refractory\\nB-precursor acute lymphoblastic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:11\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir \", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:28:16\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan \", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan  III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:18\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"At the current price a full HTA would be required.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib \", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase  and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:19\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  after at least 1 prior systemic therapy. This is a license extension.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:23\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:29\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\\n \", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib \", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib  is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:30\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel \", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel  is indicated for the treatment of facial erythema of rosacea in adult patients.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:36\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam \", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam  with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:40\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab \", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab  is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:44\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"Full HTA recommended\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder \", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\\u00ae \\u2013 Mannitol dry powder for inhalation for the treatment of cystic fibrosis \", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:46\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:53\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor \", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor \", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:55\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib -targeted therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:58\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib  is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:01\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium \", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\\u00ae is indicated for the cutaneous treatment of external genital and perianal warts  in immunocompetent patients from the age of 18 years.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:04\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin \", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin  is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:09\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch \", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch  for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:11\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel \", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel  for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:16\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib \", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\\u00ae  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:22\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab \", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab  for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:25\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline \", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:29\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam \", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam  and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:34\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended at the Submitted Price.\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam \", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\\u00ae is indicated for the treatment of complicated urinary tract infections  in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:36\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib \", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\\u00ae is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:40\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa \", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:44\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol \", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol  for the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:29:49\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops \", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\\u00ae is indicated for the treatment of severe keratitis in adult patients with dry eye disease , which has not improved despite treatment with tear substitutes.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:54\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine \", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine  as defined by clinical or imaging features\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:58\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% \", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025%  is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:02\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib \", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\\u00ae is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:03\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam \", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam \", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:06\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium \", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium  aged 6 years and older.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:17\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum \", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum  is indicated for the treatment of Dupuytren\\u2019s contracture in adult patients with a palpable cord.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:20\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa \", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa .\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:24\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for first line ALK+ NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:29\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for ROS1 NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:34\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib \", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase \", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:37\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release \", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\\u00ae for the treatment of proven nephropathic cystinosis.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:43\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the treatment of DVT and PE\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:51\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate  \\u2013 for the prevention of stroke and systematic embolisom in atrial fibrillation\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate  for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:57\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:59\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib \", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib  is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:02\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir \", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir . \", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:08\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab \", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:12\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin \", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin  in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:18\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin \", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin  is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\\nMonotherapy\\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\\nAdd-on combination therapy\\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:21\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab \", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:25\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide \", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide  is indicated for the treatment of HIV-1 in adults and adolescents.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:30\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat \", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:35\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel \", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel  for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn\\u2019s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:40\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine \", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine  is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:44\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide \", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide  therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:47\", \"rr_start\": \"2009-10-15T00:00:00\", \"rr_end\": \"2009-10-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-10-15\", \"rr_multiple\": 0, \"drug_name\": \"Degarelix \", \"trade_name\": \"Firmagon\", \"indication\": \"Cost-effectiveness of Degarelix \", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-17T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2009-10-15T00:00:00\", \"latest\": \"2009-10-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:52\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex\\u00ae compared with the current standard of care.\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD \", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:59\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol \", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:04\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab  for the Prevention of Osteoporotic Fractures in Postmenopausal Women.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:08\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab  for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:12\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant \", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\\u00ae in the treatment of macular oedema following Retinal Vein Occlusion.\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:15\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine \", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine  for the treatemnt of ICU adult patients requiring light to moderate sedation.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:21\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest \", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest  for the Treatment of Endometriosis\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:24\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate  for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:26\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:29\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"Following assessment of the applicant\\u2019s submission, the NCPE recommends that dinutuximab beta (Qarziba\\u00ae) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta \", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients \\u2265 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:34\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine \", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:36\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir \", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir  infected adults and adolescents above 12 years of age.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:39\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone \", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:42\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide \", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:46\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab \", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab  is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:53\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab \", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab  in the Irish healthcare setting.\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:55\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban \", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:00\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir \", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir .\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:03\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat \", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat  is indicated for the long-term treatment of adult patients with Gaucher disease type 1.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:05\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa \", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa  in patients of all ages.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:12\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag  for Thrombocytopenia in HCV\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag  infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:17\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag \", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\\u00ae for the treatment adult patients with acquired severe aplastic anaemia  who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:23\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag  for ITP\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag .\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:26\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide \", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\\u00ae is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus \\u2013 1 .\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:32\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin \", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:37\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate \", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\\u00ae is indicated in combination with safer sex practices for pre\\u2011exposure prophylaxis  to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:43\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil \", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil  for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:48\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\\u00ae  type 1.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:52\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide  on or after chemotherapy\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide  whose disease has progressed on or after docetaxel therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:59\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol \", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\\u00ae is indicated for the treatment of pulmonary arterial hypertension  in patients with WHO FC III\\u2013IV symptoms to improve exercise capacity.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:03\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab \", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab   is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig\\u00ae.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:07\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin \", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin  for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:09\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine \", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine  for the treatment of Epilepsy\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:12\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept \", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\\u00ae is a biosimilar of the TNF-\\u03b1 inhibitor Etanercept  for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:15\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide \", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide  on haemodialysis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:21\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin \", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\\u00ae  for uncomplicated malaria caused by the Plasmodium falciparum parasite\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:24\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive , in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:26\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus : adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:29\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus  who require therapeutic intervention but are not amenable to surgery\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:36\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab \", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab  is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:34:41\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide \", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide  for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:44\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine \", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine .\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:48\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol \", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia  in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:34:51\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin \", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:56\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod \", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod  for the treatment of highly active relapsing-remitting multiple sclerosis.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:01\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide \", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\\u00ae is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema  considered insufficiently responsive to available therapies.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:05\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy\\u2122 Ellipta\\u2122 be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero \", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\\u2122 Ellipta\\u2122 which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:09\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\\n\", \"rr_dates\": \"2017-07-25, 2017-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Follitropin delta \", \"trade_name\": \"Rekovelle\", \"indication\": \"Follitropin delta  cycle\", \"ncpe_year\": 2019, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Ferring\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2019-02-01T00:00:00\", \"ta_list\": \"Anovulation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:12\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib \", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib  for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:15\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin \", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin  which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:19\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir \", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir  infection in adults \\u2013 pangenotypic GT1-6.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:25\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate \", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate  for the treatment of oestoarthritis in the Irish Healthcare setting.\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:32\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti\\u00ae) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate \", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:38\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:40\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide  in children and adolescents aged 3 years and older with chronic neurological disorders\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:47\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab  for UC\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:54\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab \", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab  in the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:56\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract \", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract  with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:00\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride \", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\\u00ae is indicated for the treatment of attention deficit hyperactivity disorder  in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:02\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab \", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab  for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI .\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:14\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\\u00ae is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency  as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:17\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 \", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10  for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:22\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  \", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone  for the treatment of adrenal insufficiency in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:27\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide \", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide  is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:32\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for previously untreated CLL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib . This indication is an extension to the original licence in the relapsed/refractory setting.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:36\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for MCL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:40\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant \", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant .\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:43\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab \", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa  when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:50\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone \", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\\u00ae is indicated for the treatment of visual impairment in adolescent and adult patients with Leber\\u2019s Hereditary Optic Neuropathy .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:56\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib \", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia  who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:59\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% \", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75% of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:01\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A \", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A  and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:04\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol \", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol  for the treatment of COPD.\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:07\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab \", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\\u00ae is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn\\u2019s disease, Paediatric Crohn\\u2019s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:37:09\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin \", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:16\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:21\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:25\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec \", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:30\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.  \", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide \", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus  or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:36\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine \", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\\u00ae is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:40\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 \", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\\u00ae is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:43\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab  melanoma in adult patients who have received prior therapy.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:49\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\\u00ae is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:52\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Monover\", \"indication\": \"Monover\\u00ae is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:02\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 \", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:07\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of invasive aspergillosis.\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated for the treatment of invasive aspergillosis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:09\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended. \", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of mucormycosis\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:15\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor \", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:21\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmaoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for patients with CF 2 years +\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating  mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:24\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for the treatment of CF patients with the R117H mutation.\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:29\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib \", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:34\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab  for psoriatic arthritis\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab  therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:37\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab \", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\\u00ae is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:39\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate \", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate  for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:44\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended at the submitted price.\\n \", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \\u00ae is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:50\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib \", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib  for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:38:56\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir \", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir   in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:05\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide \", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\\u00ae for the treatment of adult patients with previously untreated multiple myelomas .\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib -targeted therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:11\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib  for HCC\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib  which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:15\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated , refractory to radioactive iodine.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:20\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad \", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad  for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:25\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir \", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus .\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:28\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel \", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\\u2019s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa\\u00ae administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:34\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price. \", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin \", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin  is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:39\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 \", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\\u00ae   which is indicated for contraception for up to 5 years.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:44\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS \", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS  for contraception for up to three years.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:46\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters \", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection .\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:51\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide \", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide  in adults.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:54\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin \", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin  for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:57\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim \", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\\u00ae is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:00\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"A Full Pharmacoeconomic Assessment is recommended\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine \", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine  or AML with myelodysplasia-related changes.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:06\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan \", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan  is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment \", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:13\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide \", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\\u00ae  is indicated for treatment of adults with type 2 diabetes mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:17\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide \", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide  for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:19\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide \", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\\u00ae is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:22\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam \", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam  for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:24\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension \", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:30\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder \", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:34\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor \", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\\u00ae is indicated for the treatment of cystic fibrosis  in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:36\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium \", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium  in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:41\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan \", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension  II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:43\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin \", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin  For The Short-Term Treatment of Primary Insomnia.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:40:45\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab \", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab  is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:51\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane \", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\\u00ae is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:56\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for AML\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin  who are FLT3 mutation positive.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:02\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for ASM\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:04\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide \", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide  for the treatment of osteosarcoma.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:06\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat \", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:13\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron \", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder  syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:15\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel \", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel  in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:18\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene \", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene  is indicated for the reduction of alcohol consumption in those aged \\u226518 years with alcohol dependence, who do not require immediate detoxification.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel \", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:26\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion \", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion  in the presence of one or more weight-related co-morbidities.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:30\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab \", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab  for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:35\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin \", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin  versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:38\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac \", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac  for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:41\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron \", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\\u00ae is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:44\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  newly diagnosed CML\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib  for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:51\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  CML resistant/intolerant to imatinib\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib  for the treatment of chronic phase CML.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:53\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:56\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib  indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:00\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib \", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:06\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for Melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:13\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for non-squamous NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:20\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:26\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:31\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended \", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for advanced renal cell carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:33\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for classical Hodgkin Lymphoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:36\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for head and neck cancer\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  in adults progressing on or after platinum-based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:41\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for urothelial carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:46\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:42:51\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab \", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\\u00ae plus Yervoy\\u00ae Is indicated for the treatment of advanced melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:42:56\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol \", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol  oral contraception\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:02\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin \", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen \", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:07\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid \", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis  in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:10\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Follicular Lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:15\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for previously untreated advanced follicular lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:21\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Lymphocytic Leukaemia\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:24\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for PPMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:30\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for RMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  with active disease defined by clinical or imaging features.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:34\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin \", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin , including when associated with macular hole of diameter less than or equal to 400 microns.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:39\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab  who have not received prior therapy and who are not eligible for fludarabine-based therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:46\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:52\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol \", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:57\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib \", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\\u00ae is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated  to platinum-based chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:03\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib  for platinum sensitive relapsed ovarian cancer\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:08\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab  for the treatment of severe allergic asthma\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function  as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:14\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended for this indication.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab \", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab  patients with inadequate response to H1-antihistamine treatment. \", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:19\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone \", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet  for severe pain, which can be adequately managed only with opioid analgesics.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:22\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib  for the first-line treatment of metastatic NSCLC\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:39\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib \", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:40\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\\n \\n \", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin \", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin  10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:44:43\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:47\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib \", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:53\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate \", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate  is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:57\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat \", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:01\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir \", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\\u00ae is indicated in combination with other medicinal products for the treatment of chronic hepatitis c  in adults. Exviera\\u00ae must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera\\u00ae combination therapy are viekirax\\u00ae or viekirax\\u00ae   and ribavirin.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:07\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer \", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer  is indicated for the treatment of hyperkalaemia in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:10\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  1L NSCLC with chemotherapy\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:15\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Adjuvant melanoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma  as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:18\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Classical Hodgkin Lymphoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab , or who are transplant-ineligible and have failed BV.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:23\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of locally advanced or metastatic non-small cell lung carcinoma  with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:28\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:31\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:36\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab  for Urothelial  Carcinoma 1L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:38\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Urothelial Carcinoma 2L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:45\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:50\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel \", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel  indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. \", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:45:56\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab   for Adjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:02\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  in neoadjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta  is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:04\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab \", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use  in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:09\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride \", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\\u00ae is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:46:11\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone \", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency  for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:14\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin \", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined  dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:20\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride \", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride  is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone \", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\\u00ae is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas .\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:27\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:30\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide \", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:32\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib \", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib  patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:38\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel \", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel  for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:46\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of neuropathic pain\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\\u00ae is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:52\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder.\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:58\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride \", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride  for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:00\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 \", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223  is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:03\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab \", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction  adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:06\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine \", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine \", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:13\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson \", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson \", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:17\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for GIST\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI\\u2019s.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:23\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab \", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\\u00ae is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:27\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine \", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine \", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:29\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib \", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib  negative locally advanced or metastatic breast cancer as initial endocrine based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:35\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin \", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin  is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients \\u2265 18 years of age. \", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:38\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for mCRC\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:42\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1  infection in antiretroviral treatment-naive adult patients with a viral load \\u2264 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:45\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Reimbursement Not Recommeded\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\\u00ae  infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load \\u2264 100,000 HIV 1 RNA copies/ml.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:47:48\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant \", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant  in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:47:53\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"Full HTA recommended at the current price.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat \", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat .\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:59\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab \", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab :\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:05\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for Atrial Fibrillation patients undergoing PCI\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:10\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Treatment of Deep Vein Thrombosis\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban  following an acute DVT in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:15\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Prevention of Stroke in Atrial Fibrillation\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the prevention of stroke in atrial fibrillation.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:18\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the prevention of atherothrombotic events\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban  at high risk of ischaemic events.\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:25\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  low dose for prevention of recurrent venous thromboembolism\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:30\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:33\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast \", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast  for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:40\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant \", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:43\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim \", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim  is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:47\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\\u00ae\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block  via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:48:50\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib  for Polycythaemia Vera\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\\u00ae is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:55\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib \", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib , post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:58\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan \", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\\u00ae for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:04\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate \", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\\u00ae for the treatment of adult patients with idiopathic Parkinson\\u2019s disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:49:07\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin \", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:11\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price.\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab \", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab . Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:16\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa \", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:20\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Ankylosing Spondylitis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:25\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Psoriatic Arthritis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae alone or in combination with methotrexate  therapy has been inadequate.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:31\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab \", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:34\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag \", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag  inhibitor, or as monotherapy in patients who are not candidates for these therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:39\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide \", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide  for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:44\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil \", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil  is indicated for:\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:49\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir  in combination with Sofosbuvir\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:53\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir \", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  Genotypes 1 and 4 who are treatment na\\u00efve or have previously been treated.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:00\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml \", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\\u00ae is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb\\u00ae is classified as a medical device and carries a CE mark.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:06\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:15\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate \", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate  is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:18\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir \", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir  is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:22\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \" Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir  \\u2013 pangenotypic\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir  i.e. pangenotypic.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:26\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir \", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir .\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:32\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort \", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\\u00ae is indicated for the short term treatment of mild depressive symptoms.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:38\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol \", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol  for use in conjunction with clobazam and valproate as adjunctive therapy of\\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\\n whose seizures are not adequately controlled with clobazam and\\nvalproate\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:43\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil \", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years and over who are antiretroviral treatment-na\\u00efve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild\\u00ae.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:49\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy \", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy  for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:50\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone \", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:54\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil \", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil  is indicated for the management of acute moderate to severe post-operative pain in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:59\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib \", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours  was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:51:04\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil \", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil  II and III, to improve exercise capacity.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:09\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine \", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine  for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"last_scrape\": \"2018-12-13T16:51:15\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost \", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost  for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:24\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec \", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec  with no bone, brain, lung or other visceral disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:28\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol \", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol  for the management of adult patients with severe chronic/acute pain.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:34\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate \", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate  in adults\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:38\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide \", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide  is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:44\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil \", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:48\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir \", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:52\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin \", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia .  Vabitiv\\u00ae should be used only in situations where it is known or suspected that other alternatives are not suitable.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:56\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide \", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\\u00ae is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:58\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor  and a high risk of developing an atherothrombotic event.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:01\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor .\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:07\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for ALL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  that is refractory, in relapse post-transplant or in second or later relapse.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:13\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for DLBCL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:19\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin \", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin  for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:52:24\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at theSubmitted Price.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC \", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis  antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:30\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib  for Ulcerative Colitis\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:35\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib \", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib  in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:40\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan \", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\\u00ae) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease  in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:45\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"Reimursement not recommended at the submitted price\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen \", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen  for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:52:51\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib \", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\\u00ae for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:56\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine \", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine  is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:00\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil \", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil  is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:04\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended \", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  intermittent treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:08\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  single course treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate  is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:10\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol \", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol  is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:12\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is not recommended. The NCPE recommends that GlucoRx Allpresan Diabetic Foam Cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea \", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\\u00ae Diabetic Foam Cream for the treatment of dry and sensitive foot skin  in patients with Diabetes Mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"Unknown\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:17\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab  for Crohn\\u2019s Disease\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-\\u03b1 antagonist or have medical contraindications to such therapies\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:23\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab \", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab  in the treament of moderate to severe psoriasis.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:53:29\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib \", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib  in patients with unresectable locally advanced or metastatic disease.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:32\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Crohn\\u2019s Disease\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:39\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Ulcerative Colitis\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:45\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa \", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy  in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:49\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax  in combination with rituximab\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax  in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:52\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax \", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia \", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:58\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib \", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:00\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant \", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant  for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:04\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib \", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib  is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:11\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine \", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine  is indicated for the treatment of major depressive episodes in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"e52e89cd-3043-45e2-b227-6e0e6edd7c36\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd7a276a0>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#e52e89cd-3043-45e2-b227-6e0e6edd7c36"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#e52e89cd-3043-45e2-b227-6e0e6edd7c36"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Graph before Cleaning\n",
    "df1 = pd.DataFrame(drugs)\n",
    "df1.groupby('company')\n",
    "upto_chart=alt.Chart(df1,title=\"Ncpe Appproval count(Companies)\").mark_rule( color='#ff1493').encode(\n",
    "     alt.X('count(drug_name):Q'),\n",
    "     alt.Y(\n",
    "        'company',\n",
    "        sort=alt.EncodingSortField(\n",
    "            field=\"drug_name\",  # The field to use for the sorting\n",
    "            op=\"count\",  # The operation to run on the field prior to sorting\n",
    "            order=\"descending\"  # The order to sort in\n",
    "        )\n",
    "        )\n",
    "\n",
    ")\n",
    "text = upto_chart.mark_text(\n",
    "        color='#ff1493',\n",
    "        align='left',\n",
    "        baseline='middle',\n",
    "        dx=3  # Nudges text to right so it doesn't appear on top of the bar\n",
    "        ).encode(\n",
    "        text='count(drug_name):Q'\n",
    "        )\n",
    "(upto_chart + text).properties()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Unknown           15\n",
       "sanofi-aventis     5\n",
       "Sanofi-aventis     2\n",
       "Ferring            2\n",
       "Sanofi-Aventis     1\n",
       "                   1\n",
       "Name: company, dtype: int64"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#From the graph,it is clear that there are Unknown and Null company names, but to re-check I am using value_counts()-\n",
    "#for the same, to avoid repetative data with different format and also for the company('Ferring') that will be giving- \n",
    "#application of drugs in the year 2019. \n",
    "newdf1 = df1[(df1['company']=='sanofi-aventis') | (df1['company']=='Sanofi-aventis') |(df1['company']=='Sanofi-Aventis')| \n",
    "             (df1['company']=='') |(df1['company']=='Unknown') | (df1['company']=='Ferring')]\n",
    "newdf1['company'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Cleaning the data for the company('Sanofi-Aventis') as it is appearing thrice with the same name but without a proper format-\n",
    "#Thus,correcting the names by Caplitalising the first letter in each word of the company name, as this follows the pattern -\n",
    "#of the other company names. Also replacing Unknown and the company name('Ferring') with Null as they are irrelevant.\n",
    "\n",
    "df1[\"company\"]= df1[\"company\"].str.replace(\"sanofi-aventis\", \"Sanofi-Aventis\", case = False) \n",
    "df1[\"company\"]= df1[\"company\"].str.replace(\"Unknown\", \"NULL\", case = False) \n",
    "df1[\"company\"]= df1[\"company\"].str.replace(\"Ferring\", \"NULL\", case = False) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Sanofi-Aventis    8\n",
       "                  1\n",
       "Name: company, dtype: int64"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Re-checking the value count after performing above operation\n",
    "newdf1 = df1[(df1['company']=='sanofi-aventis') | (df1['company']=='Sanofi-aventis') |(df1['company']=='Sanofi-Aventis')| \n",
    "             (df1['company']=='') |(df1['company']=='Unknown') | (df1['company']=='Ferring')]\n",
    "newdf1['company'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Cleaning the data for blank values and Null values\n",
    "cleaned_data = df1[(df1['company']!='') & (df1['company']!= 'NULL') ]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"layer\": [{\"mark\": {\"type\": \"rule\", \"color\": \"#ff1493\"}, \"encoding\": {\"x\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"drug_name\"}, \"y\": {\"type\": \"nominal\", \"field\": \"company\", \"sort\": {\"field\": \"drug_name\", \"op\": \"count\", \"order\": \"descending\"}}}, \"title\": \"Ncpe Appproval count(Companies)\"}, {\"mark\": {\"type\": \"text\", \"align\": \"left\", \"baseline\": \"middle\", \"color\": \"#ff1493\", \"dx\": 3}, \"encoding\": {\"text\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"drug_name\"}, \"x\": {\"type\": \"quantitative\", \"aggregate\": \"count\", \"field\": \"drug_name\"}, \"y\": {\"type\": \"nominal\", \"field\": \"company\", \"sort\": {\"field\": \"drug_name\", \"op\": \"count\", \"order\": \"descending\"}}}, \"title\": \"Ncpe Appproval count(Companies)\"}], \"data\": {\"name\": \"data-b85621793cfc60af3e50bf09437d5941\"}, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-b85621793cfc60af3e50bf09437d5941\": [{\"last_scrape\": \"2018-12-13T16:24:36\", \"rr_start\": \"2018-10-03T00:00:00\", \"rr_end\": \"2018-11-15T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-03, 2018-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mHSPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Abiraterone acetate .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2018-10-03T00:00:00\", \"latest\": \"2018-11-15T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:41\", \"rr_start\": \"2013-01-03T00:00:00\", \"rr_end\": \"2013-02-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-01-03, 2013-02-01\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone acetate  for mCRPC post ADT\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation of Abiratone acetate  in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-01-03T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:46\", \"rr_start\": \"2011-10-21T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-21, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Abiraterone Acetate  for mCRPC\", \"trade_name\": \"Zytiga\", \"indication\": \"Pharmacoeconomic evaluation and resource implications of Zytiga \\u00ae  who have received prior docetaxel-based chemotherapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-09-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-21T00:00:00\", \"latest\": \"2014-04-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:24:56\", \"rr_start\": \"2012-10-23T00:00:00\", \"rr_end\": \"2012-10-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2012-10-23, 2012-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide \", \"trade_name\": \"Eklira Genuair\", \"indication\": \"Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease \", \"ncpe_year\": 2012, \"eu_market\": \"2012-07-20T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-23T00:00:00\", \"latest\": \"2012-10-26T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:00\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-01-05, 2015-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Aclidinium bromide / formoterol fumarate dihydrate \", \"trade_name\": \"Brimica Genuair\", \"indication\": \"Brimica\\u00ae Genuair\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2015-02-09T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:37\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0, \"drug_name\": \"Adalimumab \", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab  in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.\", \"ncpe_year\": 2011, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:40\", \"rr_start\": \"2009-12-08T00:00:00\", \"rr_end\": \"2009-12-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-12-08\", \"rr_multiple\": 0, \"drug_name\": \"Adenuric \", \"trade_name\": \"Febuxostat\", \"indication\": \"NCPE review of Adenuric  a xanthine oxidase inhibitor for the treatment of gout.\", \"ncpe_year\": 2009, \"eu_market\": \"2008-04-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2009-12-08T00:00:00\", \"latest\": \"2009-12-08T00:00:00\", \"ta_list\": \"Gout\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:45\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Afatinib \", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:25:49\", \"rr_start\": \"2012-12-10T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-10, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Eylea\", \"indication\": \"Aflibercept .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-11-21T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2012-12-10T00:00:00\", \"latest\": \"2012-12-21T00:00:00\", \"ta_list\": \"Wet Macular Degeneration; Macular Edema; Diabetes Complications\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:52\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Aflibercept \", \"trade_name\": \"Zaltrap\", \"indication\": \"Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid  that is resistant to or has progressed after an oxaliplatin-containing regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-01T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-02-12T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:25:58\", \"rr_start\": \"\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Agomelatine \", \"trade_name\": \"Valdoxan\", \"indication\": \"Economic evaluation of Agomelatine  for the treatment of major depressive disorder.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-02-19T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2009-09-03T00:00:00\", \"latest\": \"2009-12-11T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:26:06\", \"rr_start\": \"2017-01-03T00:00:00\", \"rr_end\": \"2017-12-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-01-03, 2017-02-27, 2017-11-08, 2017-12-04\", \"rr_multiple\": 1, \"drug_name\": \"Alectinib \", \"trade_name\": \"Alecensa\", \"indication\": \"Alectinib  whose disease has progressed following treatment with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-02-16T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:12\", \"rr_start\": \"2013-11-08T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-08, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Alemtuzumab \", \"trade_name\": \"Lemtrada\", \"indication\": \"Alemtuzumab  with active disease defined by clinical or imaging features\", \"ncpe_year\": 2014, \"eu_market\": \"2013-09-12T00:00:00\", \"company\": \"Sanofi\", \"orphan\": 0, \"earliest\": \"2013-11-08T00:00:00\", \"latest\": \"2014-06-25T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:14\", \"rr_start\": \"2015-10-13T00:00:00\", \"rr_end\": \"2015-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-10-13, 2015-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Alirocumab \", \"trade_name\": \"Praluent\", \"indication\": \"Praluent\\u00ae is indicated for both primary hypercholesterolaemia  or mixed dyslipidaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-23T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2015-10-13T00:00:00\", \"latest\": \"2018-03-20T00:00:00\", \"ta_list\": \"Dyslipidemias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:16\", \"rr_start\": \"2013-09-27T00:00:00\", \"rr_end\": \"2013-10-30T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-09-27, 2013-10-30\", \"rr_multiple\": 0, \"drug_name\": \"Alogliptin \", \"trade_name\": \"Vipidia\", \"indication\": \"Alogliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-18T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2013-09-27T00:00:00\", \"latest\": \"2013-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:21\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Ambrisentan \", \"trade_name\": \"Volibris\", \"indication\": \"Cost Effectiveness of ambrisentan  in the treatment of patients with Functional Class II or III pulmonary arterial hypertension.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-04-20T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 1, \"earliest\": \"2008-10-01T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:23\", \"rr_start\": \"2011-11-07T00:00:00\", \"rr_end\": \"2011-12-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-11-07, 2011-12-09\", \"rr_multiple\": 0, \"drug_name\": \"Amifampridine \", \"trade_name\": \"Firdapse\", \"indication\": \"For Lambert Eaton Myasthenic Syndrome .  This high cost drug is likely to require a full HTA due to significant budget impact.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-11-07T00:00:00\", \"latest\": \"2011-12-09T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:35\", \"rr_start\": \"2014-07-29T00:00:00\", \"rr_end\": \"2014-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2014-07-29, 2014-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban , and prevention of recurrent DVT and\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-07-29T00:00:00\", \"latest\": \"2014-08-10T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:39\", \"rr_start\": \"2011-10-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-10-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee\", \"trade_name\": \"Eliquis\", \"indication\": \"Apixaban  for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-05-18T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-10-19T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:45\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for moderate to severe chronic plaque psoriasis.\", \"trade_name\": \"Otezla\", \"indication\": \"Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:47\", \"rr_start\": \"2015-02-24T00:00:00\", \"rr_end\": \"2015-04-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2015-02-24, 2015-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Apremilast  for psoriatic arthritis.\", \"trade_name\": \"Otezla\", \"indication\": \"Apremilist , alone or in combination with DMARDs, for the treatment of active PsA in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-15T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2015-02-24T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:49\", \"rr_start\": \"2014-07-02T00:00:00\", \"rr_end\": \"2014-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-07-02, 2014-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Aripiprazole \", \"trade_name\": \"Abilify Maintena\", \"indication\": \"Aripiprazole  for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-14T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2014-07-02T00:00:00\", \"latest\": \"2014-08-06T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:26:55\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-17, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Asenapine \", \"trade_name\": \"Sycrest\", \"indication\": \"Asenapine  for the treatment of moderate to severe manic episodes associated with biopolar 1 disorder in adults.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Organon\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Bipolar Disorder\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:00\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-10-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-10-09\", \"rr_multiple\": 0, \"drug_name\": \"Atezolizumab \", \"trade_name\": \"Tecentriq\", \"indication\": \"Atezolizumab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR activating mutations or ALK\\u2011positive tumour mutations should also have received targeted therapy before receiving atezolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-21T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-09-20T00:00:00\", \"ta_list\": \"Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:05\", \"rr_start\": \"2014-02-19T00:00:00\", \"rr_end\": \"2014-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-02-19, 2014-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Avanafil \", \"trade_name\": \"Spedra\", \"indication\": \"Avanafil  is indicated for the treatment of erectile dysfunction in adult men.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Menarini\", \"orphan\": 0, \"earliest\": \"2014-02-19T00:00:00\", \"latest\": \"2014-03-12T00:00:00\", \"ta_list\": \"Erectile Dysfunction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:06\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-10-17, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Avelumab \", \"trade_name\": \"Bavencio\", \"indication\": \"Avelumab  is indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2018-10-08T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:08\", \"rr_start\": \"2012-04-12T00:00:00\", \"rr_end\": \"2012-04-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-04-12, 2012-04-20\", \"rr_multiple\": 0, \"drug_name\": \"Aspirin 81mg/Esomeprazole 20mg \", \"trade_name\": \"Axanum\", \"indication\": \"Prevention of thrombotic cardiovascular and cerebrovascular events in patients requiring continuous low-dose acetylsalicylic acid treatment, and who are in need of prophylaxis against acetylsalicylic acid associated gastric and /or duodenal ulcers.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-04-12T00:00:00\", \"latest\": \"2012-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:14\", \"rr_start\": \"2018-09-10T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of  axi-cel compared with the current standard of care.\\n \", \"rr_dates\": \"2018-09-10, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Axicabtagene Ciloleucel \", \"trade_name\": \"Yescarta\", \"indication\": \"Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Kite\", \"orphan\": 1, \"earliest\": \"2018-09-10T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:23\", \"rr_start\": \"2012-11-07T00:00:00\", \"rr_end\": \"2012-11-19T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-11-07, 2012-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Axitinib \", \"trade_name\": \"Inlyta\", \"indication\": \"For the treatment of adult patients with advanced renal cell carcinoma  after failure of prior treatment with sunitinib or a cytokine\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-03T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-11-07T00:00:00\", \"latest\": \"2012-11-19T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:25\", \"rr_start\": \"2012-01-10T00:00:00\", \"rr_end\": \"2012-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2012-01-10, 2012-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Azilsartan \", \"trade_name\": \"Edarbi\", \"indication\": \"Edarbi is indicated for the treatment of essential hypertension in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-12-07T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2012-01-10T00:00:00\", \"latest\": \"2012-01-11T00:00:00\", \"ta_list\": \"Hypertension\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:27\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-06-14, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Baricitinib \", \"trade_name\": \"Olumiant\", \"indication\": \"Baricitinib  is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-02-12T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:33\", \"rr_start\": \"2011-09-20T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-20, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Bazedoxifene \", \"trade_name\": \"Conbriza\", \"indication\": \"Bazedoxifene  for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.  A significant reduction in the incidence of verterbral fractures has been demonstrated; efficacy on hip fractures has not been established.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-17T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-09-20T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Osteoporosis, Postmenopausal\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:36\", \"rr_start\": \"2015-01-23T00:00:00\", \"rr_end\": \"2015-02-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-23, 2015-02-20\", \"rr_multiple\": 0, \"drug_name\": \"Bedaquiline \", \"trade_name\": \"Sirturo\", \"indication\": \"Bedaquiline  is indicated for use as part of an appropriate combination regimen for pulmonary MDR\\u2011TB in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-03-05T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2015-01-23T00:00:00\", \"latest\": \"2015-02-20T00:00:00\", \"ta_list\": \"Tuberculosis, Multidrug-Resistant\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:37\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2012-01-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-11-15, 2012-01-23\", \"rr_multiple\": 0, \"drug_name\": \"Belatacept \", \"trade_name\": \"Nulojix\", \"indication\": \"Belatacept, in combination with corticosteroids and a mycophenolic acid -2 receptor antagonist for induction therapy to this belatacept-based regimen.\\n\", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2012-01-23T00:00:00\", \"ta_list\": \"Graft Rejection; Kidney Transplantation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:40\", \"rr_start\": \"2011-08-11T00:00:00\", \"rr_end\": \"2011-08-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-11, 2011-08-11\", \"rr_multiple\": 0, \"drug_name\": \"Belimumab \", \"trade_name\": \"Benlysta\", \"indication\": \"Cost-effectiveness of Belimumab \", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-08-01T00:00:00\", \"latest\": \"2011-08-11T00:00:00\", \"ta_list\": \"Lupus Erythematosus, Systemic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:46\", \"rr_start\": \"2011-03-21T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-21, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Bendamustine \", \"trade_name\": \"Levact\", \"indication\": \"Bendamustine \", \"ncpe_year\": 2012, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2012-11-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:50\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"Full pharamcoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0, \"drug_name\": \"Benralizumab \", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab  is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting \\u03b2-agonists.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:56\", \"rr_start\": \"2017-05-11T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-05-11, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Bezlotoxumab \", \"trade_name\": \"Zinplava\", \"indication\": \"Bezlotoxumab  in adults at high risk for recurrence of CDI.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-05-11T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Enterocolitis, Pseudomembranous\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:27:58\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended. The NCPE recommends that Biktarvy\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-04-30, 2018-06-07\", \"rr_multiple\": 0, \"drug_name\": \"Bictegravir/emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Biktarvy\", \"indication\": \"Biktarvy\\u00ae for the treatment of adults infected with HIV-1 without any known mutations associated with resistance to the individual components.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:01\", \"rr_start\": \"2011-03-10T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-10, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Bilastine \", \"trade_name\": \"Drynol\", \"indication\": \" Bilastine  and urticaria.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-03-10T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:05\", \"rr_start\": \"2015-12-08T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.  The NCPE cannot recommend reimbursement of Blinctyo\\u00ae at this point in time.\", \"rr_dates\": \"2015-12-08, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Blinatumomab \", \"trade_name\": \"Blincyto\", \"indication\": \"Blincyto\\u00ae is indicated for the treatment of adults with Philadelphia chromosome negative  relapsed or refractory\\nB-precursor acute lymphoblastic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-23T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-08T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:11\", \"rr_start\": \"\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Boceprevir \", \"trade_name\": \"Victrelis\", \"indication\": \"Economic evaluation of Boceprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2011-08-19T00:00:00\", \"latest\": \"2012-01-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:28:16\", \"rr_start\": \"2014-06-27T00:00:00\", \"rr_end\": \"2014-07-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-06-27, 2014-07-04\", \"rr_multiple\": 0, \"drug_name\": \"Bosentan \", \"trade_name\": \"Tracleer\", \"indication\": \"Bosentan  III and WHO FC II.  It is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.\", \"ncpe_year\": 2014, \"eu_market\": \"2002-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-06-27T00:00:00\", \"latest\": \"2014-07-04T00:00:00\", \"ta_list\": \"Scleroderma, Systemic; Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:18\", \"rr_start\": \"2013-08-09T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"At the current price a full HTA would be required.\", \"rr_dates\": \"2013-08-09, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Bosutinib \", \"trade_name\": \"Bosulif\", \"indication\": \"Bosutinib is indicated for the treatment of adult patients with chronic phase  and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-26T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:19\", \"rr_start\": \"2018-02-07T00:00:00\", \"rr_end\": \"2018-03-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-02-07, 2018-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  after at least 1 prior systemic therapy. This is a license extension.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-02-07T00:00:00\", \"latest\": \"2018-03-06T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:23\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.\", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:29\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of brigatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\\n \", \"rr_dates\": \"2018-11-19, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Brigatinib \", \"trade_name\": \"Alunbrig\", \"indication\": \"Brigatinib  is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-11-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:30\", \"rr_start\": \"2014-04-09T00:00:00\", \"rr_end\": \"2014-04-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-09\", \"rr_multiple\": 0, \"drug_name\": \"Brimonidine 3.3 mg/g gel \", \"trade_name\": \"Mirvaso\", \"indication\": \"Brimonidine 3.3 mg/g gel  is indicated for the treatment of facial erythema of rosacea in adult patients.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-02-20T00:00:00\", \"company\": \"Galderma\", \"orphan\": 0, \"earliest\": \"2014-04-09T00:00:00\", \"latest\": \"2014-04-09T00:00:00\", \"ta_list\": \"Skin Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:36\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-02-15, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Brivaracetam \", \"trade_name\": \"Briviact\", \"indication\": \"Brivaracetam  with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.\", \"ncpe_year\": 2016, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-22T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:40\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Brodalumab \", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab  is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:44\", \"rr_start\": \"2012-09-11T00:00:00\", \"rr_end\": \"2012-09-21T00:00:00\", \"rr_outcome\": \"Full HTA recommended\", \"rr_dates\": \"2012-09-11, 2012-09-21\", \"rr_multiple\": 0, \"drug_name\": \"Mannitol Dry Powder \", \"trade_name\": \"Bronchitol\", \"indication\": \"Bronchitol\\u00ae \\u2013 Mannitol dry powder for inhalation for the treatment of cystic fibrosis \", \"ncpe_year\": 2014, \"eu_market\": \"2012-04-13T00:00:00\", \"company\": \"Pharmaxis\", \"orphan\": 1, \"earliest\": \"2012-09-11T00:00:00\", \"latest\": \"2014-08-29T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:46\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-06-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-05-17, 2016-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Calcipotriol and betamethasone dipropionate cutaneous foam \", \"trade_name\": \"Enstilar\", \"indication\": \"Calcipotriol and betamethasone dipropionate cutaneous foam is indicated for the topical treatment of psoriasis vulgaris in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-06-21T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:53\", \"rr_start\": \"2012-10-22T00:00:00\", \"rr_end\": \"2012-11-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2012-10-22, 2012-11-14\", \"rr_multiple\": 0, \"drug_name\": \"C1inhibitor \", \"trade_name\": \"Cinryze\", \"indication\": \"C1inhibitor \", \"ncpe_year\": 2012, \"eu_market\": \"2011-06-15T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2012-10-22T00:00:00\", \"latest\": \"2012-11-14T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:28:55\", \"rr_start\": \"2017-03-20T00:00:00\", \"rr_end\": \"2017-04-25T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-03-20, 2017-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cabometyx\", \"indication\": \"Cabozantinib -targeted therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-03-20T00:00:00\", \"latest\": \"2018-07-03T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:28:58\", \"rr_start\": \"2014-07-10T00:00:00\", \"rr_end\": \"2014-08-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2014-07-10, 2014-08-12\", \"rr_multiple\": 0, \"drug_name\": \"Cabozantinib \", \"trade_name\": \"Cometriq\", \"indication\": \"Cabozantinib  is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-21T00:00:00\", \"company\": \"Ipsen\", \"orphan\": 1, \"earliest\": \"2014-07-10T00:00:00\", \"latest\": \"2014-08-12T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:01\", \"rr_start\": \"2015-05-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2015-05-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Camellia sinensis, folium \", \"trade_name\": \"Catephen 10%\", \"indication\": \"Catephen 10%\\u00ae is indicated for the cutaneous treatment of external genital and perianal warts  in immunocompetent patients from the age of 18 years.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-05-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:04\", \"rr_start\": \"2013-11-25T00:00:00\", \"rr_end\": \"2013-12-02T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-11-25, 2013-12-02\", \"rr_multiple\": 0, \"drug_name\": \"Canagliflozin \", \"trade_name\": \"Invokana\", \"indication\": \"Canagliflozin  is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin\", \"ncpe_year\": 2014, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2013-11-25T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:09\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Capsaicin 8%w/w patch \", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch  for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.\", \"ncpe_year\": 2012, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:11\", \"rr_start\": \"2011-06-02T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-06-02, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Cabazitaxel \", \"trade_name\": \"Jevtana\", \"indication\": \"Economic Evaluation of cabazitaxel  for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2011-06-02T00:00:00\", \"latest\": \"2014-03-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:16\", \"rr_start\": \"2015-12-07T00:00:00\", \"rr_end\": \"2016-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-12-07, 2016-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Carfilzomib \", \"trade_name\": \"Kyprolis\", \"indication\": \"Kyprolis\\u00ae  for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-12-07T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:22\", \"rr_start\": \"2011-08-05T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-08-05, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Catumaxomab \", \"trade_name\": \"Removab\", \"indication\": \"Catumazomab  for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-04-20T00:00:00\", \"company\": \"Neovii\", \"orphan\": 0, \"earliest\": \"2011-08-05T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Ascites; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:25\", \"rr_start\": \"2012-10-08T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-10-08, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Ceftaroline \", \"trade_name\": \"Zinforo\", \"indication\": \"For the treatment of adult patients with complicated Skin and Soft Tissue Infections .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-08-22T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2012-10-08T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:29\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-17, 2017-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Ceftazidime-avibactam \", \"trade_name\": \"Zavicefta\", \"indication\": \"Ceftazidime-avibactam  and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-06-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:34\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended at the Submitted Price.\", \"rr_dates\": \"2016-03-03, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Ceftolozane/tazobactam \", \"trade_name\": \"Zerbaxa\", \"indication\": \"Zerbaxa\\u00ae is indicated for the treatment of complicated urinary tract infections  in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Bacterial Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:36\", \"rr_start\": \"2015-05-29T00:00:00\", \"rr_end\": \"2015-07-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2015-05-29, 2015-07-22\", \"rr_multiple\": 0, \"drug_name\": \"Ceritinib \", \"trade_name\": \"Zykadia\", \"indication\": \"Zykadia\\u00ae is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-06T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-05-29T00:00:00\", \"latest\": \"2015-07-22T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:40\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended.\", \"rr_dates\": \"2017-10-11, 2017-11-27\", \"rr_multiple\": 0, \"drug_name\": \"Cerliponase alfa \", \"trade_name\": \"Brineura\", \"indication\": \"Cerliponase alfa  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-08-02T00:00:00\", \"ta_list\": \"Neuronal Ceroid-Lipofuscinoses\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:44\", \"rr_start\": \"\", \"rr_end\": \"2017-11-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Certolizumab pegol \", \"trade_name\": \"Cimzia\", \"indication\": \"Cost-effectiveness of certolizumab pegol  for the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2010-03-13T00:00:00\", \"latest\": \"2010-09-02T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:29:49\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops \", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\\u00ae is indicated for the treatment of severe keratitis in adult patients with dry eye disease , which has not improved despite treatment with tear substitutes.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:29:54\", \"rr_start\": \"2017-08-22T00:00:00\", \"rr_end\": \"2017-09-18T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-08-22, 2017-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Cladribine \", \"trade_name\": \"Mavenclad\", \"indication\": \"Cladribine  as defined by clinical or imaging features\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-08-22T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:29:58\", \"rr_start\": \"2014-04-08T00:00:00\", \"rr_end\": \"2014-05-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-08, 2014-05-06\", \"rr_multiple\": 0, \"drug_name\": \"Clindamycin 1% with tretinoin 0.025% \", \"trade_name\": \"Treclinac\", \"indication\": \"Clindamycin 1% with tretinoin 0.025%  is indicated for the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-04-08T00:00:00\", \"latest\": \"2014-05-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:02\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Cobimetinib \", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\\u00ae is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:03\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Colesevelam \", \"trade_name\": \"Cholestagel\", \"indication\": \"Cost-effectiveness of Colesevelam \", \"ncpe_year\": 2010, \"eu_market\": \"2004-03-09T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:06\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Colistimethate sodium \", \"trade_name\": \"Colobreathe\", \"indication\": \"Colistimethate sodium  aged 6 years and older.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-13T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:17\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Collagenase Clostridium Histolyticum \", \"trade_name\": \"Xiapex\", \"indication\": \" Collagenase Clostridium Histolyticum  is indicated for the treatment of Dupuytren\\u2019s contracture in adult patients with a palpable cord.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-02-28T00:00:00\", \"company\": \"Swedish\", \"orphan\": 0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Dupuytren Contracture\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:20\", \"rr_start\": \"2010-10-22T00:00:00\", \"rr_end\": \"2010-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-10-22, 2010-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Corifollitropin alfa \", \"trade_name\": \"Elonva\", \"indication\": \"Cost-effectiveness of Corifollitropin alfa .\", \"ncpe_year\": 2010, \"eu_market\": \"2010-01-25T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2010-09-01T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Reproductive Techniques, Assisted; Ovulation Induction\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:24\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for first line ALK+ NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the first-line treatment of adults with anaplastic lymphoma kinase .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:29\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib  for ROS1 NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer .\", \"ncpe_year\": 2017, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:34\", \"rr_start\": \"2013-01-09T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-09, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Crizotinib \", \"trade_name\": \"Xalkori\", \"indication\": \"For the treatment of adults with previously treated anaplastic lymphoma kinase \", \"ncpe_year\": 2015, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-01-09T00:00:00\", \"latest\": \"2015-08-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:37\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2015-12-01, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Cysteamine bitartrate delayed-release \", \"trade_name\": \"Procysbi\", \"indication\": \"Procysbi\\u00ae for the treatment of proven nephropathic cystinosis.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-09-05T00:00:00\", \"company\": \"Chiesi\", \"orphan\": 1, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Cystinosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:30:43\", \"rr_start\": \"2014-05-09T00:00:00\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-09, 2014-06-13\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the treatment of DVT and PE\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate , and prevention of recurrent DVT and PE in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-09T00:00:00\", \"latest\": \"2014-06-13T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:30:51\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran etexilate  \\u2013 for the prevention of stroke and systematic embolisom in atrial fibrillation\", \"trade_name\": \"Pradaxa\", \"indication\": \"Dabigatran etexilate  for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation\", \"ncpe_year\": 2012, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2010-11-02T00:00:00\", \"latest\": \"2012-10-03T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:57\", \"rr_start\": \"\", \"rr_end\": \"2014-06-13T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Pradaxa\", \"indication\": \"Economic Evaluation of the Cost Effectiveness of Dabigatran Etexilate  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have undergone Total Hip Replacement or Total Knee Surgery.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-03-17T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2008-07-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:30:59\", \"rr_start\": \"2013-09-11T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-11, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Dabrafenib \", \"trade_name\": \"Tafinlar\", \"indication\": \"Dabrafenib  is indicated for the treatment of adult patients with unresectable or Metastic Melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2013-09-11T00:00:00\", \"latest\": \"2014-06-24T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:02\", \"rr_start\": \"2014-08-05T00:00:00\", \"rr_end\": \"2014-09-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-05, 2014-09-12\", \"rr_multiple\": 0, \"drug_name\": \"Daclatasvir \", \"trade_name\": \"Daklinza\", \"indication\": \"Daclatasvir . \", \"ncpe_year\": 2015, \"eu_market\": \"2014-08-22T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2014-08-05T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:08\", \"rr_start\": \"2016-09-26T00:00:00\", \"rr_end\": \"2016-11-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-09-26, 2016-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Daclizumab \", \"trade_name\": \"Zinbryta\", \"indication\": \"Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-07-01T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2016-09-26T00:00:00\", \"latest\": \"2018-03-07T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:12\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Dalbavancin \", \"trade_name\": \"Xydalba\", \"indication\": \"Dalbavancin  in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-02-19T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:18\", \"rr_start\": \"2012-10-10T00:00:00\", \"rr_end\": \"2012-10-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-10-10, 2012-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Dapagliflozin \", \"trade_name\": \"Forxiga\", \"indication\": \"Dapagliflozin  is indicated in adults aged 18 years and older with Type 2 Diabetes Mellitus to improve glycaemic control as:\\nMonotherapy\\nWhen diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.\\nAdd-on combination therapy\\nIn combination with other glucose lowering drugs including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-11T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2012-10-10T00:00:00\", \"latest\": \"2013-12-31T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:21\", \"rr_start\": \"2016-05-31T00:00:00\", \"rr_end\": \"2016-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-31, 2016-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Daratumumab \", \"trade_name\": \"Darzalex\", \"indication\": \"Daratumumab monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-04-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-05-31T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:25\", \"rr_start\": \"2017-09-27T00:00:00\", \"rr_end\": \"2017-10-26T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-27, 2017-10-26\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide \", \"trade_name\": \"Symtuza\", \"indication\": \"Darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide  is indicated for the treatment of HIV-1 in adults and adolescents.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-09-27T00:00:00\", \"latest\": \"2017-10-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:30\", \"rr_start\": \"2014-12-02T00:00:00\", \"rr_end\": \"2015-01-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-12-02, 2015-01-08\", \"rr_multiple\": 0, \"drug_name\": \"Darunavir & cobicistat \", \"trade_name\": \"Rezolsta\", \"indication\": \"Indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years or older.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-12-02T00:00:00\", \"latest\": \"2015-01-08T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:31:35\", \"rr_start\": \"2018-06-14T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of darvadstrocel compared with the current standard of care.\", \"rr_dates\": \"2018-06-14, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Darvadstrocel \", \"trade_name\": \"Alofisel\", \"indication\": \"Darvadstrocel  for the treatment of complex perianal fistulae in adult patients with non-active/ mildly active luminal Crohn\\u2019s Disease when fistulae have shown an inadequate response to at least one conventional or biologic therapy and should be used after conditioning of fistula.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-03-23T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2018-06-14T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Rectal Fistula\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:40\", \"rr_start\": \"2012-11-08T00:00:00\", \"rr_end\": \"2012-12-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-08, 2012-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Decitabine \", \"trade_name\": \"Dacogen\", \"indication\": \"Decitabine  is indicated for AML in patients who are >65yrs who are not candidates for standard induction therapy\", \"ncpe_year\": 2013, \"eu_market\": \"2012-09-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2012-11-08T00:00:00\", \"latest\": \"2013-12-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:44\", \"rr_start\": \"2014-05-12T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2014-05-12, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Defibrotide \", \"trade_name\": \"Defitelio\", \"indication\": \"Defibrotide  therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-10-18T00:00:00\", \"company\": \"Gentium\", \"orphan\": 1, \"earliest\": \"2014-05-12T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Hepatic Veno-Occlusive Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:52\", \"rr_start\": \"2018-02-12T00:00:00\", \"rr_end\": \"2018-04-03T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex\\u00ae compared with the current standard of care.\", \"rr_dates\": \"2018-02-12, 2018-04-03\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD \", \"trade_name\": \"Sativex\", \"indication\": \"Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-02-12T00:00:00\", \"latest\": \"2018-04-20T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:31:59\", \"rr_start\": \"2012-12-05T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-05, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Delta-9-tetrahydrocannabinol \", \"trade_name\": \"Sativex\", \"indication\": \"For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis  who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2012-12-05T00:00:00\", \"latest\": \"2014-09-26T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:04\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Prolia\", \"indication\": \"The Cost-effectiveness of Denosumab  for the Prevention of Osteoporotic Fractures in Postmenopausal Women.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-05-26T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2010-05-27T00:00:00\", \"latest\": \"2010-07-01T00:00:00\", \"ta_list\": \"Bone Resorption; Osteoporosis, Postmenopausal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:08\", \"rr_start\": \"\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Denosumab \", \"trade_name\": \"Xgeva\", \"indication\": \"Cost-effectiveness of denosumab  for the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-07-13T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2011-08-15T00:00:00\", \"latest\": \"2011-12-08T00:00:00\", \"ta_list\": \"Fractures, Bone; Neoplasm Metastasis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:12\", \"rr_start\": \"2010-11-12T00:00:00\", \"rr_end\": \"2010-12-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-12, 2010-12-16\", \"rr_multiple\": 0, \"drug_name\": \"Dexamethasone Intravitreal Implant \", \"trade_name\": \"Ozurdex\", \"indication\": \"Cost-effectiveness of Ozurdex\\u00ae in the treatment of macular oedema following Retinal Vein Occlusion.\", \"ncpe_year\": 2012, \"eu_market\": \"2010-07-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2010-11-12T00:00:00\", \"latest\": \"2012-03-16T00:00:00\", \"ta_list\": \"Macular Edema; Uveitis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:15\", \"rr_start\": \"2011-07-08T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-07-08, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Dexmedetomidine \", \"trade_name\": \"Dexdor\", \"indication\": \"Dexmedetomidine  for the treatemnt of ICU adult patients requiring light to moderate sedation.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-15T00:00:00\", \"company\": \"Orion\", \"orphan\": 0, \"earliest\": \"2011-07-08T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Conscious Sedation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:21\", \"rr_start\": \"2010-09-17T00:00:00\", \"rr_end\": \"2010-10-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-09-17, 2010-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Dienogest \", \"trade_name\": \"Visanne\", \"indication\": \"Dienogest  for the Treatment of Endometriosis\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-09-17T00:00:00\", \"latest\": \"2010-10-04T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:24\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2018-01-15, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Skilarence\", \"indication\": \"Dimethyl fumarate  for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Almirall\", \"orphan\": 0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-06T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:26\", \"rr_start\": \"2014-02-04T00:00:00\", \"rr_end\": \"2014-03-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-04, 2014-03-06\", \"rr_multiple\": 0, \"drug_name\": \"Dimethyl fumarate \", \"trade_name\": \"Tecfidera\", \"indication\": \"Dimethyl fumarate .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-01-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-02-04T00:00:00\", \"latest\": \"2015-04-14T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:29\", \"rr_start\": \"2017-10-19T00:00:00\", \"rr_end\": \"2017-11-23T00:00:00\", \"rr_outcome\": \"Following assessment of the applicant\\u2019s submission, the NCPE recommends that dinutuximab beta (Qarziba\\u00ae) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Goods) Act 2013.\", \"rr_dates\": \"2017-10-19, 2017-11-23\", \"rr_multiple\": 0, \"drug_name\": \"Dinutuximab beta \", \"trade_name\": \"Qarziba\", \"indication\": \"Dinutuximab beta EUSA for the treatment of high-risk neuroblastoma in patients \\u2265 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-10-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:34\", \"rr_start\": \"2018-06-08T00:00:00\", \"rr_end\": \"2018-07-12T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca\\u00ae not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-06-08, 2018-07-12\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir/Rilpivirine \", \"trade_name\": \"Juluca\", \"indication\": \"Dolutegravir/rilpivirine is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-05-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2018-06-08T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:36\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Dolutegravir \", \"trade_name\": \"Tivicay\", \"indication\": \"Dolutegravir  infected adults and adolescents above 12 years of age.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-01-16T00:00:00\", \"company\": \"ViiV\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-13T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:39\", \"rr_start\": \"2010-01-12T00:00:00\", \"rr_end\": \"2010-01-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-12, 2010-01-01\", \"rr_multiple\": 0, \"drug_name\": \"Dronedarone \", \"trade_name\": \"Multaq\", \"indication\": \"Rapid Review\", \"ncpe_year\": 2010, \"eu_market\": \"2009-11-25T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2010-01-12T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:42\", \"rr_start\": \"2015-03-04T00:00:00\", \"rr_end\": \"2015-04-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2015-03-04, 2015-04-29\", \"rr_multiple\": 0, \"drug_name\": \"Dulaglutide \", \"trade_name\": \"Trulicity\", \"indication\": \"Dulaglutide is indicated as monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2015-03-04T00:00:00\", \"latest\": \"2015-04-29T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:32:46\", \"rr_start\": \"2017-11-13T00:00:00\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-13, 2017-11-24\", \"rr_multiple\": 0, \"drug_name\": \"Dupilumab \", \"trade_name\": \"Dupixent\", \"indication\": \"Dupilumab  is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-27T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2017-11-13T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Dermatitis, Atopic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:32:53\", \"rr_start\": \"\", \"rr_end\": \"2017-11-24T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Eculizumab \", \"trade_name\": \"Soliris\", \"indication\": \"An Economic Evaluation of Eculizumab  in the Irish healthcare setting.\", \"ncpe_year\": 2013, \"eu_market\": \"2007-06-20T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2010-01-01T00:00:00\", \"latest\": \"2013-10-14T00:00:00\", \"ta_list\": \"Hemoglobinuria, Paroxysmal\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:32:55\", \"rr_start\": \"2015-06-26T00:00:00\", \"rr_end\": \"2015-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-06-26, 2015-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Edoxaban \", \"trade_name\": \"Lixiana\", \"indication\": \"Edoxaban is indicated for the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2015-06-26T00:00:00\", \"latest\": \"2015-07-10T00:00:00\", \"ta_list\": \"Stroke; Venous Thromboembolism\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:00\", \"rr_start\": \"2016-08-10T00:00:00\", \"rr_end\": \"2016-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-08-10, 2016-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Elbasvir/Grazoprevir \", \"trade_name\": \"Zepatier\", \"indication\": \"Elbasvir 50mg/100mg grazoprevir .\", \"ncpe_year\": 2016, \"eu_market\": \"2016-07-22T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-10T00:00:00\", \"latest\": \"2016-10-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:03\", \"rr_start\": \"2016-03-21T00:00:00\", \"rr_end\": \"2016-05-17T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-03-21, 2016-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Eliglustat \", \"trade_name\": \"Cerdelga\", \"indication\": \"Eliglustat  is indicated for the long-term treatment of adult patients with Gaucher disease type 1.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-01-19T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 1, \"earliest\": \"2016-03-21T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Gaucher Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:05\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0, \"drug_name\": \"Elosulfase alfa \", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa  in patients of all ages.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:12\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-02-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-01-10, 2014-02-13\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag  for Thrombocytopenia in HCV\", \"trade_name\": \"Revolade\", \"indication\": \"Eltrombopag  infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy\", \"ncpe_year\": 2014, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-02-13T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:17\", \"rr_start\": \"2016-02-05T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-05, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Eltrombopag \", \"trade_name\": \"Revolade\", \"indication\": \"Revolade\\u00ae for the treatment adult patients with acquired severe aplastic anaemia  who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-02-05T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:23\", \"rr_start\": \"2017-12-04T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.\", \"rr_dates\": \"2017-12-04, 2018-04-16, 2017-12-01\", \"rr_multiple\": 1, \"drug_name\": \"Eltrombopag  for ITP\", \"trade_name\": \"Revolade\", \"indication\": \"Cost-effectiveness of eltrombopag .\", \"ncpe_year\": 2018, \"eu_market\": \"2010-03-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-07-30T00:00:00\", \"latest\": \"2018-04-16T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:26\", \"rr_start\": \"2015-11-24T00:00:00\", \"rr_end\": \"2016-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-24, 2016-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide \", \"trade_name\": \"Genvoya\", \"indication\": \"Genvoya\\u00ae is indicated for the treatment of adults and adolescents infected with human immunodeficiency virus \\u2013 1 .\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2015-11-24T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:32\", \"rr_start\": \"2014-05-22T00:00:00\", \"rr_end\": \"2014-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-22, 2014-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Empagliflozin \", \"trade_name\": \"Jardiance\", \"indication\": \"Add-on combination therapy \", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2014-05-22T00:00:00\", \"latest\": \"2014-06-12T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:33:37\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-07-18T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-12, 2017-07-18\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine / tenofovir disoproxil fumarate \", \"trade_name\": \"Truvada\", \"indication\": \"Truvada\\u00ae is indicated in combination with safer sex practices for pre\\u2011exposure prophylaxis  to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"2005-02-20T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-07-19T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:43\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil \", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil  for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:48\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\\u00ae  type 1.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:52\", \"rr_start\": \"2013-06-28T00:00:00\", \"rr_end\": \"2013-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-28, 2013-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Enzalutamide  on or after chemotherapy\", \"trade_name\": \"Xtandi\", \"indication\": \"Enzalutamide  whose disease has progressed on or after docetaxel therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-06-21T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2013-06-28T00:00:00\", \"latest\": \"2014-04-10T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:33:59\", \"rr_start\": \"2016-12-13T00:00:00\", \"rr_end\": \"2017-02-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-12-13, 2017-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Epoprostenol \", \"trade_name\": \"Veletri\", \"indication\": \"Veletri\\u00ae is indicated for the treatment of pulmonary arterial hypertension  in patients with WHO FC III\\u2013IV symptoms to improve exercise capacity.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2016-12-13T00:00:00\", \"latest\": \"2017-02-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:03\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-15T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-15\", \"rr_multiple\": 0, \"drug_name\": \"Erenumab \", \"trade_name\": \"Aimovig\", \"indication\": \"Erenumab   is indicated for the treatment of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig\\u00ae.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-07-26T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-15T00:00:00\", \"ta_list\": \"Migraine Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:07\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-03-11, 2011-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Eribulin \", \"trade_name\": \"Halaven\", \"indication\": \"Eribulin  for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.\", \"ncpe_year\": 2014, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2011-02-09T00:00:00\", \"latest\": \"2014-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Liposarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:09\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-08-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2009-09-01, 2009-08-01\", \"rr_multiple\": 0, \"drug_name\": \"Eslicarbazepine \", \"trade_name\": \"Zebinix\", \"indication\": \"Eslicarbazepine  for the treatment of Epilepsy\", \"ncpe_year\": 2009, \"eu_market\": \"2009-04-21T00:00:00\", \"company\": \"BIAL\", \"orphan\": 0, \"earliest\": \"2009-08-01T00:00:00\", \"latest\": \"2009-09-01T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:12\", \"rr_start\": \"2016-03-22T00:00:00\", \"rr_end\": \"2016-05-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2016-03-22, 2016-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Etanercept \", \"trade_name\": \"Benepali\", \"indication\": \"Benepali\\u00ae is a biosimilar of the TNF-\\u03b1 inhibitor Etanercept  for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-01-13T00:00:00\", \"company\": \"Samsung\", \"orphan\": 0, \"earliest\": \"2016-03-22T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:15\", \"rr_start\": \"2017-06-14T00:00:00\", \"rr_end\": \"2017-09-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-06-14, 2017-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Etelcalcetide \", \"trade_name\": \"Parsabiv\", \"indication\": \"Etelcalcitide  on haemodialysis.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-11T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2017-06-14T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Hyperparathyroidism, Secondary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:21\", \"rr_start\": \"2012-05-22T00:00:00\", \"rr_end\": \"2012-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-05-22, 2012-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Piperaquine tetraphosphate/dihidroartemisinin \", \"trade_name\": \"Eurartesim\", \"indication\": \"Eurartesim\\u00ae  for uncomplicated malaria caused by the Plasmodium falciparum parasite\", \"ncpe_year\": 2012, \"eu_market\": \"2011-10-27T00:00:00\", \"company\": \"Alfasigma\", \"orphan\": 0, \"earliest\": \"2012-05-22T00:00:00\", \"latest\": \"2012-05-28T00:00:00\", \"ta_list\": \"Malaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:24\", \"rr_start\": \"2012-09-21T00:00:00\", \"rr_end\": \"2012-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-09-21, 2012-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Afinitor\", \"indication\": \"Treatment of hormone receptor-positive , in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor\", \"ncpe_year\": 2012, \"eu_market\": \"2009-08-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-09-21T00:00:00\", \"latest\": \"2012-10-12T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell; Breast Neoplasms; Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:26\", \"rr_start\": \"2017-04-19T00:00:00\", \"rr_end\": \"2017-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-04-19, 2017-04-26\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus : adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.\", \"ncpe_year\": 2017, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2017-04-19T00:00:00\", \"latest\": \"2017-04-26T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:29\", \"rr_start\": \"2011-09-30T00:00:00\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-30, 2011-10-14\", \"rr_multiple\": 0, \"drug_name\": \"Everolimus \", \"trade_name\": \"Votubia\", \"indication\": \"Everolimus  who require therapeutic intervention but are not amenable to surgery\", \"ncpe_year\": 2011, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2011-09-30T00:00:00\", \"latest\": \"2011-10-14T00:00:00\", \"ta_list\": \"Tuberous Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:36\", \"rr_start\": \"\", \"rr_end\": \"2011-10-14T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Evolocumab \", \"trade_name\": \"Repatha\", \"indication\": \"Evolocumab  is indicated for both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-17T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-01-01T00:00:00\", \"latest\": \"2018-05-16T00:00:00\", \"ta_list\": \"Dyslipidemias; Hypercholesterolemia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:34:41\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Exenatide \", \"trade_name\": \"Bydureon\", \"indication\": \"Exenatide  for the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-06-17T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2011-06-09T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:34:44\", \"rr_start\": \"2011-09-11T00:00:00\", \"rr_end\": \"2011-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-09-11, 2011-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Fampridine \", \"trade_name\": \"Fampyra\", \"indication\": \"Fampridine .\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-20T00:00:00\", \"company\": \"Blogen\", \"orphan\": 0, \"earliest\": \"2011-09-01T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:48\", \"rr_start\": \"2016-08-12T00:00:00\", \"rr_end\": \"2016-09-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended\", \"rr_dates\": \"2016-08-12, 2016-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Ferric maltol \", \"trade_name\": \"Feraccru\", \"indication\": \"Ferric maltol indicated for the treatment of iron deficiency anaemia  in adult patients.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Shield\", \"orphan\": 0, \"earliest\": \"2016-08-12T00:00:00\", \"latest\": \"2016-09-06T00:00:00\", \"ta_list\": \"Anemia, Iron-Deficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:34:51\", \"rr_start\": \"2012-03-09T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2012-03-09, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Fidaxomicin \", \"trade_name\": \"Dificlir\", \"indication\": \"Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-12-05T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-03-09T00:00:00\", \"latest\": \"2013-02-05T00:00:00\", \"ta_list\": \"Clostridium Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:34:56\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0, \"drug_name\": \"Fingolimod \", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod  for the treatment of highly active relapsing-remitting multiple sclerosis.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:01\", \"rr_start\": \"2016-02-15T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2016-02-15, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Fluocinolone acetonide \", \"trade_name\": \"Iluvien\", \"indication\": \"Iluvien\\u00ae is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema  considered insufficiently responsive to available therapies.\", \"ncpe_year\": 2016, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-02-15T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:05\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy\\u2122 Ellipta\\u2122 be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero \", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\\u2122 Ellipta\\u2122 which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:12\", \"rr_start\": \"\", \"rr_end\": \"2017-08-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Gefitinib \", \"trade_name\": \"Iressa\", \"indication\": \"A review of the economic evaluation of oral gefitinib  for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-06-24T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-16T00:00:00\", \"latest\": \"2010-11-05T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:15\", \"rr_start\": \"2018-06-21T00:00:00\", \"rr_end\": \"2018-07-17T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of gemtuzumab ozogamicin compared with the current standard of care.\", \"rr_dates\": \"2018-06-21, 2018-07-17\", \"rr_multiple\": 0, \"drug_name\": \"Gemtuzumab ozogamicin \", \"trade_name\": \"Mylotarg\", \"indication\": \"Gemtuzumab ozogamicin  which is indicated for combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-04-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-06-21T00:00:00\", \"latest\": \"2018-07-31T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:19\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-07-11, 2017-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glecaprevir/Pibrentasvir \", \"trade_name\": \"Maviret\", \"indication\": \"Glecaprevir/pibrentasvir  infection in adults \\u2013 pangenotypic GT1-6.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-08-17T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:25\", \"rr_start\": \"\", \"rr_end\": \"2017-08-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Glucosamine sulfate \", \"trade_name\": \"Dona\", \"indication\": \"Economic evalution of glucosamine sulfate  for the treatment of oestoarthritis in the Irish Healthcare setting.\", \"ncpe_year\": 2009, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2009-04-01T00:00:00\", \"latest\": \"2009-06-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:35:32\", \"rr_start\": \"2018-03-26T00:00:00\", \"rr_end\": \"2018-06-20T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti\\u00ae) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-26, 2018-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Glycerol Phenylbutyrate \", \"trade_name\": \"Ravicti\", \"indication\": \"Glycerol phenylbutyrate .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-11-26T00:00:00\", \"company\": \"Horizon\", \"orphan\": 1, \"earliest\": \"2018-03-26T00:00:00\", \"latest\": \"2018-06-20T00:00:00\", \"ta_list\": \"Urea Cycle Disorders, Inborn\", \"rr_status\": \"Reimbursement without HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:38\", \"rr_start\": \"2012-08-12T00:00:00\", \"rr_end\": \"2012-08-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2012-08-12, 2012-08-17\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Seebri Breezhaler\", \"indication\": \"Seebri Breezhaler\\u00ae is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2012, \"eu_market\": \"2012-09-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2012-08-12T00:00:00\", \"latest\": \"2012-08-17T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:40\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide  in children and adolescents aged 3 years and older with chronic neurological disorders\", \"ncpe_year\": 2017, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:35:47\", \"rr_start\": \"2013-10-11T00:00:00\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-11, 2013-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab  for UC\", \"trade_name\": \"Simponi\", \"indication\": \"Golimumab is indicated for the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments.\", \"ncpe_year\": 2013, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2013-10-11T00:00:00\", \"latest\": \"2013-10-31T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:54\", \"rr_start\": \"\", \"rr_end\": \"2013-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Golimumab \", \"trade_name\": \"Simponi\", \"indication\": \"Cost-effectiveness of golimumab  in the treatment of moderate to severe rheumatoid arthritis.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-10-01T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2009-11-20T00:00:00\", \"latest\": \"2010-06-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:36:00\", \"rr_start\": \"2015-12-01T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-01, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Guanfacine hydrochloride \", \"trade_name\": \"Intuniv\", \"indication\": \"Intuniv\\u00ae is indicated for the treatment of attention deficit hyperactivity disorder  in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-09-17T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2015-12-01T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Attention Deficit Disorder with Hyperactivity\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:02\", \"rr_start\": \"2017-12-01T00:00:00\", \"rr_end\": \"2018-02-06T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-01, 2018-02-06\", \"rr_multiple\": 0, \"drug_name\": \"Guselkumab \", \"trade_name\": \"Tremfya\", \"indication\": \"Guselkumab  for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-10T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2017-12-01T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-06-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-05, 2017-06-08\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Prolastin\", \"indication\": \"Human A1PI .\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-06-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:14\", \"rr_start\": \"2016-01-20T00:00:00\", \"rr_end\": \"2016-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-20, 2016-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Human alpha1-proteinase inhibitor \", \"trade_name\": \"Respreeza\", \"indication\": \"Respreeza\\u00ae is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency  as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-08-20T00:00:00\", \"company\": \"CSL\", \"orphan\": 0, \"earliest\": \"2016-01-20T00:00:00\", \"latest\": \"2017-01-01T00:00:00\", \"ta_list\": \"Genetic Diseases, Inborn; Lung Diseases\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:17\", \"rr_start\": \"2017-11-06T00:00:00\", \"rr_end\": \"2017-11-30T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-06, 2017-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Hyaluronic acid and co enzyme Q10 \", \"trade_name\": \"VisuXL\", \"indication\": \"Cross linked hyaluronic acid and co enzyme Q10  for the treatment of dry eye disease and the treatment of post-surgical intervention following elective surgery and trauma.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-11-06T00:00:00\", \"latest\": \"2017-11-30T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:22\", \"rr_start\": \"2017-11-08T00:00:00\", \"rr_end\": \"2017-11-01T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2017-11-08, 2018-01-11, 2017-11-01\", \"rr_multiple\": 1, \"drug_name\": \"Modified Release Hydrocortisone  \", \"trade_name\": \"Plenadren\", \"indication\": \"Modified release hydrocortisone  for the treatment of adrenal insufficiency in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-03T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-08-09T00:00:00\", \"latest\": \"2018-01-11T00:00:00\", \"ta_list\": \"Adrenal Insufficiency\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:36:27\", \"rr_start\": \"2011-08-22T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-22, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Hydroxycarbamide \", \"trade_name\": \"Siklos\", \"indication\": \" Hydroxycarbamide  is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"Addmedica\", \"orphan\": 1, \"earliest\": \"2011-08-22T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Anemia, Sickle Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:32\", \"rr_start\": \"2016-08-02T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2016-08-02, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for previously untreated CLL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib . This indication is an extension to the original licence in the relapsed/refractory setting.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2016-08-02T00:00:00\", \"latest\": \"2016-08-24T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:36\", \"rr_start\": \"2014-11-07T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-11-07, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ibrutinib  for MCL\", \"trade_name\": \"Imbruvica\", \"indication\": \"Ibrutinib .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-10-21T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-11-07T00:00:00\", \"latest\": \"2015-10-06T00:00:00\", \"ta_list\": \"Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:40\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Icatibant \", \"trade_name\": \"Firazyr\", \"indication\": \"Icatibant .\", \"ncpe_year\": 2013, \"eu_market\": \"2008-07-11T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Angioedemas, Hereditary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:43\", \"rr_start\": \"2015-12-11T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-11, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Idarucizumab \", \"trade_name\": \"Praxbind\", \"indication\": \"Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa  when rapid reversal of its anticoagulant effects is required:\", \"ncpe_year\": 2015, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-12-11T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Hemorrhage\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:36:50\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-04-14T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2016-02-10, 2016-04-14\", \"rr_multiple\": 0, \"drug_name\": \"Idebenone \", \"trade_name\": \"Raxone\", \"indication\": \"Raxone\\u00ae is indicated for the treatment of visual impairment in adolescent and adult patients with Leber\\u2019s Hereditary Optic Neuropathy .\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-08T00:00:00\", \"company\": \"Santhera\", \"orphan\": 1, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2018-08-28T00:00:00\", \"ta_list\": \"Optic Atrophy, Hereditary, Leber\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:56\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0, \"drug_name\": \"Idelalisib \", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia  who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:36:59\", \"rr_start\": \"2013-09-10T00:00:00\", \"rr_end\": \"2013-09-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-09-10, 2013-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Imiquimod 3.75% \", \"trade_name\": \"Zyclara\", \"indication\": \"Imiquimod 3.75% of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Meda\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-18T00:00:00\", \"ta_list\": \"Keratosis; Keratosis, Actinic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:01\", \"rr_start\": \"2014-02-07T00:00:00\", \"rr_end\": \"2014-03-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-07, 2014-03-05\", \"rr_multiple\": 0, \"drug_name\": \"Incobotulinum Toxin Type A \", \"trade_name\": \"Xeomin\", \"indication\": \"Incobotulinum Toxin Type A  and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-02-07T00:00:00\", \"latest\": \"2014-03-05T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:07\", \"rr_start\": \"\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Infliximab \", \"trade_name\": \"Inflectra\", \"indication\": \"Inflectra\\u00ae is a biosimilar product indicated for Rheumatoid Arthritis, Adult Crohn\\u2019s disease, Paediatric Crohn\\u2019s disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-09-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-10T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:37:09\", \"rr_start\": \"2017-07-03T00:00:00\", \"rr_end\": \"2017-09-08T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-03, 2017-09-08\", \"rr_multiple\": 0, \"drug_name\": \"Inotuzumab ozogamicin \", \"trade_name\": \"Besponsa\", \"indication\": \"Inotuzumab ozogamicin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-06-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2017-07-03T00:00:00\", \"latest\": \"2018-09-14T00:00:00\", \"ta_list\": \"Precursor Cell Lymphoblastic Leukemia-Lymphoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:16\", \"rr_start\": \"2017-05-17T00:00:00\", \"rr_end\": \"2017-06-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-17, 2017-06-14\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"Fiasp\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-01-09T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2017-05-17T00:00:00\", \"latest\": \"2017-06-14T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:25\", \"rr_start\": \"2012-12-17T00:00:00\", \"rr_end\": \"2013-01-04T00:00:00\", \"rr_outcome\": \" Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-12-17, 2013-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Degludec \", \"trade_name\": \"Tresiba\", \"indication\": \"Treatment of diabetes mellitus\", \"ncpe_year\": 2015, \"eu_market\": \"2013-01-20T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2012-12-17T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:30\", \"rr_start\": \"2016-09-19T00:00:00\", \"rr_end\": \"2016-10-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.  \", \"rr_dates\": \"2016-09-19, 2016-10-17\", \"rr_multiple\": 0, \"drug_name\": \"Insulin degludec/liraglutide \", \"trade_name\": \"Xultophy\", \"indication\": \"IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus  or basal insulin does not provide adequate glycaemic control.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2016-09-19T00:00:00\", \"latest\": \"2016-10-17T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:36\", \"rr_start\": \"2015-09-04T00:00:00\", \"rr_end\": \"2015-10-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-09-04, 2015-10-12\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine \", \"trade_name\": \"Abasaglar\", \"indication\": \"Abasaglar\\u00ae is indicated in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-09-04T00:00:00\", \"latest\": \"2015-10-12T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:40\", \"rr_start\": \"2015-05-14T00:00:00\", \"rr_end\": \"2015-07-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2015-05-14, 2015-07-02\", \"rr_multiple\": 0, \"drug_name\": \"Insulin Glargine U300 \", \"trade_name\": \"Toujeo\", \"indication\": \"Toujeo\\u00ae is indicated for the treatment of diabetes mellitus in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-05-14T00:00:00\", \"latest\": \"2015-07-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:43\", \"rr_start\": \"2011-05-31T00:00:00\", \"rr_end\": \"2011-06-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-05-31, 2011-06-09\", \"rr_multiple\": 0, \"drug_name\": \"Ipilimumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Pharmacoeconomic evaluation of Ipilimumab  melanoma in adult patients who have received prior therapy.\", \"ncpe_year\": 2013, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2011-05-31T00:00:00\", \"latest\": \"2013-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:37:49\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Diafer\", \"indication\": \"Diafer\\u00ae is indicated in adults for the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:52\", \"rr_start\": \"2015-10-10T00:00:00\", \"rr_end\": \"2015-11-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-10-10, 2015-11-18\", \"rr_multiple\": 0, \"drug_name\": \"Iron \", \"trade_name\": \"Monover\", \"indication\": \"Monover\\u00ae is indicated in the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2015-10-10T00:00:00\", \"latest\": \"2015-11-18T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:02\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0, \"drug_name\": \"Iron isomaltoside 1000 \", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:07\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of invasive aspergillosis.\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated for the treatment of invasive aspergillosis\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:09\", \"rr_start\": \"2016-04-11T00:00:00\", \"rr_end\": \"2016-05-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended. \", \"rr_dates\": \"2016-04-11, 2016-05-11\", \"rr_multiple\": 0, \"drug_name\": \"Isavuconazole  for the treatment of mucormycosis\", \"trade_name\": \"Cresemba\", \"indication\": \"Isavuconazole  is indicated in adults for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-10-15T00:00:00\", \"company\": \"Basilea\", \"orphan\": 1, \"earliest\": \"2016-04-11T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Aspergillosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:15\", \"rr_start\": \"2012-08-13T00:00:00\", \"rr_end\": \"2012-08-22T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2012-08-13, 2012-08-22\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor \", \"trade_name\": \"Kalydeco\", \"indication\": \"For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation\", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2012-08-13T00:00:00\", \"latest\": \"2013-01-21T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:21\", \"rr_start\": \"2015-11-19T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmaoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-19, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for patients with CF 2 years +\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae is indicated for the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating  mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2015-11-19T00:00:00\", \"latest\": \"2016-10-12T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:24\", \"rr_start\": \"2016-01-14T00:00:00\", \"rr_end\": \"2016-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-14, 2016-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Ivacaftor  for the treatment of CF patients with the R117H mutation.\", \"trade_name\": \"Kalydeco\", \"indication\": \"Kalydeco\\u00ae for the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.\", \"ncpe_year\": 2017, \"eu_market\": \"2012-07-22T00:00:00\", \"company\": \"Vertex\", \"orphan\": 1, \"earliest\": \"2016-01-14T00:00:00\", \"latest\": \"2017-01-05T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:29\", \"rr_start\": \"2016-11-23T00:00:00\", \"rr_end\": \"2017-01-16T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-23, 2017-01-16\", \"rr_multiple\": 0, \"drug_name\": \"Ixazomib \", \"trade_name\": \"Ninlaro\", \"indication\": \"Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-11-21T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2016-11-23T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:34\", \"rr_start\": \"2018-10-16T00:00:00\", \"rr_end\": \"2018-11-19T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is not recommended. The NCPE recommends that ixekizumab not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013\", \"rr_dates\": \"2018-10-16, 2018-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab  for psoriatic arthritis\", \"trade_name\": \"Taltz\", \"indication\": \"Ixekizumab  therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2018-10-16T00:00:00\", \"latest\": \"2018-11-19T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:37\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-28, 2016-07-26\", \"rr_multiple\": 0, \"drug_name\": \"Ixekizumab \", \"trade_name\": \"Taltz\", \"indication\": \"Taltz\\u00ae is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-09-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:39\", \"rr_start\": \"2013-02-09T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-02-09, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Lisdexamfetamine dimesylate \", \"trade_name\": \"Tyvense\", \"indication\": \"Lisdexamfetamine dimesylate  for Attention Deficit Hyperactivity Disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.\", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-02-09T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:38:44\", \"rr_start\": \"2017-09-11T00:00:00\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic evaluation is recommended at the submitted price.\\n \", \"rr_dates\": \"2017-09-11, 2017-10-31\", \"rr_multiple\": 0, \"drug_name\": \"Lacosamide \", \"trade_name\": \"Vimpat\", \"indication\": \"Vimpat \\u00ae is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-08-29T00:00:00\", \"company\": \"UCB\", \"orphan\": 0, \"earliest\": \"2017-09-11T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:38:50\", \"rr_start\": \"\", \"rr_end\": \"2017-10-31T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Lapatinib \", \"trade_name\": \"Tyverb\", \"indication\": \"Cost-effectiveness of Lapatinib  for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-06-10T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-01-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:38:56\", \"rr_start\": \"2014-11-14T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-11-14, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ledipasvir/sofosbuvir \", \"trade_name\": \"Harvoni\", \"indication\": \"Ledipasvir/sofosbuvir   in adults.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-11-17T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2014-11-14T00:00:00\", \"latest\": \"2015-11-20T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:05\", \"rr_start\": \"2015-10-05T00:00:00\", \"rr_end\": \"2015-11-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at submitted price.\", \"rr_dates\": \"2015-10-05, 2015-11-20\", \"rr_multiple\": 0, \"drug_name\": \"Lenalidomide \", \"trade_name\": \"Revlimid\", \"indication\": \"Revlimid\\u00ae for the treatment of adult patients with previously untreated multiple myelomas .\", \"ncpe_year\": 2018, \"eu_market\": \"2007-06-14T00:00:00\", \"company\": \"Celgene\", \"orphan\": 1, \"earliest\": \"2015-10-05T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:07\", \"rr_start\": \"2017-05-05T00:00:00\", \"rr_end\": \"2017-05-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-05-05, 2017-05-18\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Kisplyx\", \"indication\": \"Lenvatinib -targeted therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-25T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2017-05-05T00:00:00\", \"latest\": \"2017-05-18T00:00:00\", \"ta_list\": \"Carcinoma, Renal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:11\", \"rr_start\": \"2018-08-07T00:00:00\", \"rr_end\": \"2018-08-16T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-08-07, 2018-08-16\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib  for HCC\", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib  which is indicated as monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2018-08-07T00:00:00\", \"latest\": \"2018-08-16T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:15\", \"rr_start\": \"2015-05-05T00:00:00\", \"rr_end\": \"2015-07-09T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2015-05-05, 2015-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Lenvatinib \", \"trade_name\": \"Lenvima\", \"indication\": \"Lenvatinib is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated , refractory to radioactive iodine.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-28T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2015-05-05T00:00:00\", \"latest\": \"2015-07-09T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:20\", \"rr_start\": \"2017-03-15T00:00:00\", \"rr_end\": \"2017-03-20T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-15, 2017-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Lesinurad \", \"trade_name\": \"Zurampic\", \"indication\": \"Lesinurad  for the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2017-03-15T00:00:00\", \"latest\": \"2018-12-06T00:00:00\", \"ta_list\": \"Hyperuricemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:25\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Letermovir \", \"trade_name\": \"Prevymis\", \"indication\": \"Letermovir for the prophylaxis of cytomegalovirus .\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Merck\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Cytomegalovirus Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:34\", \"rr_start\": \"2016-02-10T00:00:00\", \"rr_end\": \"2016-03-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price. \", \"rr_dates\": \"2016-02-10, 2016-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Levofloxacin \", \"trade_name\": \"Quinsair\", \"indication\": \"Levofloxacin  is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-03-25T00:00:00\", \"company\": \"Horizon\", \"orphan\": 0, \"earliest\": \"2016-02-10T00:00:00\", \"latest\": \"2016-03-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis; Respiratory Tract Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:39\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-02-08, 2017-03-16\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine delivery system LNG IUS 12 \", \"trade_name\": \"Kyleena\", \"indication\": \"Kyleena\\u00ae   which is indicated for contraception for up to 5 years.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2017-03-16T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:51\", \"rr_start\": \"2013-05-28T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-05-28, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Linaclotide \", \"trade_name\": \"Constella\", \"indication\": \"Linaclotide  in adults.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-11-26T00:00:00\", \"company\": \"Allergan\", \"orphan\": 0, \"earliest\": \"2013-05-28T00:00:00\", \"latest\": \"2013-06-28T00:00:00\", \"ta_list\": \"Irritable Bowel Syndrome\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:54\", \"rr_start\": \"2011-08-18T00:00:00\", \"rr_end\": \"2011-09-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-08-18, 2011-09-06\", \"rr_multiple\": 0, \"drug_name\": \"Linagliptin \", \"trade_name\": \"Trajenta\", \"indication\": \"Lingagliptin  for treatment of type 2 diabetes mellitus to improve glycaemic control in adults, as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment, as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control, in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-08-23T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2011-08-18T00:00:00\", \"latest\": \"2011-09-06T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:57\", \"rr_start\": \"2013-08-20T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2013-08-20, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Lipegfilgrastim \", \"trade_name\": \"Lonquex\", \"indication\": \"Lonquex\\u00ae is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy .\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-25T00:00:00\", \"company\": \"Sicor\", \"orphan\": 0, \"earliest\": \"2013-08-20T00:00:00\", \"latest\": \"2013-09-20T00:00:00\", \"ta_list\": \"Neutropenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:00\", \"rr_start\": \"2018-09-28T00:00:00\", \"rr_end\": \"2018-11-08T00:00:00\", \"rr_outcome\": \"A Full Pharmacoeconomic Assessment is recommended\", \"rr_dates\": \"2018-09-28, 2018-11-08\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal daunorubicin and cytarabine \", \"trade_name\": \"Vyxeos\", \"indication\": \"Liposomal daunorubicin and cytarabine  or AML with myelodysplasia-related changes.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-23T00:00:00\", \"company\": \"Jazz\", \"orphan\": 1, \"earliest\": \"2018-09-28T00:00:00\", \"latest\": \"2018-11-08T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:06\", \"rr_start\": \"2017-06-13T00:00:00\", \"rr_end\": \"2017-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2017-06-13, 2017-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Liposomal irinotecan \", \"trade_name\": \"Onivyde\", \"indication\": \"Liposomal irinotecan  is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-10-14T00:00:00\", \"company\": \"Baxalta\", \"orphan\": 1, \"earliest\": \"2017-06-13T00:00:00\", \"latest\": \"2017-07-13T00:00:00\", \"ta_list\": \"Pancreatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Liquid Paraffin Ointment \", \"trade_name\": \"VitA-POS Opthalmic\", \"indication\": \"Liquid Paraffin Ointment  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:13\", \"rr_start\": \"2009-09-01T00:00:00\", \"rr_end\": \"2009-10-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2009-09-01, 2009-10-07\", \"rr_multiple\": 0, \"drug_name\": \"Liraglutide \", \"trade_name\": \"Victoza\", \"indication\": \"Victoza\\u00ae  is indicated for treatment of adults with type 2 diabetes mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"2009-06-30T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2009-09-01T00:00:00\", \"latest\": \"2018-10-30T00:00:00\", \"ta_list\": \"Diabetes Mellitus, Type 2\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:17\", \"rr_start\": \"2013-03-21T00:00:00\", \"rr_end\": \"2013-04-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-03-21, 2013-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Lixisenatide \", \"trade_name\": \"Lyxumia\", \"indication\": \"Lixisenatide  for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-03-21T00:00:00\", \"latest\": \"2014-08-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:19\", \"rr_start\": \"2014-09-09T00:00:00\", \"rr_end\": \"2014-09-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-09, 2014-09-15\", \"rr_multiple\": 0, \"drug_name\": \"Lomitapide \", \"trade_name\": \"Lojuxta\", \"indication\": \"Lojuxta\\u00ae is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-07-31T00:00:00\", \"company\": \"Amryt\", \"orphan\": 0, \"earliest\": \"2014-09-09T00:00:00\", \"latest\": \"2014-09-15T00:00:00\", \"ta_list\": \"Hypercholesterolemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:22\", \"rr_start\": \"2011-06-23T00:00:00\", \"rr_end\": \"2011-07-07T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-23, 2011-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Lornoxicam \", \"trade_name\": \"Xefo\", \"indication\": \" Lornoxicam  for the Short-term relief of acute mild to moderate pain and symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis\", \"ncpe_year\": 2011, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2011-06-23T00:00:00\", \"latest\": \"2011-07-07T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:30\", \"rr_start\": \"2016-06-21T00:00:00\", \"rr_end\": \"2016-07-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-06-21, 2016-07-28\", \"rr_multiple\": 0, \"drug_name\": \"Loxapine inhalation powder \", \"trade_name\": \"Adasuve\", \"indication\": \"Inhaled loxapine is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-02-20T00:00:00\", \"company\": \"Ferrer\", \"orphan\": 0, \"earliest\": \"2016-06-21T00:00:00\", \"latest\": \"2016-07-28T00:00:00\", \"ta_list\": \"Schizophrenia; Bipolar Disorder\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:34\", \"rr_start\": \"2015-11-26T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-26, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Lumacaftor/ivacaftor \", \"trade_name\": \"Orkambi\", \"indication\": \"Orkambi\\u00ae is indicated for the treatment of cystic fibrosis  in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Vertex\", \"orphan\": 0, \"earliest\": \"2015-11-26T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Cystic Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:36\", \"rr_start\": \"2018-10-23T00:00:00\", \"rr_end\": \"2018-11-16T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-10-23, 2018-11-16\", \"rr_multiple\": 0, \"drug_name\": \"Lutetium \", \"trade_name\": \"Lutathera\", \"indication\": \"Lutetium  in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-26T00:00:00\", \"company\": \"Advanced\", \"orphan\": 1, \"earliest\": \"2018-10-23T00:00:00\", \"latest\": \"2018-11-16T00:00:00\", \"ta_list\": \"Neuroendocrine Tumors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:41\", \"rr_start\": \"2014-01-10T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-10, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Macitentan \", \"trade_name\": \"Opsumit\", \"indication\": \"Macitentan is indicated as monotherapy or in combination, for the long term treatment of pulmonary arterial hypertension  II to III.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-12-20T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 1, \"earliest\": \"2014-01-10T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:43\", \"rr_start\": \"\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Melatonin \", \"trade_name\": \"Circadin\", \"indication\": \"A Review of the Economic Evaluation of Prolonged Release Melatonin  For The Short-Term Treatment of Primary Insomnia.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-06-29T00:00:00\", \"company\": \"RAD\", \"orphan\": 0, \"earliest\": \"2008-08-01T00:00:00\", \"latest\": \"2008-10-01T00:00:00\", \"ta_list\": \"Sleep Initiation and Maintenance Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:40:45\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Mepolizumab \", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab  is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:56\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for AML\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin  who are FLT3 mutation positive.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:02\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0, \"drug_name\": \"Midostaurin  for ASM\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:04\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-07-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-07-13\", \"rr_multiple\": 0, \"drug_name\": \"Mifamurtide \", \"trade_name\": \"Mepact\", \"indication\": \"Mifamurtide  for the treatment of osteosarcoma.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-03-06T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1, \"earliest\": \"2010-06-22T00:00:00\", \"latest\": \"2010-07-13T00:00:00\", \"ta_list\": \"Osteosarcoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:06\", \"rr_start\": \"2016-07-14T00:00:00\", \"rr_end\": \"2016-08-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-07-14, 2016-08-18\", \"rr_multiple\": 0, \"drug_name\": \"Migalastat \", \"trade_name\": \"Galafold\", \"indication\": \"Migalastat is indicated for the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-05-25T00:00:00\", \"company\": \"Amicus\", \"orphan\": 1, \"earliest\": \"2016-07-14T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Fabry Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:13\", \"rr_start\": \"2012-12-19T00:00:00\", \"rr_end\": \"2013-03-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2012-12-19, 2013-03-12\", \"rr_multiple\": 0, \"drug_name\": \"Mirabegron \", \"trade_name\": \"Betmiga\", \"indication\": \"Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder  syndrome\", \"ncpe_year\": 2013, \"eu_market\": \"2012-12-20T00:00:00\", \"company\": \"Astellas\", \"orphan\": 0, \"earliest\": \"2012-12-19T00:00:00\", \"latest\": \"2013-03-12T00:00:00\", \"ta_list\": \"Urinary Bladder, Overactive\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:15\", \"rr_start\": \"2014-01-23T00:00:00\", \"rr_end\": \"2014-03-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-01-23, 2014-03-02\", \"rr_multiple\": 0, \"drug_name\": \"Nab-paclitaxel \", \"trade_name\": \"Abraxane\", \"indication\": \"Nab-paclitaxel  in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.\", \"ncpe_year\": 2015, \"eu_market\": \"2008-01-10T00:00:00\", \"company\": \"Celgene\", \"orphan\": 0, \"earliest\": \"2014-01-23T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:18\", \"rr_start\": \"2013-06-07T00:00:00\", \"rr_end\": \"2013-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-07, 2013-06-28\", \"rr_multiple\": 0, \"drug_name\": \"Nalmefene \", \"trade_name\": \"Selincro\", \"indication\": \"Nalmefene  is indicated for the reduction of alcohol consumption in those aged \\u226518 years with alcohol dependence, who do not require immediate detoxification.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-02-24T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2013-06-07T00:00:00\", \"latest\": \"2014-04-08T00:00:00\", \"ta_list\": \"Alcohol-Related Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-04-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-04-13\", \"rr_multiple\": 0, \"drug_name\": \"Naloxegel \", \"trade_name\": \"Moventig\", \"indication\": \"Naloxegel .\", \"ncpe_year\": 2015, \"eu_market\": \"2014-12-07T00:00:00\", \"company\": \"Kyowa\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-04-13T00:00:00\", \"ta_list\": \"Constipation; Opioid-Related Disorders\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:26\", \"rr_start\": \"2017-03-12T00:00:00\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-03-12, 2017-03-28\", \"rr_multiple\": 0, \"drug_name\": \"Naltrexone / bupropion \", \"trade_name\": \"Mysimba\", \"indication\": \"Naltrexone / bupropion  in the presence of one or more weight-related co-morbidities.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-03-26T00:00:00\", \"company\": \"Orexigen\", \"orphan\": 0, \"earliest\": \"2017-03-12T00:00:00\", \"latest\": \"2018-05-09T00:00:00\", \"ta_list\": \"Obesity; Overweight\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:30\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Natalizumab \", \"trade_name\": \"Tysabri\", \"indication\": \" Economic Evaluation of Natalizumab  for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.\", \"ncpe_year\": 2007, \"eu_market\": \"2006-06-27T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2007-01-01T00:00:00\", \"latest\": \"2007-03-01T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:35\", \"rr_start\": \"\", \"rr_end\": \"2017-03-28T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Inhaled insulin \", \"trade_name\": \"Exubera\", \"indication\": \"In April 2006, Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin  versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes. The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-01-24T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-03-01T00:00:00\", \"latest\": \"2006-03-01T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:38\", \"rr_start\": \"2011-06-14T00:00:00\", \"rr_end\": \"2011-06-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-06-14, 2011-06-27\", \"rr_multiple\": 0, \"drug_name\": \"Nepafenac \", \"trade_name\": \"Nevanac\", \"indication\": \"Nepafenac  for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"2007-12-11T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2011-06-14T00:00:00\", \"latest\": \"2011-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative; Ophthalmologic Surgical Procedures\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:41\", \"rr_start\": \"2015-08-26T00:00:00\", \"rr_end\": \"2015-10-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-08-26, 2015-10-13\", \"rr_multiple\": 0, \"drug_name\": \"Netupitant/palonosetron \", \"trade_name\": \"Akynzeo\", \"indication\": \"Akynzeo\\u00ae is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and for prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Helsinn\", \"orphan\": 0, \"earliest\": \"2015-08-26T00:00:00\", \"latest\": \"2015-10-13T00:00:00\", \"ta_list\": \"Vomiting; Cancer; Nausea\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:41:44\", \"rr_start\": \"2010-10-06T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-10-06, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  newly diagnosed CML\", \"trade_name\": \"Tasigna\", \"indication\": \"Nilotinib  for the newly diagnosed Chronic Phase Philadelpha Chromosone positive CML.\", \"ncpe_year\": 2010, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-10-06T00:00:00\", \"latest\": \"2010-10-22T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:51\", \"rr_start\": \"\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nilotinib  CML resistant/intolerant to imatinib\", \"trade_name\": \"Tasigna\", \"indication\": \"Cost-effectiveness of Nilotinib  for the treatment of chronic phase CML.\", \"ncpe_year\": 2008, \"eu_market\": \"2007-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2008-01-01T00:00:00\", \"latest\": \"2008-02-01T00:00:00\", \"ta_list\": \"Leukemia, Myelogenous, Chronic, BCR-ABL Positive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:41:53\", \"rr_start\": \"2015-01-30T00:00:00\", \"rr_end\": \"2015-02-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-30, 2015-02-18\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Ofev\", \"indication\": \"Nintedanib .\", \"ncpe_year\": 2017, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 1, \"earliest\": \"2015-01-30T00:00:00\", \"latest\": \"2017-06-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:41:56\", \"rr_start\": \"2015-01-02T00:00:00\", \"rr_end\": \"2015-02-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-02, 2015-02-10\", \"rr_multiple\": 0, \"drug_name\": \"Nintedanib \", \"trade_name\": \"Vargatef\", \"indication\": \"Nintedanib  indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-11-21T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0, \"earliest\": \"2015-01-02T00:00:00\", \"latest\": \"2017-02-01T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:00\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care\", \"rr_dates\": \"2018-06-01, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Niraparib \", \"trade_name\": \"Zejula\", \"indication\": \"Niraparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-11-16T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 1, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:06\", \"rr_start\": \"2015-05-28T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-05-28, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for Melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated as for monotherapy treatment for patients diagnosed with unresectable metastatic melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-05-28T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:13\", \"rr_start\": \"2016-03-03T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-03-03, 2016-04-04\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for non-squamous NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is indicated for the treatment of adults with locally advanced or metastatic non-squamous NSCLC after prior chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-03-03T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:20\", \"rr_start\": \"2015-07-02T00:00:00\", \"rr_end\": \"2015-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-07-02, 2015-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for NSCLC\", \"trade_name\": \"Opdivo\", \"indication\": \"Opdivo\\u00ae is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2015-07-02T00:00:00\", \"latest\": \"2018-09-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:26\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care.\", \"rr_dates\": \"2018-07-09, 2018-07-27\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy for the adjuvant treatment of adults with melanoma  with involvement of lymph nodes or metastatic disease who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-11-30T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:31\", \"rr_start\": \"2016-04-27T00:00:00\", \"rr_end\": \"2016-05-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended \", \"rr_dates\": \"2016-04-27, 2016-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for advanced renal cell carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-04-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:33\", \"rr_start\": \"2016-11-22T00:00:00\", \"rr_end\": \"2017-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-22, 2017-01-18\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for classical Hodgkin Lymphoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2016-11-22T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:36\", \"rr_start\": \"2017-05-03T00:00:00\", \"rr_end\": \"2017-05-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price \", \"rr_dates\": \"2017-05-03, 2017-05-30\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for head and neck cancer\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  in adults progressing on or after platinum-based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-05-03T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:41\", \"rr_start\": \"2017-06-28T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-06-28, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab  for urothelial carcinoma\", \"trade_name\": \"Opdivo\", \"indication\": \"Nivolumab  as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-06-19T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2017-06-28T00:00:00\", \"latest\": \"2018-09-12T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:42:46\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma .\", \"ncpe_year\": 2018, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:42:51\", \"rr_start\": \"\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Nivolumab plus ipilimumab \", \"trade_name\": \"Opdivo plus Yervoy\", \"indication\": \"Opdivo\\u00ae plus Yervoy\\u00ae Is indicated for the treatment of advanced melanoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2016-06-27T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:42:56\", \"rr_start\": \"2011-12-08T00:00:00\", \"rr_end\": \"2012-01-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-08, 2012-01-03\", \"rr_multiple\": 0, \"drug_name\": \"Nomegestrol acetate/estradiol \", \"trade_name\": \"Zoely\", \"indication\": \"Nomegestrol acetate/estradiol  oral contraception\", \"ncpe_year\": 2012, \"eu_market\": \"2011-07-26T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2011-12-08T00:00:00\", \"latest\": \"2012-01-03T00:00:00\", \"ta_list\": \"Contraception\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:02\", \"rr_start\": \"2017-07-11T00:00:00\", \"rr_end\": \"2017-08-02T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2017-07-11, 2017-08-02\", \"rr_multiple\": 0, \"drug_name\": \"Nusinersin \", \"trade_name\": \"Spinraza\", \"indication\": \"Nusinersen \", \"ncpe_year\": 2017, \"eu_market\": \"2017-05-30T00:00:00\", \"company\": \"Biogen\", \"orphan\": 1, \"earliest\": \"2017-07-11T00:00:00\", \"latest\": \"2017-12-19T00:00:00\", \"ta_list\": \"Muscular Atrophy, Spinal\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:07\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-18, 2016-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Obeticholic acid \", \"trade_name\": \"Ocaliva\", \"indication\": \"Obeticholic acid is indicated for the treatment of primary biliary cirrhosis  in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-12-12T00:00:00\", \"company\": \"Intercept\", \"orphan\": 1, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2017-10-31T00:00:00\", \"ta_list\": \"Liver Cirrhosis, Biliary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:10\", \"rr_start\": \"2016-05-11T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-05-11, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Follicular Lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2016-05-11T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:15\", \"rr_start\": \"2017-08-08T00:00:00\", \"rr_end\": \"2017-09-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-08-08, 2017-09-13\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for previously untreated advanced follicular lymphoma\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2017-08-08T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:21\", \"rr_start\": \"2014-08-08T00:00:00\", \"rr_end\": \"2014-09-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-08-08, 2014-09-11\", \"rr_multiple\": 0, \"drug_name\": \"Obinutuzumab  for Lymphocytic Leukaemia\", \"trade_name\": \"Gazyvaro\", \"indication\": \"Obinutuzumab  in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-07-22T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2014-08-08T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:24\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for PPMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-10-04T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:30\", \"rr_start\": \"2017-11-29T00:00:00\", \"rr_end\": \"2017-12-14T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-29, 2017-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Ocrelizumab  for RMS\", \"trade_name\": \"Ocrevus\", \"indication\": \"Ocrelizumab  with active disease defined by clinical or imaging features.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2017-11-29T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:34\", \"rr_start\": \"2013-06-12T00:00:00\", \"rr_end\": \"2013-07-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2013-06-12, 2013-07-09\", \"rr_multiple\": 0, \"drug_name\": \"Ocriplasmin \", \"trade_name\": \"Jetrea\", \"indication\": \"Ocriplasmin , including when associated with macular hole of diameter less than or equal to 400 microns.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-13T00:00:00\", \"company\": \"ThromboGenics\", \"orphan\": 0, \"earliest\": \"2013-06-12T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Retinal Diseases\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:39\", \"rr_start\": \"2014-10-13T00:00:00\", \"rr_end\": \"2014-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2014-10-13, 2014-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Ofatumumab  who have not received prior therapy and who are not eligible for fludarabine-based therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2014-10-13T00:00:00\", \"latest\": \"2014-12-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:46\", \"rr_start\": \"2010-06-22T00:00:00\", \"rr_end\": \"2010-06-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-06-22, 2010-06-01\", \"rr_multiple\": 0, \"drug_name\": \"Ofatumumab \", \"trade_name\": \"Arzerra\", \"indication\": \"Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-04-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2010-06-01T00:00:00\", \"latest\": \"2010-06-22T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:43:52\", \"rr_start\": \"2014-04-07T00:00:00\", \"rr_end\": \"2014-05-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-04-07, 2014-05-02\", \"rr_multiple\": 0, \"drug_name\": \"Oladaterol \", \"trade_name\": \"Striverdi, Respimat\", \"indication\": \"Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease .\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-04-07T00:00:00\", \"latest\": \"2014-05-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:43:57\", \"rr_start\": \"2015-01-05T00:00:00\", \"rr_end\": \"2015-02-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-01-05, 2015-02-19\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib \", \"trade_name\": \"Lynparza\", \"indication\": \"Lynparza\\u00ae is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated  to platinum-based chemotherapy.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2015-01-05T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:03\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"The NCPE recommend  a full HTA to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Olaparib  for platinum sensitive relapsed ovarian cancer\", \"trade_name\": \"Lynparza\", \"indication\": \"Olaparib  to platinum-based chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-12-16T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-01T00:00:00\", \"ta_list\": \"Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:08\", \"rr_start\": \"\", \"rr_end\": \"2018-10-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab  for the treatment of severe allergic asthma\", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function  as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.\", \"ncpe_year\": 2015, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-08-22T00:00:00\", \"latest\": \"2015-06-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:14\", \"rr_start\": \"2014-03-25T00:00:00\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended for this indication.\", \"rr_dates\": \"2014-03-25, 2014-04-25\", \"rr_multiple\": 0, \"drug_name\": \"Omalizumab \", \"trade_name\": \"Xolair\", \"indication\": \"Omalizumab  patients with inadequate response to H1-antihistamine treatment. \", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-25T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-03-25T00:00:00\", \"latest\": \"2014-04-25T00:00:00\", \"ta_list\": \"Asthma; Urticaria\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:19\", \"rr_start\": \"\", \"rr_end\": \"2014-04-25T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Oxycodone/naloxone \", \"trade_name\": \"Targin\", \"indication\": \"Cost-effectiveness of oral oxycodone/naloxone prolonged release tablet  for severe pain, which can be adequately managed only with opioid analgesics.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-05-05T00:00:00\", \"latest\": \"2010-10-19T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:44:22\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0, \"drug_name\": \"Osimertinib  for the first-line treatment of metastatic NSCLC\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:39\", \"rr_start\": \"2016-02-26T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-02-26, 2016-03-22, 2017-01-10\", \"rr_multiple\": 1, \"drug_name\": \"Osimertinib \", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor [EGFR] T790M mutation positive non-small cell lung cancer [NSCLC].\", \"ncpe_year\": 2018, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-26T00:00:00\", \"latest\": \"2018-05-03T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:43\", \"rr_start\": \"2014-11-25T00:00:00\", \"rr_end\": \"2014-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2014-11-25, 2014-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Pegylated Interferon beta-1a \", \"trade_name\": \"Plegridy\", \"indication\": \"Treatment of adult patients with relapsing remitting multiple sclerosis\", \"ncpe_year\": 2014, \"eu_market\": \"2014-07-17T00:00:00\", \"company\": \"Biogen\", \"orphan\": 0, \"earliest\": \"2014-11-25T00:00:00\", \"latest\": \"2014-12-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:47\", \"rr_start\": \"2016-09-10T00:00:00\", \"rr_end\": \"2016-09-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-09-10, 2016-09-28\", \"rr_multiple\": 0, \"drug_name\": \"Palbociclib \", \"trade_name\": \"Ibrance\", \"indication\": \"Palbociclib is indicated for the treatment of women with metastatic hormone receptor-positive, HER2-negative breast cancer.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-11-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2016-09-10T00:00:00\", \"latest\": \"2017-07-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:44:53\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Paliperidone palmitate \", \"trade_name\": \"Xeplion\", \"indication\": \"Paliperidone palmitate  is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.\", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-04T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-23T00:00:00\", \"ta_list\": \"Schizophrenia\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:57\", \"rr_start\": \"2016-01-26T00:00:00\", \"rr_end\": \"2016-02-09T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-01-26, 2016-02-09\", \"rr_multiple\": 0, \"drug_name\": \"Panobinostat \", \"trade_name\": \"Farydak\", \"indication\": \"Panobinostat in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2016-01-26T00:00:00\", \"latest\": \"2016-02-09T00:00:00\", \"ta_list\": \"Multiple Myeloma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:01\", \"rr_start\": \"2014-12-21T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-21, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Paritaprevir boosted with ritonavir and ombitasvir \", \"trade_name\": \"Exviera\", \"indication\": \"Exviera\\u00ae is indicated in combination with other medicinal products for the treatment of chronic hepatitis c  in adults. Exviera\\u00ae must not be administered as monotherapy. Depending on the patient population The recommended co-administered medicinal products for exviera\\u00ae combination therapy are viekirax\\u00ae or viekirax\\u00ae   and ribavirin.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0, \"earliest\": \"2014-12-21T00:00:00\", \"latest\": \"2016-02-10T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:07\", \"rr_start\": \"2017-10-11T00:00:00\", \"rr_end\": \"2017-11-17T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment\\nrecommended\", \"rr_dates\": \"2017-10-11, 2017-11-17\", \"rr_multiple\": 0, \"drug_name\": \"Patiromer \", \"trade_name\": \"Veltassa\", \"indication\": \"Patiromer  is indicated for the treatment of hyperkalaemia in adults.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-07-19T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2017-10-11T00:00:00\", \"latest\": \"2018-11-13T00:00:00\", \"ta_list\": \"Hyperkalemia\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:10\", \"rr_start\": \"2018-08-14T00:00:00\", \"rr_end\": \"2018-08-29T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-08-14, 2018-08-29\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  1L NSCLC with chemotherapy\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-08-14T00:00:00\", \"latest\": \"2018-08-29T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:15\", \"rr_start\": \"2018-11-19T00:00:00\", \"rr_end\": \"2018-12-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.\", \"rr_dates\": \"2018-11-19, 2018-12-07\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Adjuvant melanoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizuma  as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2018-11-19T00:00:00\", \"latest\": \"2018-12-07T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:18\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Classical Hodgkin Lymphoma\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab , or who are transplant-ineligible and have failed BV.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:23\", \"rr_start\": \"2016-12-19T00:00:00\", \"rr_end\": \"2017-01-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-12-19, 2017-01-10\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of locally advanced or metastatic non-small cell lung carcinoma  with no EGFR or ALK positive tumour mutations and no prior systemic therapy for advanced disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-12-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:28\", \"rr_start\": \"2016-08-03T00:00:00\", \"rr_end\": \"2016-08-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-08-03, 2016-08-24\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab \", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2016-08-03T00:00:00\", \"latest\": \"2018-11-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:31\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae for the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-06-01T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:36\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2018-07-27T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies\", \"rr_dates\": \"2017-12-06, 2017-12-21, 2018-06-21, 2018-07-10, 2018-07-27\", \"rr_multiple\": 1, \"drug_name\": \"Pembrolizumab  for Urothelial  Carcinoma 1L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-07-27T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:38\", \"rr_start\": \"2017-12-06T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-06, 2017-12-21\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for Urothelial Carcinoma 2L\", \"trade_name\": \"Keytruda\", \"indication\": \"Pembrolizumab  is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2017-12-06T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:45\", \"rr_start\": \"2015-08-06T00:00:00\", \"rr_end\": \"2015-08-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-06, 2015-08-13\", \"rr_multiple\": 0, \"drug_name\": \"Pembrolizumab  for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"trade_name\": \"Keytruda\", \"indication\": \"Keytruda\\u00ae is indicated for the first line treatment of unresectable or advanced metastatic melanoma in adults.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-07-16T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-08-06T00:00:00\", \"latest\": \"2016-02-08T00:00:00\", \"ta_list\": \"Melanoma; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:45:50\", \"rr_start\": \"2013-07-01T00:00:00\", \"rr_end\": \"2013-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2013-07-01, 2013-07-01\", \"rr_multiple\": 0, \"drug_name\": \"Perampanel \", \"trade_name\": \"Fycompa\", \"indication\": \"Perampanel  indicated for treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. \", \"ncpe_year\": 2013, \"eu_market\": \"2012-07-23T00:00:00\", \"company\": \"Eisai\", \"orphan\": 0, \"earliest\": \"2013-07-01T00:00:00\", \"latest\": \"2013-07-01T00:00:00\", \"ta_list\": \"Epilepsies, Partial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:45:56\", \"rr_start\": \"2018-06-01T00:00:00\", \"rr_end\": \"2018-06-22T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.\", \"rr_dates\": \"2018-06-01, 2018-06-22\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab   for Adjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Pertuzumab is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.\", \"ncpe_year\": 2018, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2018-06-01T00:00:00\", \"latest\": \"2018-12-03T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:02\", \"rr_start\": \"2015-08-10T00:00:00\", \"rr_end\": \"2015-09-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-08-10, 2015-09-01\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab  in neoadjuvant HER2 positive breast cancer\", \"trade_name\": \"Perjeta\", \"indication\": \"Perjeta  is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2015-08-10T00:00:00\", \"latest\": \"2016-05-10T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:04\", \"rr_start\": \"2013-01-14T00:00:00\", \"rr_end\": \"2013-01-31T00:00:00\", \"rr_outcome\": \"Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-01-14, 2013-01-31\", \"rr_multiple\": 0, \"drug_name\": \"Pertuzumab \", \"trade_name\": \"Perjeta\", \"indication\": \"The proposed licensed indication is for use  in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. \", \"ncpe_year\": 2013, \"eu_market\": \"2013-03-04T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-01-14T00:00:00\", \"latest\": \"2013-08-28T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:11\", \"rr_start\": \"2011-12-15T00:00:00\", \"rr_end\": \"2012-01-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-15, 2012-01-05\", \"rr_multiple\": 0, \"drug_name\": \"Pirfenidone \", \"trade_name\": \"Esbriet\", \"indication\": \"Pirfenidone has been licensed by the European Medicines Agency  for the treatment of mild to moderate idiopathic pulmonary fibrosis.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-02-27T00:00:00\", \"company\": \"Roche\", \"orphan\": 1, \"earliest\": \"2011-12-15T00:00:00\", \"latest\": \"2015-03-01T00:00:00\", \"ta_list\": \"Idiopathic Pulmonary Fibrosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:14\", \"rr_start\": \"2010-12-22T00:00:00\", \"rr_end\": \"2010-12-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-12-22, 2010-12-24\", \"rr_multiple\": 0, \"drug_name\": \"Pitavastatin \", \"trade_name\": \"Livazo\", \"indication\": \"Pitavastatin is indicated for the reduction of elevated TC and LDL-C, in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and combined  dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-12-22T00:00:00\", \"latest\": \"2010-12-24T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:20\", \"rr_start\": \"2017-06-12T00:00:00\", \"rr_end\": \"2017-06-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-06-12, 2017-06-15\", \"rr_multiple\": 0, \"drug_name\": \"Pitolisant hydrochloride \", \"trade_name\": \"Wakix\", \"indication\": \"Pitolisant hydrochloride  is indicated for the treatment of narcolepsy with or without cataplexy and should be initiated by a physician experienced in the treatment of sleep disorders.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-03-31T00:00:00\", \"company\": \"Bioprojet\", \"orphan\": 1, \"earliest\": \"2017-06-12T00:00:00\", \"latest\": \"2017-06-15T00:00:00\", \"ta_list\": \"Narcolepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:24\", \"rr_start\": \"2015-02-10T00:00:00\", \"rr_end\": \"2015-03-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-02-10, 2015-03-20\", \"rr_multiple\": 0, \"drug_name\": \"Pixantrone \", \"trade_name\": \"Pixuvri\", \"indication\": \"Pixurvi\\u00ae is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas .\", \"ncpe_year\": 2015, \"eu_market\": \"2012-05-10T00:00:00\", \"company\": \"CTI\", \"orphan\": 0, \"earliest\": \"2015-02-10T00:00:00\", \"latest\": \"2015-03-20T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:27\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-09-12, 2014-10-08\", \"rr_multiple\": 0, \"drug_name\": \"Polynuclear iron\", \"trade_name\": \"Velphoro\", \"indication\": \"Polynuclear iron.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-08-26T00:00:00\", \"company\": \"Vifor\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-10-08T00:00:00\", \"ta_list\": \"Hyperphosphatemia; Renal Dialysis\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:46:30\", \"rr_start\": \"2013-09-20T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-20, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Pomalidomide \", \"trade_name\": \"Imnovid\", \"indication\": \"Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-09-20T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:32\", \"rr_start\": \"2013-10-02T00:00:00\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"Full HTA Recommended\", \"rr_dates\": \"2013-10-02, 2013-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Ponatinib \", \"trade_name\": \"Iclusig\", \"indication\": \"Ponatinib  patients who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.\", \"ncpe_year\": 2016, \"eu_market\": \"2013-07-01T00:00:00\", \"company\": \"Incyte\", \"orphan\": 1, \"earliest\": \"2013-10-02T00:00:00\", \"latest\": \"2016-01-05T00:00:00\", \"ta_list\": \"Leukemia, Myeloid; Leukemia, Lymphoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:46:38\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Prasugrel \", \"trade_name\": \"Efient\", \"indication\": \"Economic Evaluation of Prasugrel  for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.\", \"ncpe_year\": 2010, \"eu_market\": \"2009-02-24T00:00:00\", \"company\": \"Daiichi\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2010-02-01T00:00:00\", \"ta_list\": \"Acute Coronary Syndrome; Angina, Unstable; Myocardial Infarction\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:46\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of neuropathic pain\", \"trade_name\": \"Lyrica\", \"indication\": \"Lyrica\\u00ae is indicated for the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy.\", \"ncpe_year\": 2015, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2013-09-30T00:00:00\", \"latest\": \"2015-06-12T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:52\", \"rr_start\": \"\", \"rr_end\": \"2013-12-01T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder\", \"trade_name\": \"Lyrica\", \"indication\": \"Pregabalin  for the treatment of Generalised Anxiety Disorder.\", \"ncpe_year\": 2014, \"eu_market\": \"2004-07-05T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2014-12-15T00:00:00\", \"ta_list\": \"Epilepsy; Anxiety Disorders; Neuralgia\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:46:58\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-01-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-01-17\", \"rr_multiple\": 0, \"drug_name\": \"Prucalopride \", \"trade_name\": \"Resolor\", \"indication\": \"Prucalopride  for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-14T00:00:00\", \"company\": \"Shire\", \"orphan\": 0, \"earliest\": \"2011-01-17T00:00:00\", \"latest\": \"2011-03-01T00:00:00\", \"ta_list\": \"Constipation\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:00\", \"rr_start\": \"2013-11-28T00:00:00\", \"rr_end\": \"2013-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-11-28, 2013-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Radium-223 \", \"trade_name\": \"Xofigo\", \"indication\": \"Radium-223  is indicated for the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-13T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Prostatic Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:03\", \"rr_start\": \"2014-12-20T00:00:00\", \"rr_end\": \"2014-12-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-20, 2014-12-23\", \"rr_multiple\": 0, \"drug_name\": \"Ramucirumab \", \"trade_name\": \"Cyramza\", \"indication\": \"Indicated in combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction  adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.\", \"ncpe_year\": 2016, \"eu_market\": \"2014-12-19T00:00:00\", \"company\": \"Eli\", \"orphan\": 0, \"earliest\": \"2014-12-20T00:00:00\", \"latest\": \"2016-07-26T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:06\", \"rr_start\": \"2009-11-19T00:00:00\", \"rr_end\": \"2009-11-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2009-11-19\", \"rr_multiple\": 0, \"drug_name\": \"Ranolazine \", \"trade_name\": \"Ranexa\", \"indication\": \"Cost-effectiveness of Ranolazine \", \"ncpe_year\": 2009, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2009-11-19T00:00:00\", \"latest\": \"2009-11-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:13\", \"rr_start\": \"2011-09-19T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-09-19, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Regadenoson \", \"trade_name\": \"Rapiscan\", \"indication\": \"Cost-effectiveness of Regadenoson \", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-06T00:00:00\", \"company\": \"GE\", \"orphan\": 0, \"earliest\": \"2011-09-19T00:00:00\", \"latest\": \"2011-11-02T00:00:00\", \"ta_list\": \"Myocardial Perfusion Imaging\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:17\", \"rr_start\": \"2014-09-18T00:00:00\", \"rr_end\": \"2014-10-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2014-09-18, 2014-10-06\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for GIST\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI\\u2019s.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2014-09-18T00:00:00\", \"latest\": \"2014-10-06T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:23\", \"rr_start\": \"2017-01-23T00:00:00\", \"rr_end\": \"2017-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the submitted price.\", \"rr_dates\": \"2017-01-23, 2017-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Reslizumab \", \"trade_name\": \"Cinqaero\", \"indication\": \"Cinqaero\\u00ae is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-08-15T00:00:00\", \"company\": \"Teva\", \"orphan\": 0, \"earliest\": \"2017-01-23T00:00:00\", \"latest\": \"2017-03-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:27\", \"rr_start\": \"2011-04-06T00:00:00\", \"rr_end\": \"2011-03-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-04-06, 2011-03-01\", \"rr_multiple\": 0, \"drug_name\": \"Retigabine \", \"trade_name\": \"Trobalt\", \"indication\": \"Cost-effectiveness of Retigabine \", \"ncpe_year\": 2011, \"eu_market\": \"2011-03-27T00:00:00\", \"company\": \"Glaxo\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-04-06T00:00:00\", \"ta_list\": \"Epilepsy\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:29\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0, \"drug_name\": \"Ribociclib \", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib  negative locally advanced or metastatic breast cancer as initial endocrine based therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:35\", \"rr_start\": \"2013-07-09T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-09, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Rifaximin \", \"trade_name\": \"Targaxan\", \"indication\": \"Rifaximin  is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients \\u2265 18 years of age. \", \"ncpe_year\": 2013, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2013-07-09T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:38\", \"rr_start\": \"2013-09-12T00:00:00\", \"rr_end\": \"2013-10-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-09-12, 2013-10-02\", \"rr_multiple\": 0, \"drug_name\": \"Regorafenib  for mCRC\", \"trade_name\": \"Stivarga\", \"indication\": \"Regorafenib  who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2013-09-12T00:00:00\", \"latest\": \"2014-06-30T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:42\", \"rr_start\": \"2011-12-14T00:00:00\", \"rr_end\": \"2012-01-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-12-14, 2012-01-06\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Edurant\", \"indication\": \"Rilpivirine in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1  infection in antiretroviral treatment-naive adult patients with a viral load \\u2264 100,000 HIV-1 RNA copies/ml.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-11-28T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-12-14T00:00:00\", \"latest\": \"2012-01-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:47:45\", \"rr_start\": \"2016-06-28T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Reimbursement Not Recommeded\", \"rr_dates\": \"2016-06-28, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Rilpivirine \", \"trade_name\": \"Odefsey\", \"indication\": \"Odefsey\\u00ae  infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load \\u2264 100,000 HIV 1 RNA copies/ml.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-06-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2016-06-28T00:00:00\", \"latest\": \"2016-10-04T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:47:48\", \"rr_start\": \"\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rimonabant \", \"trade_name\": \"Acomplia\", \"indication\": \"In June 2006, Sanofi-Aventis submitted an evaluation of the cost-effectiveness of rimonabant  in the management of multiple cardiovascular risks in overweight or obese patients in Ireland, to support its application for reimbursement of rimonabant under the Community Drugs Schemes. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-06-19T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2006-06-01T00:00:00\", \"latest\": \"2006-06-01T00:00:00\", \"ta_list\": \"Obesity\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:47:53\", \"rr_start\": \"2014-04-11T00:00:00\", \"rr_end\": \"2014-05-16T00:00:00\", \"rr_outcome\": \"Full HTA recommended at the current price.\", \"rr_dates\": \"2014-04-11, 2014-05-16\", \"rr_multiple\": 0, \"drug_name\": \"Riociguat \", \"trade_name\": \"Adempas\", \"indication\": \"Riociguat .\", \"ncpe_year\": 2014, \"eu_market\": \"2014-03-27T00:00:00\", \"company\": \"Bayer\", \"orphan\": 1, \"earliest\": \"2014-04-11T00:00:00\", \"latest\": \"2014-05-16T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:47:59\", \"rr_start\": \"2014-05-26T00:00:00\", \"rr_end\": \"2014-09-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-05-26, 2014-09-22\", \"rr_multiple\": 0, \"drug_name\": \"Rituximab \", \"trade_name\": \"MabThera\", \"indication\": \"Rituximab :\", \"ncpe_year\": 2014, \"eu_market\": \"1998-06-02T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-05-26T00:00:00\", \"latest\": \"2014-09-22T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:05\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for Atrial Fibrillation patients undergoing PCI\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:10\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Treatment of Deep Vein Thrombosis\", \"trade_name\": \"Xarelto\", \"indication\": \"Economic evaluation of Rivaroxaban  following an acute DVT in adults.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-02-24T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:15\", \"rr_start\": \"2011-08-17T00:00:00\", \"rr_end\": \"2011-08-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-08-17, 2011-08-31\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Prevention of Stroke in Atrial Fibrillation\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the prevention of stroke in atrial fibrillation.\", \"ncpe_year\": 2012, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2011-08-17T00:00:00\", \"latest\": \"2012-06-19T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:18\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-11T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Rivaroxaban compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-11\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the prevention of atherothrombotic events\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban  at high risk of ischaemic events.\", \"ncpe_year\": 2018, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-11T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:25\", \"rr_start\": \"2017-11-20T00:00:00\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-11-20, 2017-11-21\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  low dose for prevention of recurrent venous thromboembolism\", \"trade_name\": \"Xarelto\", \"indication\": \"Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.\", \"ncpe_year\": 2017, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2017-11-20T00:00:00\", \"latest\": \"2017-11-21T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:30\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement\", \"trade_name\": \"Xarelto\", \"indication\": \"Cost Effectiveness of Rivaroxaban  for the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.\", \"ncpe_year\": 2008, \"eu_market\": \"2008-09-30T00:00:00\", \"company\": \"Bayer\", \"orphan\": 0, \"earliest\": \"2008-04-01T00:00:00\", \"latest\": \"2008-09-01T00:00:00\", \"ta_list\": \"Arthroplasty, Replacement; Venous Thromboembolism\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:33\", \"rr_start\": \"\", \"rr_end\": \"2017-11-21T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Roflumilast \", \"trade_name\": \"Daxas\", \"indication\": \"Cost Effectiveness of Roflumilast  for the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.\", \"ncpe_year\": 2010, \"eu_market\": \"2010-07-05T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-06-11T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:40\", \"rr_start\": \"2017-05-15T00:00:00\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2017-05-15, 2017-06-12\", \"rr_multiple\": 0, \"drug_name\": \"Rolapitant \", \"trade_name\": \"Varuby\", \"indication\": \"Rolapitant is indicated for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-04-19T00:00:00\", \"company\": \"Tesaro\", \"orphan\": 0, \"earliest\": \"2017-05-15T00:00:00\", \"latest\": \"2017-06-12T00:00:00\", \"ta_list\": \"Vomiting; Nausea; Cancer\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:48:43\", \"rr_start\": \"\", \"rr_end\": \"2017-06-12T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Romiplostim \", \"trade_name\": \"Nplate\", \"indication\": \"Romiplostim  is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.\", \"ncpe_year\": 2015, \"eu_market\": \"2009-02-04T00:00:00\", \"company\": \"Amgen\", \"orphan\": 1, \"earliest\": \"2015-04-02T00:00:00\", \"latest\": \"2015-05-27T00:00:00\", \"ta_list\": \"Purpura, Thrombocytopenic, Idiopathic\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:48:50\", \"rr_start\": \"2015-04-15T00:00:00\", \"rr_end\": \"2015-05-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-15, 2015-05-28\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib  for Polycythaemia Vera\", \"trade_name\": \"Jakavi\", \"indication\": \"Jakavi\\u00ae is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2015-04-15T00:00:00\", \"latest\": \"2016-08-16T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:55\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Ruxolitinib \", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib , post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:48:58\", \"rr_start\": \"2015-11-06T00:00:00\", \"rr_end\": \"2015-11-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-06, 2015-11-30\", \"rr_multiple\": 0, \"drug_name\": \"Sacubitril/valsartan \", \"trade_name\": \"Entresto\", \"indication\": \"Entresto\\u00ae for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.\", \"ncpe_year\": 2017, \"eu_market\": \"2015-11-19T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-06T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Heart Failure\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:04\", \"rr_start\": \"2016-06-14T00:00:00\", \"rr_end\": \"2016-07-06T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended.\", \"rr_dates\": \"2016-06-14, 2016-07-06\", \"rr_multiple\": 0, \"drug_name\": \"Safinamide methansulfonate \", \"trade_name\": \"Xadago\", \"indication\": \"Xadago\\u00ae for the treatment of adult patients with idiopathic Parkinson\\u2019s disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-02-23T00:00:00\", \"company\": \"Zambon\", \"orphan\": 0, \"earliest\": \"2016-06-14T00:00:00\", \"latest\": \"2016-07-06T00:00:00\", \"ta_list\": \"Parkinson Disease\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:49:07\", \"rr_start\": \"2015-07-14T00:00:00\", \"rr_end\": \"2015-07-01T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2015-07-14, 2015-08-14, 2015-07-01\", \"rr_multiple\": 1, \"drug_name\": \"Sapropterin \", \"trade_name\": \"Kuvan\", \"indication\": \"Sapropterin .\", \"ncpe_year\": 2017, \"eu_market\": \"2008-12-02T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1, \"earliest\": \"2009-01-01T00:00:00\", \"latest\": \"2017-09-15T00:00:00\", \"ta_list\": \"Phenylketonurias\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:11\", \"rr_start\": \"2017-08-18T00:00:00\", \"rr_end\": \"2017-10-04T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at the submitted price.\", \"rr_dates\": \"2017-08-18, 2017-10-04\", \"rr_multiple\": 0, \"drug_name\": \"Sarilumab \", \"trade_name\": \"Kevzara\", \"indication\": \"Sarilumab . Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-06-23T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2017-08-18T00:00:00\", \"latest\": \"2017-10-04T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:16\", \"rr_start\": \"2017-02-08T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"A Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2017-02-08, 2017-03-13\", \"rr_multiple\": 0, \"drug_name\": \"Sebelipase alfa \", \"trade_name\": \"Kanuma\", \"indication\": \"Sebelipase alfa is indicated for long-term enzyme replacement therapy  deficiency.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-08-28T00:00:00\", \"company\": \"Alexion\", \"orphan\": 1, \"earliest\": \"2017-02-08T00:00:00\", \"latest\": \"2018-06-08T00:00:00\", \"ta_list\": \"Lipid Metabolism, Inborn Errors\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:20\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-14\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Ankylosing Spondylitis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-14T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:25\", \"rr_start\": \"2015-12-02T00:00:00\", \"rr_end\": \"2015-12-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-12-02, 2015-12-15\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab  for Psoriatic Arthritis\", \"trade_name\": \"Cosentyx\", \"indication\": \"Cosentyx\\u00ae alone or in combination with methotrexate  therapy has been inadequate.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-12-02T00:00:00\", \"latest\": \"2015-12-15T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:31\", \"rr_start\": \"2014-12-19T00:00:00\", \"rr_end\": \"2015-02-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-19, 2015-02-05\", \"rr_multiple\": 0, \"drug_name\": \"Secukinumab \", \"trade_name\": \"Cosentyx\", \"indication\": \"Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.\", \"ncpe_year\": 2015, \"eu_market\": \"2015-01-14T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2014-12-19T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:34\", \"rr_start\": \"2016-11-01T00:00:00\", \"rr_end\": \"2016-12-05T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-11-01, 2016-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Selexipag \", \"trade_name\": \"Uptravi\", \"indication\": \"Selexipag  inhibitor, or as monotherapy in patients who are not candidates for these therapies.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-05-12T00:00:00\", \"company\": \"Janssen\", \"orphan\": 0, \"earliest\": \"2016-11-01T00:00:00\", \"latest\": \"2018-05-21T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:39\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-04-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is recommended on the basis of the proposed price, relative to currently available therapies.\", \"rr_dates\": \"2018-03-12, 2018-04-10\", \"rr_multiple\": 0, \"drug_name\": \"Semaglutide \", \"trade_name\": \"Ozempic\", \"indication\": \"Semaglutide  for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:\", \"ncpe_year\": 2018, \"eu_market\": \"2018-02-08T00:00:00\", \"company\": \"Novo\", \"orphan\": 0, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-04-10T00:00:00\", \"ta_list\": \"Diabetes Mellitus\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:44\", \"rr_start\": \"2014-04-16T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2014-04-16, 2014-05-23\", \"rr_multiple\": 0, \"drug_name\": \"Sildenafil \", \"trade_name\": \"Revatio\", \"indication\": \"Sildenafil  is indicated for:\", \"ncpe_year\": 2014, \"eu_market\": \"2005-10-28T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2014-04-16T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Hypertension, Pulmonary\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:49:49\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir  in combination with Sofosbuvir\", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.\", \"ncpe_year\": 2015, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2015-03-13T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:49:53\", \"rr_start\": \"2014-05-27T00:00:00\", \"rr_end\": \"2014-07-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin.\", \"rr_dates\": \"2014-05-27, 2014-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Simeprevir \", \"trade_name\": \"Olysio\", \"indication\": \"Simeprevir  Genotypes 1 and 4 who are treatment na\\u00efve or have previously been treated.\", \"ncpe_year\": 2014, \"eu_market\": \"2014-05-14T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2014-05-27T00:00:00\", \"latest\": \"2014-07-11T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:00\", \"rr_start\": \"2014-02-10T00:00:00\", \"rr_end\": \"2014-03-19T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not recommended\", \"rr_dates\": \"2014-02-10, 2014-03-19\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Chloride 70mg/ml, Sodium Hyaluronate 1mg/ml \", \"trade_name\": \"Hyaneb\", \"indication\": \"Hyaneb\\u00ae is particularly indicated in patients with cystic fibrosis and in patients with bronchiectasis.  Hyaneb\\u00ae is classified as a medical device and carries a CE mark.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-02-10T00:00:00\", \"latest\": \"2014-03-19T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:06\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hyloforte 0.2%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:09\", \"rr_start\": \"2014-01-15T00:00:00\", \"rr_end\": \"2014-01-27T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-01-15, 2014-01-27\", \"rr_multiple\": 0, \"drug_name\": \"Sodium Hyaluronate \", \"trade_name\": \"Hylotear 0.1%\", \"indication\": \"Sodium Hyaluronate  is indicated for the treatment of mild to moderate form of dry eye.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2014-01-15T00:00:00\", \"latest\": \"2014-01-27T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:15\", \"rr_start\": \"2013-07-17T00:00:00\", \"rr_end\": \"2013-08-06T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-07-17, 2013-08-06\", \"rr_multiple\": 0, \"drug_name\": \"Sodium phenylbutyrate \", \"trade_name\": \"Pheburane\", \"indication\": \"Sodium phenylbutyrate  is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-07-30T00:00:00\", \"company\": \"Lucane\", \"orphan\": 0, \"earliest\": \"2013-07-17T00:00:00\", \"latest\": \"2013-08-06T00:00:00\", \"ta_list\": \"Carbamoyl-Phosphate Synthase I Deficiency Disease\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:18\", \"rr_start\": \"2014-02-12T00:00:00\", \"rr_end\": \"2014-03-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-02-12, 2014-03-10\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir \", \"trade_name\": \"Solvaldi\", \"indication\": \"Sofosbuvir  is indicated in combination with other medicinal products for the treatment of Chronic Hepatitis C in adults.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-12-09T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2014-02-12T00:00:00\", \"latest\": \"2014-10-24T00:00:00\", \"ta_list\": \"Pneumococcal Infections; Immunization\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:22\", \"rr_start\": \"2017-09-05T00:00:00\", \"rr_end\": \"2017-10-19T00:00:00\", \"rr_outcome\": \" Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-05, 2017-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir  \\u2013 pangenotypic\", \"trade_name\": \"Epclusa\", \"indication\": \"Sofosbuvir/velpatasvir  i.e. pangenotypic.\", \"ncpe_year\": 2017, \"eu_market\": \"2016-07-06T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-05T00:00:00\", \"latest\": \"2017-10-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:26\", \"rr_start\": \"2017-09-19T00:00:00\", \"rr_end\": \"2017-11-15T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment not recommended\", \"rr_dates\": \"2017-09-19, 2017-11-15\", \"rr_multiple\": 0, \"drug_name\": \"Sofosbuvir/Velpatasvir/Voxilaprevir \", \"trade_name\": \"Vosevi\", \"indication\": \"Sofosbuvir/Velpatasvir/Voxilaprevir .\", \"ncpe_year\": 2017, \"eu_market\": \"2017-07-26T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2017-09-19T00:00:00\", \"latest\": \"2017-11-15T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:50:32\", \"rr_start\": \"2015-04-14T00:00:00\", \"rr_end\": \"2015-05-29T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-04-14, 2015-05-29\", \"rr_multiple\": 0, \"drug_name\": \"St Johns Wort \", \"trade_name\": \"Pacifa\", \"indication\": \"Pacifa\\u00ae is indicated for the short term treatment of mild depressive symptoms.\", \"ncpe_year\": 2015, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2015-04-14T00:00:00\", \"latest\": \"2015-05-29T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:38\", \"rr_start\": \"2017-07-06T00:00:00\", \"rr_end\": \"2017-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-07-06, 2017-08-10\", \"rr_multiple\": 0, \"drug_name\": \"Stiripentol \", \"trade_name\": \"Diacomit\", \"indication\": \"Stiripentol  for use in conjunction with clobazam and valproate as adjunctive therapy of\\nrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy\\n whose seizures are not adequately controlled with clobazam and\\nvalproate\", \"ncpe_year\": 2018, \"eu_market\": \"2007-01-03T00:00:00\", \"company\": \"Biocodex\", \"orphan\": 1, \"earliest\": \"2017-07-06T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Myoclonic Epilepsy, Juvenile\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:43\", \"rr_start\": \"2013-04-28T00:00:00\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-04-28, 2013-05-17\", \"rr_multiple\": 0, \"drug_name\": \"Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil \", \"trade_name\": \"Stribild\", \"indication\": \"Indicated for the treatment of human immunodeficiency virus-1  infection in adults aged 18 years and over who are antiretroviral treatment-na\\u00efve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild\\u00ae.\", \"ncpe_year\": 2013, \"eu_market\": \"2013-05-24T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0, \"earliest\": \"2013-04-28T00:00:00\", \"latest\": \"2013-12-06T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:49\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sublingual Immunotherapy \", \"trade_name\": \"Grazax\", \"indication\": \"A Review of the Cost-Effectiveness of Sublingual Immunotherapy  for the Prevention of Seasonal Grass Pollen-Induced Rhinoconjunctivitis.\", \"ncpe_year\": 2007, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2007-09-01T00:00:00\", \"latest\": \"2007-09-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:50\", \"rr_start\": \"\", \"rr_end\": \"2013-05-17T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Buprenorphine/naloxone \", \"trade_name\": \"Suboxone\", \"indication\": \"An economic evaluation of suboxone for the management of opiate addiction.\", \"ncpe_year\": 2014, \"eu_market\": \"2006-09-26T00:00:00\", \"company\": \"Indivior\", \"orphan\": 0, \"earliest\": \"2007-11-01T00:00:00\", \"latest\": \"2014-05-22T00:00:00\", \"ta_list\": \"Opioid-Related Disorders\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:50:54\", \"rr_start\": \"2016-03-14T00:00:00\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-14, 2016-03-22\", \"rr_multiple\": 0, \"drug_name\": \"Sufentanil \", \"trade_name\": \"Zalviso\", \"indication\": \"Sufentanil  is indicated for the management of acute moderate to severe post-operative pain in adult patients.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-09-18T00:00:00\", \"company\": \"Gr\\u00fcnenthal\", \"orphan\": 0, \"earliest\": \"2016-03-14T00:00:00\", \"latest\": \"2018-06-27T00:00:00\", \"ta_list\": \"Pain, Postoperative\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:50:59\", \"rr_start\": \"\", \"rr_end\": \"2016-03-22T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Sunitinib \", \"trade_name\": \"Sutent\", \"indication\": \"In September 2006, Pfizer Healthcare Ireland submitted an evaluation of the cost-effectiveness and budget impact of sunitinib as second-line treatment of patients with gastro-intestinal stromal tumours  was also presented. The purpose of the submission was to support an application for reimbursement under the High Tech Drug Scheme. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.\", \"ncpe_year\": 2006, \"eu_market\": \"2006-07-19T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2006-09-01T00:00:00\", \"latest\": \"2006-09-01T00:00:00\", \"ta_list\": \"Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:51:04\", \"rr_start\": \"2011-07-13T00:00:00\", \"rr_end\": \"2014-05-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2011-07-13, 2011-09-21, 2014-05-09, 2014-05-23\", \"rr_multiple\": 1, \"drug_name\": \"Tadalafil \", \"trade_name\": \"Adcirca\", \"indication\": \"Tadalafil  II and III, to improve exercise capacity.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-07-13T00:00:00\", \"latest\": \"2014-05-23T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:09\", \"rr_start\": \"2018-03-12T00:00:00\", \"rr_end\": \"2018-05-10T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended until additional efficacy and/or safety data is submitted. On the basis of current evidence, the NCPE recommends that tafamidis not be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-03-12, 2018-05-10\", \"rr_multiple\": 0, \"drug_name\": \"Tafamadis meglumine \", \"trade_name\": \"Vyndaqel\", \"indication\": \"Tafamadis meglumine  for the treatment of transthyretin amyloidosis in adult patients with stage I symptomatic polyneuropathy to delay peripheral neurologic impairment.\", \"ncpe_year\": 2018, \"eu_market\": \"2011-11-16T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 1, \"earliest\": \"2018-03-12T00:00:00\", \"latest\": \"2018-05-10T00:00:00\", \"ta_list\": \"Amyloidosis\", \"rr_status\": \"No HTA until more evidence\"}, {\"last_scrape\": \"2018-12-13T16:51:15\", \"rr_start\": \"2011-03-11T00:00:00\", \"rr_end\": \"2011-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2011-03-11, 2011-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Tafluprost \", \"trade_name\": \"Saflutan\", \"indication\": \"Tafluoprost  for the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2011-03-01T00:00:00\", \"latest\": \"2011-03-25T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:24\", \"rr_start\": \"2016-02-16T00:00:00\", \"rr_end\": \"2016-03-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-02-16, 2016-03-14\", \"rr_multiple\": 0, \"drug_name\": \"Talimogene Laherparepvec \", \"trade_name\": \"Imlygic\", \"indication\": \"Talimogene laherparepvec  with no bone, brain, lung or other visceral disease.\", \"ncpe_year\": 2016, \"eu_market\": \"2015-12-16T00:00:00\", \"company\": \"Amgen\", \"orphan\": 0, \"earliest\": \"2016-02-16T00:00:00\", \"latest\": \"2016-03-14T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:28\", \"rr_start\": \"2010-10-19T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-19, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Tapentadol \", \"trade_name\": \"Palexia\", \"indication\": \"Economic evaluation of oral tapentadol  for the management of adult patients with severe chronic/acute pain.\", \"ncpe_year\": 2011, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0, \"earliest\": \"2010-10-19T00:00:00\", \"latest\": \"2011-04-08T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:34\", \"rr_start\": \"2015-05-07T00:00:00\", \"rr_end\": \"2015-07-07T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation not recommended\", \"rr_dates\": \"2015-05-07, 2015-07-07\", \"rr_multiple\": 0, \"drug_name\": \"Tedizolid phosphate \", \"trade_name\": \"Sivextro\", \"indication\": \"Tedizolid phosphate  in adults\", \"ncpe_year\": 2015, \"eu_market\": \"2015-03-23T00:00:00\", \"company\": \"Merck\", \"orphan\": 0, \"earliest\": \"2015-05-07T00:00:00\", \"latest\": \"2015-07-07T00:00:00\", \"ta_list\": \"Soft Tissue Infections; Skin Diseases, Bacterial\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:38\", \"rr_start\": \"2017-03-13T00:00:00\", \"rr_end\": \"2017-04-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-03-13, 2017-04-12\", \"rr_multiple\": 0, \"drug_name\": \"Teduglutide \", \"trade_name\": \"Revestive\", \"indication\": \"Teduglutide  is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.\", \"ncpe_year\": 2018, \"eu_market\": \"2012-08-30T00:00:00\", \"company\": \"Shire\", \"orphan\": 1, \"earliest\": \"2017-03-13T00:00:00\", \"latest\": \"2018-03-16T00:00:00\", \"ta_list\": \"Malabsorption Syndromes\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:44\", \"rr_start\": \"2012-02-27T00:00:00\", \"rr_end\": \"2012-03-23T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2012-02-27, 2012-03-23\", \"rr_multiple\": 0, \"drug_name\": \"Tegafur/Gimeracil/Oteracil \", \"trade_name\": \"Teysuno\", \"indication\": \"Teysuno is indicated in adults for the treatment of advanced gastric cancer.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-03-14T00:00:00\", \"company\": \"Nordic\", \"orphan\": 0, \"earliest\": \"2012-02-27T00:00:00\", \"latest\": \"2012-03-23T00:00:00\", \"ta_list\": \"Stomach Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:48\", \"rr_start\": \"2011-10-28T00:00:00\", \"rr_end\": \"2011-11-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-10-28, 2011-11-02\", \"rr_multiple\": 0, \"drug_name\": \"Telaprevir \", \"trade_name\": \"Incivo\", \"indication\": \"Economic evaluation of Telaprevir  as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.\", \"ncpe_year\": 2012, \"eu_market\": \"2011-09-19T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2011-10-28T00:00:00\", \"latest\": \"2012-01-19T00:00:00\", \"ta_list\": \"Hepatitis C, Chronic\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:52\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2015-01-13T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2014-12-08, 2015-01-13\", \"rr_multiple\": 0, \"drug_name\": \"Telavancin \", \"trade_name\": \"Vibativ\", \"indication\": \"Indicated for the treatment of adults with nosocomial pneumonia .  Vabitiv\\u00ae should be used only in situations where it is known or suspected that other alternatives are not suitable.\", \"ncpe_year\": 2015, \"eu_market\": \"2011-09-02T00:00:00\", \"company\": \"Theravance\", \"orphan\": 0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2015-01-13T00:00:00\", \"ta_list\": \"Pneumonia, Bacterial; Cross Infection\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:51:56\", \"rr_start\": \"2013-08-27T00:00:00\", \"rr_end\": \"2013-09-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-08-27, 2013-09-20\", \"rr_multiple\": 0, \"drug_name\": \"Teriflunomide \", \"trade_name\": \"Aubagio\", \"indication\": \"Aubagio\\u00ae is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis .\", \"ncpe_year\": 2014, \"eu_market\": \"2013-08-26T00:00:00\", \"company\": \"Sanofi-Aventis\", \"orphan\": 0, \"earliest\": \"2013-08-27T00:00:00\", \"latest\": \"2014-09-05T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:51:58\", \"rr_start\": \"2016-02-29T00:00:00\", \"rr_end\": \"2016-05-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-02-29, 2016-05-04\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Ticagrelor  and a high risk of developing an atherothrombotic event.\", \"ncpe_year\": 2016, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2016-02-29T00:00:00\", \"latest\": \"2016-05-04T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:01\", \"rr_start\": \"2010-11-25T00:00:00\", \"rr_end\": \"2011-01-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-11-25, 2011-01-20\", \"rr_multiple\": 0, \"drug_name\": \"Ticagrelor \", \"trade_name\": \"Brilique\", \"indication\": \"Economic Evaluation of Ticagrelor .\", \"ncpe_year\": 2011, \"eu_market\": \"2010-12-03T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0, \"earliest\": \"2010-11-25T00:00:00\", \"latest\": \"2011-10-10T00:00:00\", \"ta_list\": \"Peripheral Vascular Diseases; Acute Coronary Syndrome\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:07\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-19T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-19\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for ALL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  that is refractory, in relapse post-transplant or in second or later relapse.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-19T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:13\", \"rr_start\": \"2018-09-19T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.\", \"rr_dates\": \"2018-09-19, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Tisagenlecleucel  for DLBCL\", \"trade_name\": \"Kymriah\", \"indication\": \"Tisagenlecleucel  after two or more lines of systemic therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2018-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1, \"earliest\": \"2018-09-19T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large B-Cell, Diffuse\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:19\", \"rr_start\": \"2010-11-10T00:00:00\", \"rr_end\": \"2010-11-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2010-11-10, 2010-11-03\", \"rr_multiple\": 0, \"drug_name\": \"Tobramycin \", \"trade_name\": \"TOBI Podhaler\", \"indication\": \"Tobramycin  for the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF.\", \"ncpe_year\": 2010, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2010-11-01T00:00:00\", \"latest\": \"2010-11-03T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:52:24\", \"rr_start\": \"2014-04-28T00:00:00\", \"rr_end\": \"2014-07-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at theSubmitted Price.\", \"rr_dates\": \"2014-04-28, 2014-07-16\", \"rr_multiple\": 0, \"drug_name\": \"Tocilizumab SC \", \"trade_name\": \"RoActemra\", \"indication\": \"It is licensed for the treatment of moderate to severe active rheumatoid arthritis  antagonists.  It is licensed in monotherapy in patients who are intolerant of methotrexate or in cases where methotrexate is inappropriate.\", \"ncpe_year\": 2014, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2014-04-28T00:00:00\", \"latest\": \"2014-07-16T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:30\", \"rr_start\": \"2018-07-16T00:00:00\", \"rr_end\": \"2018-09-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tofacitinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.\", \"rr_dates\": \"2018-07-16, 2018-09-18\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib  for Ulcerative Colitis\", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib is indicated for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy .\", \"ncpe_year\": 2018, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2018-07-16T00:00:00\", \"latest\": \"2018-09-18T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:35\", \"rr_start\": \"2017-03-08T00:00:00\", \"rr_end\": \"2017-04-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2017-03-08, 2017-04-28\", \"rr_multiple\": 0, \"drug_name\": \"Tofacitinib \", \"trade_name\": \"Xeljanz\", \"indication\": \"Tofacitinib  in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drug. Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.\", \"ncpe_year\": 2017, \"eu_market\": \"2017-03-21T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0, \"earliest\": \"2017-03-08T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Arthritis, Rheumatoid\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:40\", \"rr_start\": \"2016-01-04T00:00:00\", \"rr_end\": \"2016-01-12T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2016-01-04, 2016-01-12\", \"rr_multiple\": 0, \"drug_name\": \"Tolvaptan \", \"trade_name\": \"Jinarc\", \"indication\": \"Jinarc\\u00ae) to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease  in adults with CKD stage 1-3 at initiation of treatment with evidence of rapidly progressing disease.\", \"ncpe_year\": 2018, \"eu_market\": \"2015-05-27T00:00:00\", \"company\": \"Otsuka\", \"orphan\": 0, \"earliest\": \"2016-01-04T00:00:00\", \"latest\": \"2018-09-13T00:00:00\", \"ta_list\": \"Polycystic Kidney, Autosomal Dominant\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:45\", \"rr_start\": \"2017-10-17T00:00:00\", \"rr_end\": \"2017-12-01T00:00:00\", \"rr_outcome\": \"Reimursement not recommended at the submitted price\", \"rr_dates\": \"2017-10-17, 2017-12-01\", \"rr_multiple\": 0, \"drug_name\": \"Tramadol hydrochloride/dexketoprofen \", \"trade_name\": \"Skudexa\", \"indication\": \"Tramadol hydrochloride/dexketoprofen  for the symptomatic short-term treatment of moderate to severe acute pain in adult patients whose pain is considered to require a combination of tramadol and dexketoprofen.\", \"ncpe_year\": 2017, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2017-10-17T00:00:00\", \"latest\": \"2017-12-01T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:52:51\", \"rr_start\": \"2015-11-27T00:00:00\", \"rr_end\": \"2015-12-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-11-27, 2015-12-22\", \"rr_multiple\": 0, \"drug_name\": \"Trametinib \", \"trade_name\": \"Mekinist\", \"indication\": \"Mekinist\\u00ae for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018, \"eu_market\": \"2014-06-30T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0, \"earliest\": \"2015-11-27T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:52:56\", \"rr_start\": \"2013-09-25T00:00:00\", \"rr_end\": \"2013-10-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2013-09-25, 2013-10-24\", \"rr_multiple\": 0, \"drug_name\": \"Trastuzumab emtansine \", \"trade_name\": \"Kadcyla\", \"indication\": \"Trastuzumab emtansine  is indicated for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.\", \"ncpe_year\": 2015, \"eu_market\": \"2013-11-15T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-09-25T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:00\", \"rr_start\": \"2016-06-10T00:00:00\", \"rr_end\": \"2016-07-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price\", \"rr_dates\": \"2016-06-10, 2016-07-11\", \"rr_multiple\": 0, \"drug_name\": \"Trifluridine/tipiracil \", \"trade_name\": \"Lonsurf\", \"indication\": \"Trifluridine/tipiracil  is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.\", \"ncpe_year\": 2016, \"eu_market\": \"2016-04-25T00:00:00\", \"company\": \"Les\", \"orphan\": 0, \"earliest\": \"2016-06-10T00:00:00\", \"latest\": \"2016-07-11T00:00:00\", \"ta_list\": \"Colorectal Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:04\", \"rr_start\": \"2016-05-17T00:00:00\", \"rr_end\": \"2016-05-31T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended \", \"rr_dates\": \"2016-05-17, 2016-05-31\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  intermittent treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate is indicated for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2016, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2016-05-17T00:00:00\", \"latest\": \"2016-05-31T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:08\", \"rr_start\": \"2013-09-03T00:00:00\", \"rr_end\": \"2013-10-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2013-09-03, 2013-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Ulipristal acetate  single course treatment\", \"trade_name\": \"Esmya\", \"indication\": \"Ulipristal acetate  is indicated for the pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-22T00:00:00\", \"company\": \"Gedeon\", \"orphan\": 0, \"earliest\": \"2013-09-03T00:00:00\", \"latest\": \"2013-10-18T00:00:00\", \"ta_list\": \"Leiomyoma\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:10\", \"rr_start\": \"2014-06-11T00:00:00\", \"rr_end\": \"2014-07-10T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2014-06-11, 2014-07-10\", \"rr_multiple\": 0, \"drug_name\": \"Umeclidinium/vilanterol \", \"trade_name\": \"Anoro\", \"indication\": \"Umeclidinium/vilanterol  is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.\", \"ncpe_year\": 2014, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2014-06-11T00:00:00\", \"latest\": \"2014-07-10T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:53:17\", \"rr_start\": \"2016-11-28T00:00:00\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-11-28, 2017-01-11\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab  for Crohn\\u2019s Disease\", \"trade_name\": \"Stelara\", \"indication\": \"Ustekinumab is indicated for the treatment of adult patients with moderately to severely active Crohn\\u2019s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-\\u03b1 antagonist or have medical contraindications to such therapies\", \"ncpe_year\": 2017, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2016-11-28T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:23\", \"rr_start\": \"\", \"rr_end\": \"2017-01-11T00:00:00\", \"rr_outcome\": \"\", \"rr_dates\": \"\", \"rr_multiple\": 0, \"drug_name\": \"Ustekinumab \", \"trade_name\": \"Stelara\", \"indication\": \"Cost-effectiveness of Ustekinumab  in the treament of moderate to severe psoriasis.\", \"ncpe_year\": 2009, \"eu_market\": \"2009-01-15T00:00:00\", \"company\": \"Janssen-Cilag\", \"orphan\": 0, \"earliest\": \"2009-07-01T00:00:00\", \"latest\": \"2009-11-01T00:00:00\", \"ta_list\": \"Psoriasis; Arthritis, Psoriatic; Crohn Disease\", \"rr_status\": \"RR not conducted\"}, {\"last_scrape\": \"2018-12-13T16:53:29\", \"rr_start\": \"2013-06-06T00:00:00\", \"rr_end\": \"2013-07-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-06-06, 2013-07-03\", \"rr_multiple\": 0, \"drug_name\": \"Vandetanib \", \"trade_name\": \"Caprelsa\", \"indication\": \"Vandetanib  in patients with unresectable locally advanced or metastatic disease.\", \"ncpe_year\": 2013, \"eu_market\": \"2012-02-16T00:00:00\", \"company\": \"Genzyme\", \"orphan\": 0, \"earliest\": \"2013-06-06T00:00:00\", \"latest\": \"2013-07-03T00:00:00\", \"ta_list\": \"Thyroid Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:32\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Crohn\\u2019s Disease\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:39\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0, \"drug_name\": \"Vedolizumab  in Ulcerative Colitis\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:45\", \"rr_start\": \"2011-04-26T00:00:00\", \"rr_end\": \"2011-06-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2011-04-26, 2011-06-20\", \"rr_multiple\": 0, \"drug_name\": \"Velaglucerase Alfa \", \"trade_name\": \"VPRIV\", \"indication\": \"VPRIV is indicated for long-term enzyme replacement therapy  in patients with type1 Gaucher disease.\", \"ncpe_year\": 2011, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0, \"earliest\": \"2011-04-26T00:00:00\", \"latest\": \"2011-06-20T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:49\", \"rr_start\": \"2018-09-26T00:00:00\", \"rr_end\": \"2018-10-18T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.\", \"rr_dates\": \"2018-09-26, 2018-10-18\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax  in combination with rituximab\", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax  in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.\", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2018-09-26T00:00:00\", \"latest\": \"2018-10-18T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:52\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0, \"drug_name\": \"Venetoclax \", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia \", \"ncpe_year\": 2018, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:53:58\", \"rr_start\": \"2011-12-23T00:00:00\", \"rr_end\": \"2012-01-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2011-12-23, 2012-01-04\", \"rr_multiple\": 0, \"drug_name\": \"Vemurafenib \", \"trade_name\": \"Zelboraf\", \"indication\": \"Vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.\", \"ncpe_year\": 2014, \"eu_market\": \"2012-02-17T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2011-12-23T00:00:00\", \"latest\": \"2014-09-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:00\", \"rr_start\": \"2010-10-26T00:00:00\", \"rr_end\": \"2010-11-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2010-10-26, 2010-11-04\", \"rr_multiple\": 0, \"drug_name\": \"Vernakalant \", \"trade_name\": \"Brinavess\", \"indication\": \"Economic evaluation of Vernakalant  for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.\", \"ncpe_year\": 2011, \"eu_market\": \"2010-09-01T00:00:00\", \"company\": \"Cardiome\", \"orphan\": 0, \"earliest\": \"2010-10-26T00:00:00\", \"latest\": \"2011-05-04T00:00:00\", \"ta_list\": \"Atrial Fibrillation\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:04\", \"rr_start\": \"2013-05-02T00:00:00\", \"rr_end\": \"2013-05-20T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2013-05-02, 2013-05-20\", \"rr_multiple\": 0, \"drug_name\": \"Vismodegib \", \"trade_name\": \"Erivedge\", \"indication\": \"Vismodegib  is indicated for the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-07-12T00:00:00\", \"company\": \"Roche\", \"orphan\": 0, \"earliest\": \"2013-05-02T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Carcinoma, Basal Cell\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:54:11\", \"rr_start\": \"2014-10-01T00:00:00\", \"rr_end\": \"2014-11-14T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-10-01, 2014-11-14\", \"rr_multiple\": 0, \"drug_name\": \"Vortioxetine \", \"trade_name\": \"Brintellix\", \"indication\": \"Vortioxetine  is indicated for the treatment of major depressive episodes in adults.\", \"ncpe_year\": 2017, \"eu_market\": \"2013-12-18T00:00:00\", \"company\": \"Lundbeck\", \"orphan\": 0, \"earliest\": \"2014-10-01T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Depressive Disorder, Major\", \"rr_status\": \"HTA recommended at submitted price\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"ada752b5-a026-4aff-a8e9-6b14a742aa4f\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd7a036a0>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#ada752b5-a026-4aff-a8e9-6b14a742aa4f"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#ada752b5-a026-4aff-a8e9-6b14a742aa4f"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "##Graph after Cleaning\n",
    "upto_chart=alt.Chart(cleaned_data,title=\"Ncpe Appproval count(Companies)\").mark_rule(color='#ff1493').encode(\n",
    "    x='count(drug_name):Q',\n",
    "    y=alt.Y(\n",
    "        'company',\n",
    "         sort=alt.EncodingSortField(\n",
    "            field=\"drug_name\",  # The field to use for the sorting\n",
    "            op=\"count\",  # The operation to run on the field prior to sorting\n",
    "            order=\"descending\"  # The order to sort in\n",
    "            \n",
    "        )\n",
    "      \n",
    "        )\n",
    ")\n",
    "text = upto_chart.mark_text(\n",
    "        color='#ff1493',\n",
    "        align='left',\n",
    "        baseline='middle',\n",
    "        dx=3  # Nudges text to right so it doesn't appear on top of the bar\n",
    "        ).encode(\n",
    "        text='count(drug_name):Q'\n",
    "        )\n",
    "(upto_chart + text).properties()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Visualization 3 : \n",
    "### Which are the drugs that are specific to ncpe only?\n",
    "### Reason:\n",
    "### Since the data for the column eu_market, ema_url and company name are missing for 15 drugs, I have assumed that these 15 drugs are specfic to Ireland only."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"data\": {\"name\": \"data-2ddea862c859af1ec2ad28a0d9dfa634\"}, \"mark\": \"point\", \"encoding\": {\"color\": {\"type\": \"quantitative\", \"field\": \"ncpe_year\"}, \"x\": {\"type\": \"nominal\", \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"nominal\", \"field\": \"trade_name\"}}, \"height\": 300, \"title\": \"Drugs specific to ncpe only\", \"width\": 400, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-2ddea862c859af1ec2ad28a0d9dfa634\": [{\"last_scrape\": \"2018-12-13T16:24:49\", \"rr_start\": \"2016-12-21T00:00:00\", \"rr_end\": \"2017-01-24T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic evaluation is recommended at the submitted price.\", \"rr_dates\": \"2016-12-21, 2017-01-24\", \"rr_multiple\": 0, \"drug_name\": \"Aceclofenac \", \"trade_name\": \"Vitafen\", \"indication\": \"Aceclofenac  is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2016-07-22T00:00:00\", \"latest\": \"2017-11-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:26:29\", \"rr_start\": \"2017-01-10T00:00:00\", \"rr_end\": \"2017-02-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2017-01-10, 2017-02-15\", \"rr_multiple\": 0, \"drug_name\": \"Amsacrine \", \"trade_name\": \"Amsidine\", \"indication\": \"Amsidine\\u00ae is indicated for the induction and maintenance of remission in acute leukaemia of adults.\", \"ncpe_year\": 2017, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2017-01-10T00:00:00\", \"latest\": \"2017-02-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:27:24\", \"rr_start\": \"2013-02-12T00:00:00\", \"rr_end\": \"2013-02-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment not Recommended.\", \"rr_dates\": \"2013-02-12, 2013-02-28\", \"rr_multiple\": 0, \"drug_name\": \"Azelastine hydrochloride and fluticasone propionate \", \"trade_name\": \"Dymista\", \"indication\": \"Indicated for symptomatic treatment of moderate-to-severe allergic rhinitis, in patients aged 12 years and older for whom monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2013-02-12T00:00:00\", \"latest\": \"2013-02-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:35:56\", \"rr_start\": \"2011-10-11T00:00:00\", \"rr_end\": \"2011-09-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-10-11, 2011-09-26\", \"rr_multiple\": 0, \"drug_name\": \"Grass pollen allergen extract \", \"trade_name\": \"Oralair\", \"indication\": \" Grass pollen allegen extract  with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2011-09-26T00:00:00\", \"latest\": \"2011-10-01T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:04\", \"rr_start\": \"2010-01-15T00:00:00\", \"rr_end\": \"2010-01-15T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended.\", \"rr_dates\": \"2010-01-15\", \"rr_multiple\": 0, \"drug_name\": \"Indacaterol \", \"trade_name\": \"Onbrez\", \"indication\": \"Review of Indacaterol  for the treatment of COPD.\", \"ncpe_year\": 2010, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2010-01-15T00:00:00\", \"latest\": \"2010-01-15T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:37:21\", \"rr_start\": \"2014-07-22T00:00:00\", \"rr_end\": \"2014-08-28T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price.\", \"rr_dates\": \"2014-07-22, 2014-08-28\", \"rr_multiple\": 0, \"drug_name\": \"Insulin aspart \", \"trade_name\": \"NovoRapid FlexTouch\", \"indication\": \"Insulin aspart  is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.\", \"ncpe_year\": 2014, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2014-07-22T00:00:00\", \"latest\": \"2014-08-28T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:28\", \"rr_start\": \"2013-03-13T00:00:00\", \"rr_end\": \"2013-04-16T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2013-03-13, 2013-04-16\", \"rr_multiple\": 0, \"drug_name\": \"Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel \", \"trade_name\": \"Duodopa\", \"indication\": \"For the treatment of advanced levodopa-responsive Parkinson\\u2019s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa\\u00ae administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2013-03-13T00:00:00\", \"latest\": \"2018-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:39:44\", \"rr_start\": \"2013-03-07T00:00:00\", \"rr_end\": \"2013-03-25T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Not Recommended\", \"rr_dates\": \"2013-03-07, 2013-03-25\", \"rr_multiple\": 0, \"drug_name\": \"Levonorgestrel intrauterine system LNG-IUS \", \"trade_name\": \"Jaydess\", \"indication\": \"Levonorgestrel Intrauterine System LNG-IUS  for contraception for up to three years.\", \"ncpe_year\": 2013, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2013-03-07T00:00:00\", \"latest\": \"2013-03-25T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:39:46\", \"rr_start\": \"2010-09-09T00:00:00\", \"rr_end\": \"2010-10-22T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2010-09-09, 2010-10-22\", \"rr_multiple\": 0, \"drug_name\": \"Lidocaine 5% plasters \", \"trade_name\": \"Versatis\", \"indication\": \"Symptomatic relief of neuropathic pain associated with previous herpes zoster infection .\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2010-09-09T00:00:00\", \"latest\": \"2015-09-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"HTA recommended at submitted price\"}, {\"last_scrape\": \"2018-12-13T16:40:24\", \"rr_start\": \"2011-11-15T00:00:00\", \"rr_end\": \"2011-12-05T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-11-15, 2011-12-05\", \"rr_multiple\": 0, \"drug_name\": \"Lotemax 0.5% eye drops suspension \", \"trade_name\": \"Loteprednol\", \"indication\": \" Indicated for treatment of post-operative inflammation following ocular surgery.\", \"ncpe_year\": 2011, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2011-11-15T00:00:00\", \"latest\": \"2011-12-05T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:40:51\", \"rr_start\": \"2015-11-23T00:00:00\", \"rr_end\": \"2015-12-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-11-23, 2015-12-18\", \"rr_multiple\": 0, \"drug_name\": \"Methoxyflurane \", \"trade_name\": \"Penthrox\", \"indication\": \"Penthrox\\u00ae is indicated for the emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.  It is an inhaled anesthetic with analgesic effects at sub-anesthetic doses.\", \"ncpe_year\": 2015, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2015-11-23T00:00:00\", \"latest\": \"2015-12-18T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA\"}, {\"last_scrape\": \"2018-12-13T16:44:40\", \"rr_start\": \"2018-11-12T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\\n \\n \", \"rr_dates\": \"2018-11-12, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ozenoxacin \", \"trade_name\": \"Dubine\", \"indication\": \"Ozenoxacin  10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2018-11-12T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:46:09\", \"rr_start\": \"2016-11-18T00:00:00\", \"rr_end\": \"2016-12-19T00:00:00\", \"rr_outcome\": \"Reimbursement not recommended at the submitted price\", \"rr_dates\": \"2016-11-18, 2016-12-19\", \"rr_multiple\": 0, \"drug_name\": \"Phenylephrine Hydrochloride, Tropicamide & Lidocaine Hydrochloride \", \"trade_name\": \"Fydrane\", \"indication\": \"Fydrane\\u00ae is indicated for cataract surgery to obtain mydriasis and intraocular anaesthesia, during the surgical procedure.\", \"ncpe_year\": 2016, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2016-11-18T00:00:00\", \"latest\": \"2016-12-19T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Reimbursement not recommended\"}, {\"last_scrape\": \"2018-12-13T16:48:47\", \"rr_start\": \"2018-11-09T00:00:00\", \"rr_end\": \"2018-12-13T00:00:00\", \"rr_outcome\": \"A full HTA is not recommended. The NCPE recommends that Ropivicaine Readyfusor not be considered for reimbursement at the submitted price.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.\", \"rr_dates\": \"2018-11-09, 2018-12-13\", \"rr_multiple\": 0, \"drug_name\": \"Ropivacaine Readyfusor\\u00ae\", \"trade_name\": \"Ropivacaine Readyfusor\", \"indication\": \"Ropivacaine Readyfusor for acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block  via a continuous infusion.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2018-11-09T00:00:00\", \"latest\": \"2018-12-13T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"Unknown\"}, {\"last_scrape\": \"2018-12-13T16:53:12\", \"rr_start\": \"2018-07-09T00:00:00\", \"rr_end\": \"2018-07-24T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is not recommended. The NCPE recommends that GlucoRx Allpresan Diabetic Foam Cream not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2018-07-09, 2018-07-24\", \"rr_multiple\": 0, \"drug_name\": \"Urea \", \"trade_name\": \"GlucoRx Allpresan\", \"indication\": \"GlucoRx Allpresan\\u00ae Diabetic Foam Cream for the treatment of dry and sensitive foot skin  in patients with Diabetes Mellitus.\", \"ncpe_year\": 2018, \"eu_market\": \"\", \"company\": \"NULL\", \"orphan\": 0, \"earliest\": \"2018-07-09T00:00:00\", \"latest\": \"2018-07-24T00:00:00\", \"ta_list\": \"Unknown\", \"rr_status\": \"No HTA at submitted price\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"6bb163ca-bb75-4a98-ae26-7f6f36696ad2\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd7a4a2e8>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#6bb163ca-bb75-4a98-ae26-7f6f36696ad2"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#6bb163ca-bb75-4a98-ae26-7f6f36696ad2"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "ncpe_drugs = drugs[drugs['eu_market'].isna()]\n",
    "upto_chart = alt.Chart(ncpe_drugs,title=\"Drugs specific to ncpe only\").mark_point().encode(\n",
    "    x='ncpe_year:N',\n",
    "    y='trade_name',\n",
    "    color='ncpe_year',\n",
    ").properties(\n",
    "    width=400,\n",
    "    height=300,\n",
    ")\n",
    "upto_chart "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Merging the data of two tables to perform 4th Visualization\n",
    "### Visualization 4:\n",
    "### Drug count for the therapyarea, Immunization from 2011-2018?\n",
    "### Reason : \n",
    "### I have done this visualization as in Ireland much focus is on Immunization, irrespective of any health issue. Thus, for a child it is mandatory for him/her to get vaccinated 5 times in a year , so that he/she is resistant with any of the disease/infection. Also, the graph clearly shows that from the past 7 years, the drug count for therapyarea Immunization has greatly increased from the year 2017 to 2018."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "#merging the data of therapyarea with scraped table data, to focus on 4th visualization\n",
    "result = pd.concat([drugs,tas['therapyarea']], axis=1, sort=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 496 entries, 0 to 495\n",
      "Data columns (total 18 columns):\n",
      "last_scrape    398 non-null datetime64[ns]\n",
      "rr_start       366 non-null datetime64[ns]\n",
      "rr_end         398 non-null datetime64[ns]\n",
      "rr_outcome     398 non-null object\n",
      "rr_dates       398 non-null object\n",
      "rr_multiple    398 non-null float64\n",
      "drug_name      398 non-null object\n",
      "trade_name     398 non-null object\n",
      "indication     398 non-null object\n",
      "ncpe_year      398 non-null float64\n",
      "eu_market      383 non-null datetime64[ns]\n",
      "company        398 non-null object\n",
      "orphan         398 non-null float64\n",
      "earliest       398 non-null datetime64[ns]\n",
      "latest         398 non-null datetime64[ns]\n",
      "ta_list        398 non-null object\n",
      "rr_status      398 non-null object\n",
      "therapyarea    496 non-null object\n",
      "dtypes: datetime64[ns](6), float64(3), object(9)\n",
      "memory usage: 69.8+ KB\n"
     ]
    }
   ],
   "source": [
    "#checking the count of rows and columns after merging the data\n",
    "result.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "#deleting unwanted data\n",
    "result = result.dropna()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "result2 = result[(result['therapyarea'] =='Immunization')]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"data\": {\"name\": \"data-a711e5a96c9196b5a4fbba9b9f8fe510\"}, \"mark\": {\"type\": \"line\", \"color\": \"#ba55d3\"}, \"encoding\": {\"x\": {\"type\": \"nominal\", \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"nominal\", \"aggregate\": \"count\", \"field\": \"therapyarea\"}}, \"height\": 300, \"title\": \"All Immunization drugs over the past 7 years\", \"width\": 600, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-a711e5a96c9196b5a4fbba9b9f8fe510\": [{\"last_scrape\": \"2018-12-13T16:25:37\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0.0, \"drug_name\": \"Adalimumab \", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab  in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.\", \"ncpe_year\": 2011.0, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0.0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:25:45\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0.0, \"drug_name\": \"Afatinib \", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor .\", \"ncpe_year\": 2013.0, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0.0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:27:50\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"Full pharamcoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0.0, \"drug_name\": \"Benralizumab \", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab  is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting \\u03b2-agonists.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0.0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:28:23\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0.0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.\", \"ncpe_year\": 2015.0, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1.0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:28:40\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0.0, \"drug_name\": \"Brodalumab \", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab  is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0.0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:29:09\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0.0, \"drug_name\": \"Capsaicin 8%w/w patch \", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch  for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.\", \"ncpe_year\": 2012.0, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0.0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:29:49\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0.0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops \", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\\u00ae is indicated for the treatment of severe keratitis in adult patients with dry eye disease , which has not improved despite treatment with tear substitutes.\", \"ncpe_year\": 2016.0, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0.0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:30:02\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0.0, \"drug_name\": \"Cobimetinib \", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\\u00ae is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0.0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:30:29\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0.0, \"drug_name\": \"Crizotinib  for ROS1 NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer .\", \"ncpe_year\": 2017.0, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0.0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:33:05\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0.0, \"drug_name\": \"Elosulfase alfa \", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa  in patients of all ages.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1.0, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:33:43\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0.0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil \", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil  for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.\", \"ncpe_year\": 2017.0, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0.0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:33:48\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0.0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\\u00ae  type 1.\", \"ncpe_year\": 2016.0, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0.0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:34:56\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0.0, \"drug_name\": \"Fingolimod \", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod  for the treatment of highly active relapsing-remitting multiple sclerosis.\", \"ncpe_year\": 2011.0, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0.0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:35:05\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy\\u2122 Ellipta\\u2122 be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0.0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero \", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\\u2122 Ellipta\\u2122 which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0.0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:35:40\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0.0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide  in children and adolescents aged 3 years and older with chronic neurological disorders\", \"ncpe_year\": 2017.0, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0.0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:36:56\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0.0, \"drug_name\": \"Idelalisib \", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia  who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016.0, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0.0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:38:02\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0.0, \"drug_name\": \"Iron isomaltoside 1000 \", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011.0, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0.0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:40:45\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0.0, \"drug_name\": \"Mepolizumab \", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab  is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0.0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:41:02\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0.0, \"drug_name\": \"Midostaurin  for ASM\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin .\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1.0, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:42:46\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0.0, \"drug_name\": \"Nivolumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma .\", \"ncpe_year\": 2018.0, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0.0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:44:22\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0.0, \"drug_name\": \"Osimertinib  for the first-line treatment of metastatic NSCLC\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  mutations.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0.0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:47:29\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0.0, \"drug_name\": \"Ribociclib \", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib  negative locally advanced or metastatic breast cancer as initial endocrine based therapy.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0.0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:48:55\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0.0, \"drug_name\": \"Ruxolitinib \", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib , post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\", \"ncpe_year\": 2013.0, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1.0, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:53:32\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0.0, \"drug_name\": \"Vedolizumab  in Crohn\\u2019s Disease\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017.0, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0.0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:53:52\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0.0, \"drug_name\": \"Venetoclax \", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia \", \"ncpe_year\": 2018.0, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1.0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"09e09934-f14d-4b4b-ae41-687781fd1bf1\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd47505f8>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#09e09934-f14d-4b4b-ae41-687781fd1bf1"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#09e09934-f14d-4b4b-ae41-687781fd1bf1"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "upto_chart = alt.Chart(result2,title=\"All Immunization drugs over the past 7 years\").mark_line(color='#ba55d3').encode(\n",
    "    x='ncpe_year:N', \n",
    "    y='count(therapyarea)',\n",
    ").properties(\n",
    "    width=600,\n",
    "    height=300,\n",
    ")\n",
    "upto_chart"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Visualization 5:\n",
    "### List of Immunization drugs?\n",
    "### Reason : \n",
    "### I have done this visualization as in Ireland, a lot of focus is on Immunization irrespective of any health issue. 27 drugs went for rapid review analysis, of which thrice the amount of drugs went for rapid review analysis in the year 2018 than in the year 2017. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "const spec = {\"config\": {\"view\": {\"width\": 400, \"height\": 300}, \"mark\": {\"tooltip\": null}}, \"data\": {\"name\": \"data-a711e5a96c9196b5a4fbba9b9f8fe510\"}, \"mark\": \"bar\", \"encoding\": {\"color\": {\"type\": \"nominal\", \"field\": \"ncpe_year\"}, \"x\": {\"type\": \"nominal\", \"field\": \"ncpe_year\"}, \"y\": {\"type\": \"nominal\", \"field\": \"trade_name\"}}, \"height\": 600, \"title\": \"List of Immunization drugs\", \"width\": 300, \"$schema\": \"https://vega.github.io/schema/vega-lite/v3.4.0.json\", \"datasets\": {\"data-a711e5a96c9196b5a4fbba9b9f8fe510\": [{\"last_scrape\": \"2018-12-13T16:25:37\", \"rr_start\": \"2011-05-20T00:00:00\", \"rr_end\": \"2011-06-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-05-20, 2011-06-02\", \"rr_multiple\": 0.0, \"drug_name\": \"Adalimumab \", \"trade_name\": \"Humira\", \"indication\": \"Economic evaluation of Adalimumab  in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.\", \"ncpe_year\": 2011.0, \"eu_market\": \"2003-09-07T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 0.0, \"earliest\": \"2011-05-20T00:00:00\", \"latest\": \"2011-06-02T00:00:00\", \"ta_list\": \"Spondylitis, Ankylosing; Arthritis, Juvenile Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Arthritis, Rheumatoid\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:25:45\", \"rr_start\": \"2013-10-01T00:00:00\", \"rr_end\": \"2013-10-13T00:00:00\", \"rr_outcome\": \"Full HTA not recommended\", \"rr_dates\": \"2013-10-01, 2013-10-13\", \"rr_multiple\": 0.0, \"drug_name\": \"Afatinib \", \"trade_name\": \"Giotrif\", \"indication\": \"GIOTRIF as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor .\", \"ncpe_year\": 2013.0, \"eu_market\": \"2013-09-25T00:00:00\", \"company\": \"Boehringer\", \"orphan\": 0.0, \"earliest\": \"2013-10-01T00:00:00\", \"latest\": \"2013-10-13T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:27:50\", \"rr_start\": \"2018-01-15T00:00:00\", \"rr_end\": \"2018-02-14T00:00:00\", \"rr_outcome\": \"Full pharamcoeconomic assessment recommended at the submitted price\", \"rr_dates\": \"2018-01-15, 2018-02-14\", \"rr_multiple\": 0.0, \"drug_name\": \"Benralizumab \", \"trade_name\": \"Fasenra\", \"indication\": \"Benralizumab  is indicated as add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting \\u03b2-agonists.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2018-01-08T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0.0, \"earliest\": \"2018-01-15T00:00:00\", \"latest\": \"2018-02-14T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:28:23\", \"rr_start\": \"2012-11-28T00:00:00\", \"rr_end\": \"2012-12-21T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Assessment Recommended\", \"rr_dates\": \"2012-11-28, 2012-12-21\", \"rr_multiple\": 0.0, \"drug_name\": \"Brentuximab vedotin \", \"trade_name\": \"Adcetris\", \"indication\": \"Brentuximab vedotin  indicated for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.\", \"ncpe_year\": 2015.0, \"eu_market\": \"2012-10-25T00:00:00\", \"company\": \"Takeda\", \"orphan\": 1.0, \"earliest\": \"2012-11-28T00:00:00\", \"latest\": \"2015-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Hodgkin Disease\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:28:40\", \"rr_start\": \"2017-07-25T00:00:00\", \"rr_end\": \"2017-08-29T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended at submitted price\", \"rr_dates\": \"2017-07-25, 2017-08-29\", \"rr_multiple\": 0.0, \"drug_name\": \"Brodalumab \", \"trade_name\": \"Kyntheum\", \"indication\": \"Brodalumab  is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-07-17T00:00:00\", \"company\": \"LEO\", \"orphan\": 0.0, \"earliest\": \"2017-07-25T00:00:00\", \"latest\": \"2018-01-01T00:00:00\", \"ta_list\": \"Psoriasis\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:29:09\", \"rr_start\": \"2012-06-15T00:00:00\", \"rr_end\": \"2012-06-28T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2012-06-15, 2012-06-28\", \"rr_multiple\": 0.0, \"drug_name\": \"Capsaicin 8%w/w patch \", \"trade_name\": \"Qutenza\", \"indication\": \"Capsaicin 8% w/w patch  for peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.\", \"ncpe_year\": 2012.0, \"eu_market\": \"2009-05-15T00:00:00\", \"company\": \"Grunenthal\", \"orphan\": 0.0, \"earliest\": \"2012-06-15T00:00:00\", \"latest\": \"2012-06-28T00:00:00\", \"ta_list\": \"Neuralgia\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:29:49\", \"rr_start\": \"2015-01-07T00:00:00\", \"rr_end\": \"2016-01-18T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended\", \"rr_dates\": \"2015-01-07, 2016-01-18\", \"rr_multiple\": 0.0, \"drug_name\": \"Ciclosporin 1mg/ml eye drops \", \"trade_name\": \"Ikervis\", \"indication\": \"Ikervis\\u00ae is indicated for the treatment of severe keratitis in adult patients with dry eye disease , which has not improved despite treatment with tear substitutes.\", \"ncpe_year\": 2016.0, \"eu_market\": \"2015-03-19T00:00:00\", \"company\": \"Santen\", \"orphan\": 0.0, \"earliest\": \"2015-01-07T00:00:00\", \"latest\": \"2016-01-18T00:00:00\", \"ta_list\": \"Corneal Diseases\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:30:02\", \"rr_start\": \"2016-04-19T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2016-04-19, 2016-04-26\", \"rr_multiple\": 0.0, \"drug_name\": \"Cobimetinib \", \"trade_name\": \"Cotellic\", \"indication\": \"Cotellic\\u00ae is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2015-11-20T00:00:00\", \"company\": \"Roche\", \"orphan\": 0.0, \"earliest\": \"2016-04-19T00:00:00\", \"latest\": \"2018-03-01T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:30:29\", \"rr_start\": \"2017-02-06T00:00:00\", \"rr_end\": \"2017-04-24T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Not Recommended.\", \"rr_dates\": \"2017-02-06, 2017-04-24\", \"rr_multiple\": 0.0, \"drug_name\": \"Crizotinib  for ROS1 NSCLC\", \"trade_name\": \"Xalkori\", \"indication\": \"Crizotinib is indicated for the treatment of adults with ROS1-positive advanced non-small cell lung cancer .\", \"ncpe_year\": 2017.0, \"eu_market\": \"2012-10-23T00:00:00\", \"company\": \"Pfizer\", \"orphan\": 0.0, \"earliest\": \"2017-02-06T00:00:00\", \"latest\": \"2017-04-24T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:33:05\", \"rr_start\": \"2015-03-30T00:00:00\", \"rr_end\": \"2015-05-08T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2015-03-30, 2015-05-08\", \"rr_multiple\": 0.0, \"drug_name\": \"Elosulfase alfa \", \"trade_name\": \"Vimizim\", \"indication\": \"Elosulfase alfa  in patients of all ages.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2014-04-27T00:00:00\", \"company\": \"BioMarin\", \"orphan\": 1.0, \"earliest\": \"2015-03-30T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Mucopolysaccharidosis IV\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:33:43\", \"rr_start\": \"2017-12-11T00:00:00\", \"rr_end\": \"2017-12-21T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment recommended\", \"rr_dates\": \"2017-12-11, 2017-12-21\", \"rr_multiple\": 0.0, \"drug_name\": \"Emtricitabine/tenofovir disoproxil \", \"trade_name\": \"TEVA\", \"indication\": \"Emtricitabine/tenofovir disoproxil  for pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk.\", \"ncpe_year\": 2017.0, \"eu_market\": \"1996-10-04T00:00:00\", \"company\": \"CIS\", \"orphan\": 0.0, \"earliest\": \"2017-12-11T00:00:00\", \"latest\": \"2017-12-21T00:00:00\", \"ta_list\": \"Radionuclide Imaging; Ovarian Neoplasms\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:33:48\", \"rr_start\": \"2016-04-26T00:00:00\", \"rr_end\": \"2016-04-26T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.\", \"rr_dates\": \"2016-04-26, 2016-04-26\", \"rr_multiple\": 0.0, \"drug_name\": \"Emtricitabine/tenofovir alafenamide \", \"trade_name\": \"Descovy\", \"indication\": \"Descovy\\u00ae  type 1.\", \"ncpe_year\": 2016.0, \"eu_market\": \"2016-04-21T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0.0, \"earliest\": \"2016-04-26T00:00:00\", \"latest\": \"2016-04-26T00:00:00\", \"ta_list\": \"HIV Infections\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:34:56\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2010-12-03T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation recommended\", \"rr_dates\": \"2011-01-10, 2010-12-03\", \"rr_multiple\": 0.0, \"drug_name\": \"Fingolimod \", \"trade_name\": \"Gilenya\", \"indication\": \"Cost effectiveness of Fingolimod  for the treatment of highly active relapsing-remitting multiple sclerosis.\", \"ncpe_year\": 2011.0, \"eu_market\": \"2011-03-17T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0.0, \"earliest\": \"2010-12-03T00:00:00\", \"latest\": \"2011-09-22T00:00:00\", \"ta_list\": \"Multiple Sclerosis\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:35:05\", \"rr_start\": \"2018-04-30T00:00:00\", \"rr_end\": \"2018-06-18T00:00:00\", \"rr_outcome\": \"A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy\\u2122 Ellipta\\u2122 be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\\n \", \"rr_dates\": \"2018-04-30, 2018-06-18\", \"rr_multiple\": 0.0, \"drug_name\": \"Fluticasone furoate/ umeclidinium/ vilantero \", \"trade_name\": \"Trelegy Ellipta\", \"indication\": \"Trelegy\\u2122 Ellipta\\u2122 which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-11-15T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0.0, \"earliest\": \"2018-04-30T00:00:00\", \"latest\": \"2018-06-18T00:00:00\", \"ta_list\": \"Pulmonary Disease, Chronic Obstructive\", \"rr_status\": \"Reimbursement without HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:35:40\", \"rr_start\": \"2017-03-07T00:00:00\", \"rr_end\": \"2017-03-13T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended at the submitted price\", \"rr_dates\": \"2017-03-07, 2017-03-13\", \"rr_multiple\": 0.0, \"drug_name\": \"Glycopyrronium bromide \", \"trade_name\": \"Sialanar\", \"indication\": \"Glycopyrronium bromide  in children and adolescents aged 3 years and older with chronic neurological disorders\", \"ncpe_year\": 2017.0, \"eu_market\": \"2016-09-15T00:00:00\", \"company\": \"Proveca\", \"orphan\": 0.0, \"earliest\": \"2017-03-07T00:00:00\", \"latest\": \"2017-03-13T00:00:00\", \"ta_list\": \"Sialorrhea\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:36:56\", \"rr_start\": \"2014-12-08T00:00:00\", \"rr_end\": \"2014-12-30T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-12-08, 2014-12-30\", \"rr_multiple\": 0.0, \"drug_name\": \"Idelalisib \", \"trade_name\": \"Zydelig\", \"indication\": \"Indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia  who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.\", \"ncpe_year\": 2016.0, \"eu_market\": \"2014-09-18T00:00:00\", \"company\": \"Gilead\", \"orphan\": 0.0, \"earliest\": \"2014-12-08T00:00:00\", \"latest\": \"2016-12-01T00:00:00\", \"ta_list\": \"Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:38:02\", \"rr_start\": \"2011-01-10T00:00:00\", \"rr_end\": \"2011-02-02T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation not Recommended\", \"rr_dates\": \"2011-01-10, 2011-02-02\", \"rr_multiple\": 0.0, \"drug_name\": \"Iron isomaltoside 1000 \", \"trade_name\": \"MonoVer\", \"indication\": \"MonoVer is indicated for the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly.\", \"ncpe_year\": 2011.0, \"eu_market\": \"2009-10-10T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0.0, \"earliest\": \"2011-01-10T00:00:00\", \"latest\": \"2011-02-02T00:00:00\", \"ta_list\": \"Influenza, Human; Immunization; Disease Outbreaks\", \"rr_status\": \"No HTA\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:40:45\", \"rr_start\": \"2016-03-16T00:00:00\", \"rr_end\": \"2016-04-04T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended.\", \"rr_dates\": \"2016-03-16, 2016-04-04\", \"rr_multiple\": 0.0, \"drug_name\": \"Mepolizumab \", \"trade_name\": \"Nucala\", \"indication\": \"Mepolizumab  is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2015-12-01T00:00:00\", \"company\": \"GlaxoSmithKline\", \"orphan\": 0.0, \"earliest\": \"2016-03-16T00:00:00\", \"latest\": \"2018-04-01T00:00:00\", \"ta_list\": \"Asthma\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:41:02\", \"rr_start\": \"2018-08-13T00:00:00\", \"rr_end\": \"2018-09-10T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care.\", \"rr_dates\": \"2018-08-13, 2018-09-10\", \"rr_multiple\": 0.0, \"drug_name\": \"Midostaurin  for ASM\", \"trade_name\": \"Rydapt\", \"indication\": \"Midostaurin .\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-09-18T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1.0, \"earliest\": \"2018-08-13T00:00:00\", \"latest\": \"2018-09-10T00:00:00\", \"ta_list\": \"Leukemia, Myeloid, Acute; Mastocytosis\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:42:46\", \"rr_start\": \"2018-11-28T00:00:00\", \"rr_end\": \"2018-12-11T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic assessment is recommended\", \"rr_dates\": \"2018-11-28, 2018-12-11\", \"rr_multiple\": 0.0, \"drug_name\": \"Nivolumab \", \"trade_name\": \"Yervoy\", \"indication\": \"Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma .\", \"ncpe_year\": 2018.0, \"eu_market\": \"2011-07-12T00:00:00\", \"company\": \"Bristol-Myers\", \"orphan\": 0.0, \"earliest\": \"2018-11-28T00:00:00\", \"latest\": \"2018-12-11T00:00:00\", \"ta_list\": \"Melanoma\", \"rr_status\": \"Unknown\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:44:22\", \"rr_start\": \"2018-07-19T00:00:00\", \"rr_end\": \"2018-08-07T00:00:00\", \"rr_outcome\": \"A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.\", \"rr_dates\": \"2018-07-19, 2018-08-07\", \"rr_multiple\": 0.0, \"drug_name\": \"Osimertinib  for the first-line treatment of metastatic NSCLC\", \"trade_name\": \"Tagrisso\", \"indication\": \"Osimertinib  mutations.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2016-02-01T00:00:00\", \"company\": \"AstraZeneca\", \"orphan\": 0.0, \"earliest\": \"2018-07-19T00:00:00\", \"latest\": \"2018-08-07T00:00:00\", \"ta_list\": \"Carcinoma, Non-Small-Cell Lung\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:47:29\", \"rr_start\": \"2017-09-04T00:00:00\", \"rr_end\": \"2017-09-19T00:00:00\", \"rr_outcome\": \"Following NCPE assessment of the company submission, the NCPE recommends that ribociclib (in combination with an aromatase inhibitor) for the treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic BC as initial endocrine-based therapy, not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.\", \"rr_dates\": \"2017-09-04, 2017-09-19\", \"rr_multiple\": 0.0, \"drug_name\": \"Ribociclib \", \"trade_name\": \"Kisqali\", \"indication\": \"Ribociclib  negative locally advanced or metastatic breast cancer as initial endocrine based therapy.\", \"ncpe_year\": 2018.0, \"eu_market\": \"2017-08-22T00:00:00\", \"company\": \"Novartis\", \"orphan\": 0.0, \"earliest\": \"2017-09-04T00:00:00\", \"latest\": \"2018-08-13T00:00:00\", \"ta_list\": \"Breast Neoplasms\", \"rr_status\": \"No HTA at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:48:55\", \"rr_start\": \"2012-08-01T00:00:00\", \"rr_end\": \"2012-08-10T00:00:00\", \"rr_outcome\": \"Full pharmacoeconomic evaluation recommended\", \"rr_dates\": \"2012-08-01, 2012-08-10\", \"rr_multiple\": 0.0, \"drug_name\": \"Ruxolitinib \", \"trade_name\": \"Jakavi\", \"indication\": \"Ruxolitinib , post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.\", \"ncpe_year\": 2013.0, \"eu_market\": \"2012-08-23T00:00:00\", \"company\": \"Novartis\", \"orphan\": 1.0, \"earliest\": \"2012-08-01T00:00:00\", \"latest\": \"2013-07-09T00:00:00\", \"ta_list\": \"Myeloproliferative Disorders\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:53:32\", \"rr_start\": \"2014-09-12T00:00:00\", \"rr_end\": \"2014-10-01T00:00:00\", \"rr_outcome\": \"Full Pharmacoeconomic Evaluation Recommended\", \"rr_dates\": \"2014-09-12, 2014-10-01\", \"rr_multiple\": 0.0, \"drug_name\": \"Vedolizumab  in Crohn\\u2019s Disease\", \"trade_name\": \"Entyvio\", \"indication\": \"Vedolizumab  antagonist.\", \"ncpe_year\": 2017.0, \"eu_market\": \"2014-05-22T00:00:00\", \"company\": \"Takeda\", \"orphan\": 0.0, \"earliest\": \"2014-09-12T00:00:00\", \"latest\": \"2017-10-01T00:00:00\", \"ta_list\": \"Colitis, Ulcerative; Crohn Disease\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}, {\"last_scrape\": \"2018-12-13T16:53:52\", \"rr_start\": \"2018-05-08T00:00:00\", \"rr_end\": \"2018-06-21T00:00:00\", \"rr_outcome\": \"Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.\", \"rr_dates\": \"2018-05-08, 2018-06-21\", \"rr_multiple\": 0.0, \"drug_name\": \"Venetoclax \", \"trade_name\": \"Venclyxto\", \"indication\": \"Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia \", \"ncpe_year\": 2018.0, \"eu_market\": \"2016-12-04T00:00:00\", \"company\": \"AbbVie\", \"orphan\": 1.0, \"earliest\": \"2017-01-03T00:00:00\", \"latest\": \"2018-12-01T00:00:00\", \"ta_list\": \"Leukemia, Lymphocytic, Chronic, B-Cell\", \"rr_status\": \"HTA recommended at submitted price\", \"therapyarea\": \"Immunization\"}]}};\n",
       "const opt = {};\n",
       "const type = \"vega-lite\";\n",
       "const id = \"2bc533b9-5dde-4913-bed4-a92ecb1f528d\";\n",
       "\n",
       "const output_area = this;\n",
       "\n",
       "require([\"nbextensions/jupyter-vega/index\"], function(vega) {\n",
       "  const target = document.createElement(\"div\");\n",
       "  target.id = id;\n",
       "  target.className = \"vega-embed\";\n",
       "\n",
       "  const style = document.createElement(\"style\");\n",
       "  style.textContent = [\n",
       "    \".vega-embed .error p {\",\n",
       "    \"  color: firebrick;\",\n",
       "    \"  font-size: 14px;\",\n",
       "    \"}\",\n",
       "  ].join(\"\\\\n\");\n",
       "\n",
       "  // element is a jQuery wrapped DOM element inside the output area\n",
       "  // see http://ipython.readthedocs.io/en/stable/api/generated/\\\n",
       "  // IPython.display.html#IPython.display.Javascript.__init__\n",
       "  element[0].appendChild(target);\n",
       "  element[0].appendChild(style);\n",
       "\n",
       "  vega.render(\"#\" + id, spec, type, opt, output_area);\n",
       "}, function (err) {\n",
       "  if (err.requireType !== \"scripterror\") {\n",
       "    throw(err);\n",
       "  }\n",
       "});\n"
      ],
      "text/plain": [
       "<vega.vegalite.VegaLite at 0x17bd7a0fa20>"
      ]
     },
     "metadata": {
      "jupyter-vega": "#2bc533b9-5dde-4913-bed4-a92ecb1f528d"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": []
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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"
     },
     "metadata": {
      "jupyter-vega": "#2bc533b9-5dde-4913-bed4-a92ecb1f528d"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "upto_chart = alt.Chart(result2,title=\"List of Immunization drugs\").mark_bar().encode(\n",
    "    x='ncpe_year:N', \n",
    "    y='trade_name',\n",
    "    color='ncpe_year:N',\n",
    ").properties(\n",
    "    width=300,\n",
    "    height=600,\n",
    ")\n",
    "upto_chart"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
